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ABSTRACT 
Lamins A and C (A-type lamins) are type V nuclear intermediate filament 
proteins which form a complex meshwork underlining the inner nuclear 
membrane termed the nuclear lamina. A-type lamins have been implicated in 
DNA replication, regulation of gene transcription, apoptosis and regulating the 
activity of several growth promoters. As such mutations in A-type lamins give rise 
to a diverse range of genetic diseases related to premature ageing and it has 
been speculated but not proven that expression of A-type lamins may influence 
tumour progression. 
To test this hypothesis, a large (n=656) retrospective archive of colorectal cancer 
specimens from the Netherlands Cohort Study on Diet and Cancer was screened 
for the expression of A-type lamins. Data clearly show that patients lacking A-
type lamin expression in their tumours have a significantly better prognosis 
compared to clinicopathologically similar patients expressing A-type lamins [HR 
= 0.59, (95% Cl: 0.409- 0.858), p=0.006]. 
Data also show that expression of lamin A in an in vitro colorectal cancer model 
leads to genome-wide changes and in particular promotes a significant down-
regulation in Bone Morphogenic Protein 4 (BMP4) a member of the TGF-13 
superfamily which has already been linked to the pathogenesis of some solid 
tumours and also show that A-type lamin expression acts as a negative regulator 
of BMP4 mediated growth suppression. A-type lamin expression also results in a 
concomitant up-regulation in expression of the actin bundling protein T-plastin 
and down-regulation in expression of the cell adhesion molecule E-cadherin 
leading to a more motile, less adherent cellular phenotype in laminA expressing 
cells. 
Thus expression of A-type lamins may increase the risk of death in colorectal 
cancer because its presence gives rise to increased invasiveness due to the 
negative regulation of BMP mediated growth suppression. This is the first 
evidence directly linking the expression of A-type lamins to mechanisms 
promoting tumour progression. 
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CHAPTER 1 - Introduction 
1. 1 Colorecta/ Cancer 
1.1.1 The national and international perspective 
There are currently more than 200 different types of diagnosable cancer in the 
world today, but only four of them; lung, breast, prostate and large bowel 
(colorectal) account for over half of all new cases (Cancer Research UK 2007). 
Figure 1.1 shows the distribution of cancer subtypes diagnosed annually in the 
United Kingdom. Currently there are over a quarter of a million people diagnosed 
with cancer in the UK each year and more than 150,000 people die from the 
disease nationwide (Toms 2004). Figure 1.2 shows the most common causes of 
death by cancer annually in the UK. When considered globally, these figures 
reach somewhere in the region of 11 million diagnoses and 6 million deaths 
annually (Parkin, Bray et al. 2005). 
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Colorectal cancer (CRC) is one of, if not the most common cancer malignancy in 
the UK and other developed countries . lt is the second leading cause of cancer-
related death , after lung cancer, and in the UK alone this accounts for 
approximately 13% of all new cancer cases and 10% of cancer deaths per year. 
Annually, this equates to approximately 35,000 new cases (-22,000 in the colon 
and -13,000 in the rectum) and somewhere in the region of 16,000 deaths in the 
UK (Figure 1.1 and Figure 1.2) (Cancer Research UK 2007) which increases to 1 
million diagnoses and 500,000 deaths when considered globally (Parkin , Bray et 
al. 2005). The lifetime risk within the general population is calculated to be 
approximately 5 to 6 percent with men and women being affected approximately 
equally, showing an incidence ratio of 1.2:1 (m:f) (Parkin, Bray et al. 2005). 
Whilst the survival rates for patients diagnosed with colorectal cancer are 
improving annually, of those diagnosed around half of them will ultimately die 
from the disease within 5 years . 
2 
The biggest problem with colorectal cancer is that symptoms often only present 
themselves after the transition from benign adenoma to malignant carcinoma 
(Cancer Research UK 2007) and at present, the risk factors associated with this 
progression remain largely enigmatic. There is an ever increasing plethora of 
evidence for the influence of a range of environmental and genetic factors , such 
as age, nutrition, low physical activity, obesity, smoking, inflammatory bowel 
disease and family history. However, the exact cause and progression of 
colorectal cancer, a vastly complex, multifactoral disease is still poorly 
understood, yet it has been estimated that less that 10% of all cases are 'truly 
genetic' and around 80% of cases can be attributed as a direct result of diet and 
lifestyle . 
lt is estimated that around 100 new cases of colorectal cancer are diagnosed 
every day in the UK alone (Toms 2004). The distribution of colorectal cancer 
cases throughout the large bowel is shown in figure 1.3. The left side of the colon 
is typically more affected than the right, with tumours in the sigmoid colon, 
rectosigmoid junction and rectum accounting for approximately half of all new 
cases. 
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Figure 1.3 Distribution of case by site within the large bowel, England 1997-2000 
Source: Cancer Research UK (July 2007) 
http://info.cancerresearchuk.org/cancerstats/typeslbowellincidencel 
(Proximal = Caecum to Hepatic Flexure, Distal = Hepatic Flexure to Rectum) 
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1.1.2 Macroscopic and microscopic anatomy of the colon 
1. 1.2. 1 Macroscopic organisation of the colon 
The adult gastrointestinal tract is radially organised into four histologically distinct 
layers, the mucosa, submucosa, Muscularis propria and Serosa (Burkitt, Young 
et al. 1993) as shown in figure 1.4. The colonic mucosa is a simple columnar 
epithelium adjacent to the luminal surface of the colon and is underlined by 
layers of mesenchymal tissue and muscle. The microscopic organisation is 
discussed in the next section, but colorectal cancer as discussed in the context 
of this thesis constitutes tumours arising from the colonic mucosa itself. These 
are by far the most common and best studied cancerous lesion of the 
colorectum. Tumours arising in the smooth muscle and stromal layers of the 
colon and appendix do occur in the form of leiomyomas and leiomyosarcomas, 
although they are extremely rare in comparison to the prevalence of their 
epithelial counterparts (Hatch, Blanchard et al. 2000; Toms 2004). 
1.1.2.2 Microscopic architecture of the colonic mucosa 
The surface of the normal colonic mucosa is primarily composed of a mono-
layer of columnar ~pithelial cells responsible for ion and water absorption, 
interspersed with goblet cells, responsible for synthesising and secreting mucin. 
Unlike the small intestine, the surface of the colon does not possess villi, but is 
studded with crypts, with numbers reaching over 100 million in adults. Each crypt 
is approximately 50 cells deep and at the base of each crypt, there is postulated 
to be somewhere in the region of 4-10 stem cells responsible for replenishing the 
crypt and intercrypt table throughout the whole of an individuals life . 
These stem cells undergo mitotic, self-renewing divisions and the progeny then 
migrate unilaterally up the crypt (Twombly 2002). Directly above the proposed 
stem cell niche is a region of undifferentiated transiently amplifying cells which 
rapidly divide whilst continuing to migrate until they reach the upper third of the 
crypt. Here a switch occurs whereby cells stop dividing, and begin a path of 
differentiation which will 
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Figure 1.4. Diagrammatic representation (A) and immunohistochemical histology (B) of the colorectum. Staining is 
haematoxylin (purple) and Eosin (pink). (Modified from http://www.cancerline.com/ cancerlinehcpl) 
Ultimately determine their fate. Upon reaching the lumen of the colon, the cells 
have undergone final differentiation and emerge into the lumen as fully 
differentiated, functional cells. They then undergo apoptosis and are sloughed off 
into the lumen with passing waste matter. The whole process of apoptosis, 
sloughing and extrusion from the mucosal surface at the apex, under normal 
conditions must exactly balance that of cellular proliferation at the base of the 
crypt for homeostasis to be maintained. This self-renewing process takes 
approximately four to six days in total. If the rate of cellular proliferation exceeds 
that of cellular loss, resulting in hyper-proliferation of the crypts, it ultimately 
leads to the formation of neoplasms within the gut lumen. 
lt is thought that the crypts most likely evolved to protect the crypt progenitor 
stem cells from the very mutagenic environment of the colonic lumen (Potter 
1999). Under normal circumstances, interactions between colonic contents and 
replicating (progenitor) cells are practically nonexistent. By the time migrating 
crypt cells reach the luminal surface they are fully differentiated, non-replicating 
cells and imminently undergoing apoptosis. Thus any mutagenic event in these 
cells would have little or no impact on the integrity of the crypt cell population 
(Potter 1999). 
Figure 1.5 shows a diagrammatic representation of the crypt highlighting the 
stem cell niche, proliferative and differentiated zones alongside the histological 
view of the full crypt profile. 
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(A) Histological view of the crypt defined by immunoperoxidase staining with the Lamin 
A/C antibody Jol2 (Dyer, Kill et al. 1997) and counterstained with Mayers Haemalum. 
(B) Diagrammatic representation of the crypt zones (modified from (Twombly 2002)). 
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1.1.3 Clinicopathological staging of colorectal tumours 
Colorectal tumours .are solid, heterogeneous tumours and as such are classified, 
or staged clinicopathologically based on the degree of primary organ 
involvement and their metastatic spread to surrounding lymph nodes. There are 
3 major staging systems in use across the world and this sub-staging is 
fundamental since it is used to determine the prognosis of newly diagnosed 
colorectal cancer patients and ultimately helps tailor their treatment regimen. 
1.1.3. 1 Dukes' staging as the Gold Standard in the UK 
In the UK, the clinicopathological Dukes' staging system, devised some 75 years 
ago by Cuthbert Dukes and modified by Turnbull remains the "gold standard" 
for predicting prognosis in colorectal cancer patients. lt was originally published 
for rectal cancers, but is now applied to all colorectal (colon and rectal) cancers. 
The staging system is relatively straightforward and when Dukes originally 
proposed his classification system it placed patients into one of three categories 
(Stages A, B, C). The system was subsequently modified to include a fourth 
stage (Stage D); ar)d then again by subdividing Dukes' C into C1 and C2 to 
produce what is used nowadays and often termed the modified Dukes' staging 
system. 
Dukes' A tumours are those in which the tumour has penetrated into the mucosa 
of the bowel wall, but have not penetrated and spread beyond the muscularis 
mucosae. If the tumour has spread beyond this and also penetrated the 
muscularis propria (muscle layers) but shows no pathological evidence of lymph 
node involvement, then the tumour is classified as Dukes' B. Once there is 
evidence of lymph node involvement, the tumour is either classified as Dukes' 
C1 in which 1-3 of the proximal lymph nodes are affected, or Dukes' C2 if 3 or 
more of the proximal lymph nodes are affected. Dukes' D patients are those in 
which the tumour has spread beyond the confines of the lymph nodes and are 
found to have distant metastases, which are commonly located in the liver, 
lungs, or bones. Figure 1.6 shows a cross-sectional view of the layers of the 
large intestine and the extend of tumour spread as defined by Dukes' 
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Figure 1.6 Diagrammatic representation of the cross section of the colon showing the 
extent of spread according to Dukes' classification (Modified from National Cancer 
Institute) 
As has already been mentioned, the clinicopathological stage of the tumour is 
closely linked to patient survival and this was keenly observed by Dukes' in 
1932. Table 1.1 shows the frequency of diagnosis and relative 5-year disease 
free survival(%) across the different Dukes' stages. 
Table 1.1 Frequency and 5-year relative survival(%) by Dukes' stage 
Dukes' Stage Frequency of Diagnosis 5-year survival 
A 11% 83% 
8 35% 64% 
c 26% 38% 
0 28% 3% 
Source: Cancer Research UK (2007) 
http :1/info. cancerresea rch u k. org/ca ncersta tsltypes/bowellsurviva/1 
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1.1.3.2 Astler-Coller and the American TNM staging systems 
Although the original Dukes' system is useful in predicting survival outcome after 
surgical resection, it is often found that different patients within each stage have 
markedly different outcomes (Cass, Million et al. 1976). The Iumour - Node -
Metastasis System (TNM) originally proposed by the American Joint Committee 
on Cancer (AJCC) is relevant to both clinical and pathologic staging and can be 
applied (albeit with slight modifications) to almost all solid tumours (AJCC 2002). 
In terms of colorectal cancer, its advantages are that it has a more precise 
definition of the degree of primary tumour extension for lesions confined to the 
bowel wall, and defines node involvement by the number of nodes involved (N1, 
N1-3, N2, ~N4). The sixth edition has also recently been refined by the addition 
of substaging for stage 11 and stage Ill lesions based on differential survival and 
relapse rates (Jessup, Gunderson et al. 2002). To that end, it is now currently 
being phased into use in the UK alongside the more traditional Dukes' system 
and is playing a key role in deciding patient treatment regimens. Table 1.2 shows 
the breakdown of the current TNM staging system for colorectal cancer. Only 
10% of patients are diagnosed at stage 0 or stage I; the remainder are 
distributed equally between stage 11, Ill and IV. 
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Table 1.2 The AJCC TNM staging system for Colorectal Cancer 
AJCC/TNM Description 
Stage 0 
Stage I 
Stage 11 
Stage Ill 
Stage IV 
Carcinoma in situ 
No nodal involvement, no distant metastasis 
Tumour invades submucosa (T1, NO, MO) 
Tumour invades muscularis propria (T2, NO, MO) 
No nodal involvement, no distant metastasis 
Tumour invades into Subserosa (T3, NO, MO) 
Tumour invades into other organs (T4, NO, MO) 
Nodal involvement, no distant metastasis 
1 to 3 regional lymph nodes involved (any T, N 1, MO) 
4+ regional lymph nodes involved (Any T, N2, MO) 
Distant metastasis (any T, any N, M1) 
Source: Cancer Research UK (2007) 
http:llinfo.cancerresearchuk.orglcancerstatsltypes/bowel/symptomsandtreatment/ 
The pathological Astler-Coller staging system is another staging system still 
used in some parts of the world. This system was first proposed in 1954 and 
even today results in some confusion because it is often misinterpreted as 
related to the Dukes' system. The original scheme had five stages; A was limited 
to the mucosa, 81 involved the muscularis propria but did not penetrate it, 82 
penetrated the muscularis propria, and C1 and C2 were counterparts of 81 and 
82 with nodal metastases. Since then, later modifications have added three 
more stages. 83 represents involvement of adjacent structures, C3 is 83 with 
nodal metastasis, and D signifies presence of distant metastasis (Rosch 1998) 
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Table 1.3 shows a comparative analysis detailing the overlap between all three 
staging systems discussed, the extent of primary organ involvement and 
associated 5-year disease free survival. 
Table 1.3 Comparison between classification systems 
AJCC/ Astler- 5-year 
Dukes' Extension To: 
TNM Caller Survival 
A A,B1 muscularis mucosae 93% 
IIA B 82 subserosa/Pericolic Tissue 85% 
IlB 8 83 Visceral Per/Other Organs 72% 
IliA C1 C1 N1 1-3 lymph nodes 83% 
IllS C1 C2, C3 N1 1-3 lymph nodes 64% 
IIIC C2 C1 , C2, C3 N2 >3 lymph nodes 44% 
IV D D Metastatic Disease 8% 
1.1.4 Screening for Colorectal Cancer 
One of the main reasons that so many colorectal cancer patients present with 
more advanced, late-stage tumours is because of the relatively asymptomatic 
nature of the disease in the early stages and poor health seeking behaviour in 
the UK (Waters 2006). Yet, as with all cancers, treatment is markedly more 
effective if the disease is detected early. Currently the most cost-effective 
preventative measure is screening for early detection in what can be considered 
'at risk' patients in order to prevent progression of benign polyps (adenomas) to 
malignant carcinomas. At present there are two main types of screening 
available to patients with suspected colorectal cancer; endoscopic examinations, 
(which include sigmoidoscopies and colonoscopies) and stool testing. Other 
older techniques are also still routinely used in some hospitals, such as barium 
enema X-ray. Colonoscopy is considered the gold standard for investigation but 
is somewhat more time-consuming and expensive than its sigmoidoscopy 
counterpart. Whilst both are simple and relatively painless to conduct, they are 
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invasive procedur~s which must be carried out in the clinic. The other method is 
stool testing or faecal occult blood testing (FOBt) which is much simpler and can 
be carried out by the patient at home before being sent to the lab for analysis 
I 
(Hardcastle and Pye 1989). 
Several clinical trials have investigated the different methods of screening 
patients for colorectal cancer with the aim of identifying members of the 
population most at1 risk. In the UK to date, two screening programs have been 
piloted; FOBt screening and flexible sigmoidoscopy (Hardcastle, Chamberlain et 
al. 1996; Kronborg,! Fenger et al. 1996; Atkin 2002; Alexander and Weller 2003). 
The first was a ra,ndomised controlled trial using FOBt screening which was 
undertaken in Nottingham (Hardcastle, Chamberlain et al. 1996) and aimed to 
look at all individuals between the ages of 45 and 75 to determine the 
effectiveness of d!3tecting patients at risk of developing colorectal cancer. 
' 
Patients were scre~ned biennially using FOBt. Patients eliciting a positive result 
were then invited to. undergo endoscopic investigation to confirm. A control group 
was also used in w~ich patients were not screened. 
I 
The basis of FOBt screening is to detect non-visible or 'occult' blood in stools of 
I 
patients which is often indicative of early colorectal neoplasia. lt was found that 
FOBt screening wa·is a good predictor of colorectal neoplasia in approximately 
46% of cases. Of those tumours detected in patients, the majority were classified 
as Dukes' A (early • stage tumours), thus indicating that FOBt screening could 
' 
facilitate earlier colorectal cancer diagnosis. The most interesting finding 
i 
however, was that the mortality rate of patients who underwent FOBt screening 
was reduced by approximately 39% compared to the control group (Hardcastle, 
Chamberlain et al. 1'996). 
The findings of Haracastle and Chamberlain were then further supported by a 
similar study carried out in Minnesota in the US (Mandel, Bond et al. 1993; 
Mandel, Church et al. 1999). The work also aimed to make additional 
comparisons betwe~n the effectiveness of biennial and annual FOBt screening. 
They reported a sirpilar decrease in the mortality rate of patients undergoing 
biennial FOBt screening compared to control, but also showed a further 
reduction in mortal,ity rate of patients undergoing annual FOBt screening 
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compared to both the biennial FOBt screening and the unscreened control 
group. Both of these studies strongly supported the notion that FOBt screening 
could have huge potential benefits in reducing colorectal cancer mortality when 
applied to the population as a whole. 
In order to determine the feasibility of such a proposed national screening 
program in the UK population, the UK Colorectal Cancer Screening Pilot was 
established and .launched in 2000 with an independent report being 
commissioned by the UK Department of Health. Two sites were selected for a 
population-based trial: Coventry and Warwickshire in England, and Fife, Tayside 
and Grampian in Scotland. All men and women between the ages of 50 and 69 
were invited to participate in the trials. lt was reported that approximately 60% of 
those invited to participate took part in the FOBt screening program. The 
outcome was good and the results were positive which led the UK Colorectal 
Cancer Evaluation Team to conclude in their final commissioned report, that the 
' 
benefits of FOBt screening at a national level to facilitate the early diagnosis of 
colorectal cancer alild hence reduce mortality of patients, greatly outweighed the 
financial costs and logistical considerations of launching such an initiative 
(Alexander and Weller 2003). To this end, the National Bowel Cancer Screening 
Programme has becim launched and is currently being rolled out over a two year 
period across the UK, (albeit slightly behind schedule) with the aim to achieve 
nationwide coverage by 2009 in order to screen and monitor all individuals in 
their sixth decade. 
At the same time, the benefits of single flexible sigmoidoscopy screening was 
also investigated in a multi-centred, randomised controlled trial in the UK (Atkin 
2002). Flexible sigr11oidoscopy differs from FOBt screening in that it is the visual 
inspection of the rectum and sigmoid colon with a flexible endoscope. lt has the 
advantage over FOBt screening in that it is able to detect pre-malignant lesions 
or polyps as well as early stage colorectal cancer. Endoscopic examinations 
however must be ca.rried out in a clinic by trained staff and are considered highly 
invasive. There is also an associated risk of accidental perforation of the bowel 
which can occur during the procedure although this is rare. Atkins findings 
showed that approximately three quarters of cancers detected in the screened 
group could be considered as localised, early stage, i.e. Dukes' A or Dukes' B. 
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(Another advantage is that polyps detected during investigation can be removed 
by diathermy snare there and then without the need for further treatment). This 
was a much higher percentage than was detected by the FOBt screening studies 
indicating that singl,e flexible sigmoidoscopy may be more sensitive. Additionally 
there was only a single case of a perforated bowel as a result of the procedure 
out of 40,000 patients in total, further supporting the notion that it is both safe 
and effective. 
With this in mind, itwould seem sensible to initiate a national screening program 
of endoscopic investigation for early diagnosis of colorectal cancer. 
Unfortunately, the estimated cost of such a procedure exceeds £125 whereas 
the associated cost of FOBt screening, including processing, is approximately £5 
(Alexander and Weller 2003). Thus, screening by flexible sigmoidoscopy would 
have to deliver improvements in early diagnosis of colorectal cancer and a 
decrease in mortality rate much greater than that reported to date for the benefits 
of such a program to outweigh the cost and burden to the NHS. 
There are several other methods in existence for colorectal cancer screening. 
Barium enema X-ray has already been mentioned, and is a more traditional, 
albeit invasive technique. The drive however, is towards non-invasive methods. 
Magnetic resonance imaging (MRI) scans are now frequently used to stage 
tumours and plan treatment and a relatively new technique being investigated is 
Computed tomography (CT) colonography (virtual colonoscopy) and guidelines 
on its use have already been issued by the National Institute of Clinical 
Excellence (N.I.C.E1• 2005a). Currently, a randomised multicentre' prospective 
trial (SIGGAR1) is comparing CT colonography to visual colonoscopy and 
barium enema and should report its findings in the near future (The NHS Health 
Technology Assessment Programme 2006). 
1.1.5 Treatment and long-term prospects for patients 
As discussed earlier, patient prognosis is closely linked to staging of the tumour. 
The prognosis for Dukes' A and Dukes' B patients is promising and surgical 
resection of the tumour and surrounding lymphatics alone is often highly effective 
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at curing the disease. In Dukes' 8 patients, there is penetration of the tumour 
through and beyond the submucosa, but at the time of surgery there is no 
evidence of either regional or distant lymph node involvement in the specimen 
removed. The average 5-year disease free survival rate for this group of patients 
is approximately 65 to 70% following surgical resection. However, just like their 
tumours, this patient subgroup is heterogeneous and a subset of patients exhibit 
a much poorer outcome which more closely resembles that more typically 
associated with Dukes' C patients where regional and distant lymph node 
involvement has been detected. Within this group, the average 5-year disease 
free survival falls to around 40% 
The presence of lymph node involvement in Dukes' C patients predicts a 60% 
chance of recurrence within 5 years and as such, adjuvant chemdtherapy and 
sometimes radiotherapy (in rectal cancer patients) is routinely administered to 
patients following surgery if they are well enough to tolerate it. However, in 
Dukes' 8 patients, such adjuvant therapy is not routinely administered unless it is 
deemed necessary by the surgical team or pathologist. For Dukes' D patients, 
where distant metastases have been found, or in patients harbouring locally 
inoperable primary tumours adjuvant therapy is usually only administered in a 
palliative capacity. For patients with advanced (Dukes' D) colorectal cancer the 
median survival is around six months and it has been shown that chemotherapy 
can improve this median survival by three to four months (Simmonds 2000). 
1. 1.5.1 The effects of Adjuvant and Neo-adjuvant therapy on patient 
outcome 
There is evidence to suggest that a 6-month course of intravenous adjuvant 
chemotherapy following surgery significantly reduces the chance of colon cancer 
recurrence and improves five year disease free survival across the board by 
approximately 5 to 6% (Dube, Heyen et al. 1997). Evidence for the benefits of 
adjuvant chemotherapy for rectal cancer patients is less clear but results from 
randomised clinical trials do show an improvement in disease free survival (Lee, 
Ahn et al. 2002). Combined radiotherapy and chemotherapy delivered before 
surgery (so-called 'neo-adjuvant therapy') has also been shown to reduce the 
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chance of recurren~e of rectal cancer and may also improve the overall patient 
survival (Schaffer, lfhoma et al. 2002). 
Across the Dukes' staging system, clinical trials have shown that treatment with 
! 
a post-operative course of adjuvant chemotherapy in Dukes' C patients can 
! I 
reduce the recurrence rate from 60% to between 40% and 50% and has also 
been shown to red~ce the overall death rate by 16-33% . Hence, in light of this 
I 
and other such evidence, it has now made this the standard of care fbr all Dukes' 
I 
C patients in the UK. 
However, results arf less clear with regard to Dukes' 8 patients where only 30% 
to 40% will develop a recurrence and ultimately die from the disease within 5 
I 
years. Adjuvant po~t-operative chemotherapy is not routinely administered, since 
its benefits in Dukbs· 8 patients has been harder to determine and remains 
controversial. Data I from trials undertaken and statistical reviews have shown 
that insufficient nu~bers of patients are frequently used in trials and the ability to 
detect treatment benefits in these patients is heavily influenced by experimental 
I 
approach. That said, adjuvant chemotherapy is becoming more widely used in 
daily practice worlbwide to treat certain Dukes' 8 patients that it is thought 
I 
requires or may behefit from such therapy. However, the eligibility of a Dukes' 8 
patient for adjuvant! chemotherapy is still based on clinical and histopathological 
factors associated with recurrence. Among them are low-grade tumour 
differentiation; infiltration of perineurium, veins or lymphatics; intestinal 
I 
obstruction; bowel[ wall perforation at time of surgery and young age. 
Interestingly, the cqmbined use of radiotherapy in association with chemotherapy 
has also been e~aluated (Wolmark, Wieand et al. 2000) yet showed no 
I 
measurable beneficial effect on disease survival in rectal cancer patients 
[Comprehensively i reviewed (Sanghera, Wong et al. 2008)]. Radiotherapy 
' however is not use.d for cancer of the colon since the morbidity associated with 
' 
its use on the abdomen is prohibitive. 
I 
I 
I 
Mainstream admir;~istration of adjuvant chemotherapy usually includes a 
' 
combination of 5-FI:uorouracil with either high or low does of leucovorin in weekly 
I 
I 
or monthly doses :over a 6-month period. There is also the option of adding 
irinotecan and oxallplatin (N.I.C.E. 2005b) or irinotecan may also be given alone 
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as a second-line treatment. Several other drugs, including bevacizumab (trade 
name Avastin) which is a monoclonal antibody against vascular endothelial 
growth factor (v-EGF) and cetuximab (trade name Erbitux) which is a chimeric 
monoclonal antibody against epidermal growth factor receptor (EGFR), are 
currently being evaluated in clinical trials as single agents or in combination, for 
both first and second line treatment (N.I.C.E. 2005c). Other clinical trials are 
investigating the optimum dose schedules and how best to administer adjuvant 
therapy, and results from these trials may have implications for current treatment 
protocols and may result in changes in drugs routinely used to treat colorectal 
cancer. Thus, the optimal treatment of patients and decision to administer 
adjuvant chemotherapy currently depends on establishing accurate diagnoses 
through a combination of clinical staging and histopathological data that is 
ascertained post-operatively. lt is now mandatory in the NHS for each patient's 
management to be planned by multidisciplinary teams (MDT), which is resulting 
in a rising proportion of patients (Dukes' B especially) being referred for adjuvant 
chemotherapy. 
1.2 Colorectal Carcinogenesis- Aetiology and Pathogenesis 
1.2.1 Maintenance of the Crypt - Wnt signalling and its implications 
in colorectal cancer 
As already mentioned, the turnover of cells at the intercrypt table is extremely 
high, therefore the differentiated population of cells at the apex of the crypt must 
be perpetually replenished via the unidirectional transit amplification and lineage 
specific differentiation of the multipotent stem cells which are postulated to be 
located at the base of the crypt (Gordon and Hermiston 1994; Booth and Potten 
2000; Marshman, Booth et al. 2002). The whole transitional process from 
proliferation to differentiation in the healthy crypts of the colon constitutes what is 
termed the crypt axis. This highly defined axis is maintained by the canonical 
Wingless-lnt (Wnt) signalling pathway which is considered to be the most 
I 
significant regulator of both normal crypt homeostasis and also colorectal cancer 
development (Bienz and Clevers 2000; Gadal and Nehrbass 2002; van de 
Wetering, Sancho et al. 2002; Pinto and Clevers 2005). 
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The Wnt factors are a family of approximately twenty signalling molecules which 
are involved in virtually every developmental process in humans. Biochemically, 
they are secreted glycoproteins and in the case of the colon, they are thought to 
emanate from the base of the intestinal crypts and/or the underlying 
mesenchymal tissue close to the basement membrane, although the exact 
location of their origin in this tissue has not been fully elucidated (Batlle. 
Henderson et al. 2002; Pinto and Clevers 2005). 
The secreted Wnt factors perfuse the colonic epithelium and impose a 
proliferative phenotype on the lower regions of the crypt (Barker and Clevers 
2000). This is done through a signalling cascade which leads to the stabilisation 
of the cytoplasmic protein P-catenin, allowing it to transit to the nucleus and 
engage DNA binding proteins of the T-cell factor I lymphoid enhancing factor 
(Tcf/Lef) family (van de Wetering, Sancho et al. 2002). The interaction of Tcf/Lef 
factors with P-catenin transiently converts them from transcriptional repressors to 
transcriptional activators and initiates transcription of Wnt target genes (Pinto. 
Gregorieff et al. 2003; Logan and Nusse 2004; Pinto and Clevers 2005). 
For a Wnt factor to trigger this canonical signalling cascade it is required to 
interact simultaneously with a Frizzled (Fz) receptor and a co-receptor of the Low 
Density Lipoprotein receptor (Lrp) family, Lrp-5 or Lrp-6 located at the cell 
surface membrane. As a means of control, this whole process is negatively 
regulated by the adenomatous polyposis coli (APC) protein (Korinek, Barker et 
al. 1997). Through its many functional domains, APC interacts with numerous 
proteins and is involved in cell migration, adhesion, chromosome stability and 
cytoskeletal organisation (Abdei-Rahman and Peltomaki 2004). but in this 
instance, its key role is as an essential component of what is known as the 
multiprotein degradation complex, responsible for directly regulating the activity 
of cytoplasmic P-catenin. 
The multiprotein destruction complex consists of several proteins including but 
not limited to: APC; a scaffold protein named Axin; and two serine/threonine 
kinases, glycogen synthase 3p (GSK3p) and casein kinase I (CKI). The role of 
the multiprotein destruction complex is to de-activate P-catenin by 
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phosphorylation, which consequently targets it for ubiquitination by p-transducin 
repeat containing protein (p-TrCP) and then leads to its subsequent degradation 
by the proteasome. Under normal circumstances this process occurs 
constitutively in the absence of a Wnt signal (Bienz and Clevers 2000). Upon 
activation of the canonical Wnt signalling pathway (comprehensively reviewed by 
(Logan and Nusse 2004)], interaction of Wnt ligands with their membrane 
spanning co-receptors, Fz and Lrp5/6, results in the recruitment of Axin and 
another protein, Dishevelled (Dsh), to the plasma membrane. Consequently, the 
multiprotein complex is then dissociated, and P-catenin is no longer 
phosphorylated , thus leaving it free to translocate to the nucleus and initiate 
transcription of target genes (see Figure 1.7). 
In the absence of a Wnt signal, p-catenin levels in the nucleus are low and 
T cf/Lef transcription factors are bound to the transcriptional repressor Groucho 
(Gro) (Cavallo, Cox et al. 1998). In the presence of a Wnt signal, stabil ised 
nuclear p-catenin is able to overcome this repression by direct association with 
Tcf/Lef factors, namely Tcf-4 in the colon, thus transactivating the transcription of 
downstream target genes which includes c-MYC, CCND1 , MMP7, CD44, PLAUR 
and PPARD (Jo and Chung 2005). These downstream target genes are typically 
associated with initiating and driving cellular proliferation, an example being c-
MYC which represses the cell cycle inhibitor p21c1P1/WAF1 and allows cells to 
leave G 1 and enter S phase of the cell cycle. 
Therefore, it would follow that p-catenin/Tcf-4 driven gene transcription could be 
responsible for preserving the stem cell and proliferating progenitor population in 
the lower regions of the crypt which are essential in sustaining the crypt axis and 
replenishing the continual turnover of differentiated cells at the crypt lumen (van 
de Wetering, Cavallo et al. 1997; van de Wetering, Sancho et al. 2002). Since 
Wnt signalling appears to be switched off higher up the crypt in the differentiated 
zone, it would appear that it is a key component in the proliferation/differentiation 
switch associated with crypt regeneration. 
With that in mind, Wnt signalling has been shown to be reinitiated in the earliest 
stages of colorectal tumour development. Immunohistochemical studies of 
aberrant crypt foci (ACF), the earliest and usually benign progenitors of 
20 
colorectal cancer (van de Wetering, Sancho et al. 2002) have shown high 
nuclear accumulation of P-catenin. Mutational analysis of colorectal cancer 
specimens has also shown that in 85% of all patients, there are key truncating 
mutations in the APC protein (Miyoshi, Nagase et al. 1992; Powell, Zilz et al. 
1992; Kinzler and Vogelstein 1996). This same protein is also mutated in the 
hereditary form of colorectal cancer, Familial Adenomatous Polyposis (FAP) 
syndrome. Such truncations are known to disrupt the multiprotein destruction 
complex and lead to constitutively active p-catenin/Tcf-4 signalling (Korinek, 
Barker et al. 1997; Morin, Sparks et al. 1997). 
Hence it can be considered that the APC protein is central to colorectal 
tumourigenesis and may be considered the dominant switch in the malignant 
transformation of normal colonic epithelial cells by imposition of a constitutively 
proliferative phenotype at a very early stage (Fodde, Smits et al. 2001; van de 
Wetering, Sancho et al. 2002). 
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Figure 1. 7 Diagrammatic representation of the canonical Wnt Signalling pathway 
1.2.2 Molecular basis of tumour initiation and subsequent 
progression 
As I have already discussed, in order to maintain the surface lining of the colon, 
the cellular behaviour is strictly regulated and there is normally a perfect 
homeostatic balance between proliferation and apoptosis. As with all 
developmental processes, this regulation relies on a complex system of signals 
and as such, any disruption of this homeostasis has the potential to allow cells to 
escape the tight constraints used to control them. Tumourigenesis is a complex, 
multi-step process in which this delicate balance is upset, producing cells with 
significant survival advantages and ultimately leading to their often aggressive 
clonal expansion. The sequence in which the steps of tumourigenesis occur are 
reflected in the rate-limiting stages of tumour progression. 
Generally, the genes implicated in tumourigenesis are divided into three main 
categories: oncogenes, tumour-suppressor genes and DNA stability genes. In 
the general sense, oncogenes promote and drive cellular proliferation and 
growth. Mutations in oncogenes will result in constitutively active gene products 
and therefore mutations in a single oncogene allele are sufficient to initiate or 
promote tumourigenesis. As of yet, there have been no reports of inherited 
oncogenic mutations leading to colorectal cancer. Tumour-suppressor genes on 
the other hand are responsible for down-regulating the growth-stimulatory 
pathways. Thus, a mutation in both alleles of a tumour-suppressor gene is 
required in order to inactivate gene function completely, known as the two-hit 
hypothesis (Knudson 1971 ). In sporadic colorectal cancer, both of these "hits" 
can be somatically acquired through a variety of mechanisms, e.g. promoter 
hypermethylation, point mutation, deletion or chromosomal rearrangement. In 
autosomal dominant hereditary colorectal cancer syndromes, such as Familial 
Adenomatous Polyposis (FAP), one allele is mutated in the germline and the 
second is somatically mutated. Such a condition drastically increases the 
chances of loss of heterozygosity (LOH) [discussed by (Muller, Heinimann et al. 
2000)]. The mutated tumour-suppressor genes inherited in other hereditary 
colorectal cancer syndromes include, Bone Morphogenic Protein Receptor 1A 
(BMPR1A) and Mothers Against Decapentaplegic (Drosophila) Homolog 4 
(SMAD4) in Juvenile Polyposis Syndrome (JPS), and Serineffhreonine Kinase 
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11 (STK11) in Peutz-Jeghers Syndrome (PJS). The role of DNA stability genes is 
to help maintain the integrity of the genome by repairing DNA replication errors, 
inhibiting recombination between non-identical DNA sequences and eliciting 
cellular responses to DNA damage. When these systems are dysfunctional, 
deleterious mutations can accumulate throughout the genome rapidly increasing 
tumour progression. Examples of DNA stability genes mutated in hereditary 
colorectal cancer syndromes include the MisMatch Repair (MMR) genes in 
Lynch syndrome and mutY homolog (E.coli) (MUTYH) in recessive adenomatous 
polyposis syndrome. 
Hence, with this in mind, one of the key molecular steps, not only in colorectal 
cancer, but in all types of cancer formation is the loss of genomic stabilisation 
(Lengauer, Kinzler et al. 1998). When considering colorectal cancer, this can 
occur in one of two ways. In the classic adenoma-carcinoma sequence pathway 
(see Figure 1.8), the major driving force is chromosome instability (CIN) leading 
to loss of heterozygosity. More recently though, another mechanism known as 
Microsatellite Instability (MSI) has been attributed to a small subset of colorectal 
cancer cases, which whilst sharing some similar mechanisms as CIN, the main 
driving force behind neoplasia in these cases is the loss of MMR gene function. 
Underlying the whole process of colorectal tumourigenesis is a series of 
successive, cumulative genetic alterations. The most common genetic alterations 
in sporadic colorectal cancers are activating mutations in the oncogene Kirsten-
ras (Ki-ras) and mutation or loss of the tumour suppressor genes; APC, SMAD4 
and TP53. lt is widely accepted that colorectal adenomas typically develop from 
the normal stem cells at the base of the colorectal crypts through acquisition of 
such mutations . The vast majority of colorectal tumours then progress through a 
series of histopathological stages starting with the formation of dysplastic crypts 
leading to adenomas or polyps. The first somatic mutation is thought to cause 
clonal expansion of progenitor cells that initiates the neoplastic process 
producing the polyp . Hence, colorectal polyps are essentially hyperplastic 
growths that project from the lining of the colon or rectum. They can be sessile or 
pedunculate, single or multiple, but are usually benign. Histologically they are 
divided into hamartomatous, serrated and adenomatous polyps but they are 
seldom symptomatic. Their significance however lies in their potential for 
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malignant transformation. Polyps will then go on to form benign adenomas 
through a series of successive somatic mutations resulting in additional rounds 
of clonal expansion. Adenomas can vary in size from less than 1 cm up to and 
above 4cm in size (see figure 1.9 B-0), but size is by no means a deciding factor 
in undergoing further malignant transformation to produce invasive tumours with 
metastatic properties. Hence the progression of a dysplastic crypt into a 
malignant tumour is the result of a series of cumulative genetic and sometimes 
epigenetic changes involving the activation of oncogenes and inactivation of 
tumour suppressor genes controlling cell growth, differentiation and apoptosis . 
To put it into perspective, this chain of events is thought to occur by chance and 
can take anywhere from 5 to 40 years. 
Full blown adenocarcinomas themselves can be both polypoid vegetat1ng 
masses (see figure 1.9 E) and flat, infiltrating lesions, which are often ulcerated 
(see figure 1.9 F). They have the potential to reach large dimensions, especially 
when located in the caecum or ascending colon, but most colorectal 
malignancies are typically located distal to the splenic flexure, in the rectum, 
rectosigmoid junction and sigmoid colon. Colorectal malignancies will grow both 
longitudinally and laterally, often aggressively infiltrating surrounding organs, 
although at present, there is little consistent evidence to suggest that either the 
actual size or degree of differentiation of the tumours is tightly associated with 
the clinical outcome (Ponz de Lean and Di Gregorio 2001 ). 
Figure 1.8 shows a diagrammatic representation of the classical adenoma-
carcinoma sequence of events highlighting genetic alterations in both the CIN 
and MSI pathways of colorectal tumourigenesis. Figure 1.9 shows the stages of 
development of colorectal adenocarcinomas from normal colon to malignant 
carcinoma as viewed by colonoscopic investigation. 
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Figure 1.9 Colonoscopic views of (A) Normal colon (B-D) Colorectal Adenomas of increasing size (E) Polypoid vegetating 
adenocarcinoma (F) Flat infiltrating adenocarcinoma 
1.2.3 Environmental factors associated with colorectal cancer 
lt is estimated that the contribution of genetic factors alone to the development of 
colorectal cancer is somewhere in the region of 35%, and hence the remaining 
65% is due to environmental factors (Lichtenstein, Holm et al. 2000). There is a 
vast amount of research that has been and is still being undertaken concerning 
the role of lifestyle and diet in the development of colorectal cancer. This has 
been comprehensively reviewed for instance by Potter (Potter 1999); and more 
recently the final, international, commissioned report from the World Cancer 
Research Fund in collaboration with the American Institute for Cancer Research 
(World Cancer Research Fund 2007). Whilst Potter discusses the increased 
colorectal cancer risk associated with intake of processed red meat and animal 
fat, alcohol and smoking, the World Cancer Research Fund report systematically 
reviews all factors of diet, nutrition and lifestyle in relation to not just colorectal 
but all major cancers worldwide. 
lt has more recently been shown too that Nonsteroidal Anti-Inflammatory Drugs 
(NSAIDs) have been consistently associated with reductions in colorectal cancer 
risks, as have hormone replacement therapies. In addition, patients with 
inflammatory bowel disease, both ulcerative colitis and Crohn's disease, are 
widely accepted to be at an increased risk of developing colorectal cancer 
(ltzkowitz and Yio 2004), with the colorectal cancer risk in these cases being 
related to the chronic inflammation. 
lt is now widely accepted that many environmental factors may exert direct 
effects on colorectal carcinogenesis by means of induction of DNA damage 
(Young 2007). The result of such mutations subsequently affects the function of 
the encoded proteins and as a result may drive the selection of tumours 
harbouring specific mutations. A few molecular epidemiological studies have 
included the mutation status of the tumour (i.e. Ki-ras oncogene, APC and TP53 
status, as well as microsatellite instability) and have observed differences in 
associations between lifestyle and diet and colorectal tumours with and without 
such aberrations. 
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1.2.3.6 Obesity 
There is increasing evidence that the dysregulation of energy homeostasis in the 
body is associated with colorectal carcinogenesis (Cancerbackup 2008). 
Epidemiological data have consistently demonstrated a positive relation between 
increased body size and colorectal malignancy from as early as 1988 (Kiatsky, 
Armstrong et al. 1988) and almost every year throughout the last two decades 
[for example (Suadicani P 1993; Schoen, Tangen et al. 1999; Shimizu , Nagata et 
al. 2003; Pischon, Lahmann et al. 2006)] [systematically reviewed by (World 
Cancer Research Fund 2007)]. 
The phenomenon of "insulin resistance" or the impaired ability to normalise 
plasma glucose levels is considered the root cause, but other mechanisms have 
also been advanced (Gunter and Leitzmann 2006). Obesity-induced insulin 
resistance leads to elevated levels of plasma insulin, glucose and fatty acids. 
Exposure of colonic crypt cells to heightened concentrations of insulin is thought 
to induce a mitogenic effect within these cells, whereas exposure to glucose and 
fatty acids may induce metabolic perturbations, alterations in cell signalling 
pathways and oxidative stress (Gunter and Leitzmann 2006). 
Family based studies have shown that the propensity to become obese is a 
heritable trait, but it typically only manifests in situations of excess energy intake 
over expenditure. Therefore, inheritance of a genetic profile that predisposes to 
increased body size may also be predictive of colorectal cancer (Abate 2000) . 
To date, some sixty cohort studies and 86 case-control studies investigated body 
fatness (as measured by BMI) and cancers of the colon and rectum [extensively 
reviewed by (World Cancer Research Fund 2007)]. Most of the cohort studies 
showed increased risk with increased body fatness which was statistically 
significant in approximately half of the studies. When stratified according to 
cancer site, the World Cancer Research Fund report also suggests a larger and 
more consistent increased risk for colon cancer than for rectal cancer or for 
colorectal cancer as a whole. 
29 
1.2.3.3 Dietary Fat 
lt is thought that dietary fats may exert direct effects on colorectal 
tumourigenesis by augmenting bile acid production and subsequently resulting in 
increased colonic cell proliferation, ultimately increasing the risk of endogenous 
mutations. This is as well as the obvious associations of high dietary fat intake 
and increased BMI. Systemic effects of high dietary fat intake include the effect 
of specific types of fat on membrane characteristics of cells. Such changes in 
membrane characteristics are thought to increase the risk of insulin resistance 
and hence survival in tumour cells, decrease the protective effect of n-3 fatty 
acids by decreasing prostaglandin E2 production, and alter the effects of 
essential polyunsaturated fatty acids on inflammatory responses . 
Previously there has been an emphasis on the quantity of total fat in the diet; 
however research is now suggesting that it is in fact the fat quality in combination 
with quantity which is more important in predisposing an individual to colorectal 
cancer (World Cancer Research Fund 2007). For example, n-3 polyunsaturated 
fatty acids (PUFA) seem to have protective properties at different stages of 
colorectal carcinogenesis , whereas n-6 PUFAs are though to increase the risk of 
colorectal cancer. A plausible explanation of the potentially carcinogenic 
properties of the n-6 PUFA lies in the peroxidation products of malondialdehyde 
and 4-hydroxynonenal that can readily form adducts with DNA and induce G -+ T 
and G ~ A transitions . 
Investigations into the direct effect of dietary fat on specific mutations associated 
with colorectal tumourigenesis have shown there is an increased risk of tumours 
harbouring mutant Ki-ras with low dietary fat intake and low mono-unsaturated 
fatty acid intake . Similarly, Slattery et al showed strong associations between 
the quantity of dietary fat, saturated fats and mono-unsaturated fatty acids and 
tumours harbouring G-+ T mutations in the Ki-ras gene. This was then further 
supported in 2004 when it was observed that there was an increased risk of Ki-
ras mutations associated with high consumption of polyunsaturated fatty acids 
and linoleic acid . 
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With regard to mutations in the APC gene, a recent case-control study showed, 
that a high intake of dietary fat seemed to increase the risk of adenomas without 
truncating APC mutations . However, in terms of colorectal cancer, positive 
associations were observed for high dietary fat intake and tumours that did 
harbour truncating APC mutations . 
1.2.3.5 Alcohol 
Irrespective of the type of drink, alcohol (ethanol) is classified by the International 
Agency for Cancer Research as a human carcinogen (IACR 2008). The 
evidence that alcoholic drinks are a cause of cancers of the mouth, pharynx, and 
larynx, oesophagus, colorectum, and breast is convincing (World Cancer 
Research Fund 2007). Early reports concerned with food, nutrition, and the 
prevention of disease have often excluded alcohol. This is because alcohol is 
also a drug, the impact of which is behavioural and social, as well as biological. 
More recently, alcoholic drinks have been included in such reports because of 
the evidence that low to moderate consumption protects against coronary heart 
disease (but not cerebrovascular disease), and also because of the evidence on 
cancer, given that ethanol is a human carcinogen. 
In terms of colorectal cancer, to date 37 cohort studies have investigated 
alcoholic drinks and colorectal cancer and 41 case-control studies have 
investigated ethanol intake and colorectal cancer. Of these, 18 of the cohort 
studies showed an increased risk for the highest intake group when compared to 
the lowest, which was statistically significant in four. One study showed a non-
significant Increased risk in men and non-significant decreased risk in women. 
Two studies reported no effect on risk and three studies reported a decreased 
risk; none was statistically significant (World Cancer Research Fund 2007). 
Despite the evidence being weaker than was initially assumed, it has led the 
World Cancer Research fund to conclude in their 2007 report that "There is 
ample and generally consistent evidence from cohort studies. A dose-response 
is apparent. There is evidence for plausible mechanisms. The evidence that 
consumption of more than 30 g/day of ethanol from alcoholic drinks is a cause of 
colorectal cancer in men is convincing, and probably also in women'' 
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1.2.3.1 Meat and Fish 
The EPIC study (European Prospective Investigation into Cancer and Nutrition), 
based on about 1,300 colorectal cancer cases, has shown a significant (55%) 
increase in colorectal cancer risk associated with a 1 OOg/day increase in 
consumption of red and processed meat (Norat, Bingham et al. 2005). 
This is supported by results of two meta-analyses, one of which found a 
significant risk increase for colorectal cancer with higher consumption of red 
meat and processed meat (Norat, Lukanova et al. 2002), and another showing 
significant positive associations with all meat, red meat, and the strongest 
increase for processed meat (49% risk increase for a 25 g/day serving) (Sandhu, 
White et al. 2001 ). 
A large US case-control study has also reported that the highest risks are 
associated with fried meat and the lowest for baked or boiled, which may be 
related to formation of heterocyclic aromatic amines produced during the cooking 
process (Butler, Sinha et al. 2003). The EPIC study has also shown a significant 
risk reduction of approximately 50% with increased intakes of fish , including 
fresh, canned , salted and smoked (Norat, Bingham et al. 2005). 
1.2.3.2 Dietary Fibre 
Concomitantly, the EPIC study has shown a lower risk of colorectal cancer with 
higher fibre intake, (after adjustment for a number of potential confounding 
factors, including folate) (Bingham, Norat et al. 2005). There was about a 20% 
reduction in risk of colorectal cancer in men and women in the highest quintile of 
fibre consumption, compared to the lowest. The association was strongest for 
left-sided colon cancer (sigmoid colon, rectosigmoid junction), with a greater than 
40% risk reduction for the highest quintile of fibre intake. However, as with many 
other studies, there was no significant risk reduction shown for rectal cancer. 
Recently however, a new meta-analysis study, excluding the results of the 
aforementioned EPIC study, showed no significant reduction in risk of colorectal 
cancer with higher than normal fibre intake, but did show that very low fibre 
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intake (less than 10 g/day) significantly increases the risk of colorectal cancer 
(Park, Hunter et al. 2005). 
One of the biggest problems however, is that in some studies published, the 
apparent null findings may be due to flawed experimental design such as an 
insufficient range of fibre intake or other methodological problems. Alternatively, 
it could be considered that other immeasurable features of such a high fibre diet 
(i.e. a plant-based diet rich in fruits, vegetables, and whole grains) could be 
responsible for the protective effects observed. Despite the apparent lack of 
consensus, investigators agree that fibre should generally be eaten as part of a 
healthy diet because of its potential to prevent colorectal cancer as well as its 
beneficial effects on other chronic diseases, such as heart disease and diabetes. 
1.2.3.4 Cigarette smoking 
Aside from the obvious implications associated with lung cancer and heart 
disease, it is also postulated that the carcinogenic compounds present in 
tobacco smoke may cause irreversible damage to the colorectal mucosa . The 
burning of tobacco produces numerous genotoxic compounds including 
polycyclic aromatic hydrocarbons (PAH), heterocyclic aromatic amines (HCA), 
and N-nitrosamines . The colon and rectum may become exposed to these 
carcinogens either directly by ingestion of tobacco smoke or indirectly, through 
contact with blood or bile that may contain potential carcinogens . In rodent 
studies, benzo(a)pyrene was found to induce G~ T transversions and N-
nitrosamines to induce G:C-+ A:T transitions in the ras family of oncogenes , 
both of which are major constituents of cigarette smoke. Cigarette smoking has 
also been associated with microsatellite instable colorectal tumours in three 
case-control studies 
Thus it would seem that environmental and genetic influences go hand in hand 
throughout every step of colorectal tumourigenesis. Where genetic alterations 
are not hereditary, environmental factors provide the causative and also catalytic 
effect. 
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1.2.4 Differences in sporadic and hereditary cases 
Colorectal cancer is traditionally classified as either sporadic or familial , but 
these concepts are rapidly becoming less tenable in respect of the ever 
increasing understanding of the underlying mechanisms of tumourigenesis. A 
seemingly familial occurrence of cancer may not be due to genetic inheritance, 
but due to chance or more likely a shared environment. Conversely, colorectal 
cancer that appears to be sporadic may in fact be part of an unrecognised or 
undocumented familial syndrome, concealed by a small family size, reduced 
penetrance, or poor diagnostics. 
Sporadic cases of colorectal cancer are currently estimated to account for 
approximately 75% of all colorectal cancer cases and are most strongly 
associated with the aged population (Toms 2004) due to long-term exposure to 
risk factors such as those previously discussed (Potter 1999; Terry, Giovannucci 
et al. 2001 ). The majority (-85%) of colorectal cancer patients are diagnosed in 
the sixth decade of life or later. lt is thought that colorectal cancer causing 
genetic alterations may start accumulating approximately 10 years prior to the 
development of the tumour. Cases of colorectal cancer in much younger 
individuals are almost always likely to be the result of an inherited predisposition 
to the disease. 
As already mentioned, genetic predisposition to colorectal cancer greatly 
increases the chance of polyps forming and leads to the earlier onset of the 
disease. Hereditary forms of the disease are usually autosomal dominant and 
categorised according to symptoms, tumour pathology and age of onset. Certain 
'Cancer families' have been identified in which members carry hereditary 
colorectal cancer-causing mutations, and the first such family to be diagnosed 
with hereditary bowel cancer in Britain originated from West Cornforth, County 
Durham (Dunstone and Knaggs 1972). 
Three types of hereditary colorectal cancer syndrome are recognised and 
described below. In most cases, the predisposing germ-line aberration has been 
identified . 
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1.2.4.1 Familial Adenomatous Polyposis Syndrome 
The familia l adenomatous polyposis (FAP) syndrome is a rare autosomal 
dominant disease with a prevalence of approximately 1/8000 (Abdei-Rahman 
and Peltomaki 2004) and is marked by a germ line mutation in the Adenomatous 
Polyposis Coli (APC) gene that predisposes individuals to developing large 
numbers (often thousands) of benign adenomas (polyps) throughout the length 
of the colon. These polyps have the potential to eventually develop into 
malignant carcinomas . FAP currently accounts for approximately 1% of all 
colorectal cancers in the west; with the average age of polyp appearance of 
affected individuals being 16 years of age. Since the penetrance of this 
syndrome is 100%, the average age of colorectal cancer diagnosis in these 
patients if the polyps are left untreated is 40 years, but inter- and intra-familial 
variation is common. 
The gene for FAP, the APC tumour suppressor gene is located on chromosome 
5q21-q22 (Bodmer, Bailey et al. 1987). The mutation spectrum is very wide, and 
more than 800 different germline mutations have been found. The different 
mutation sites within the gene are associated with varying severities of the 
disease, though people with the same germline mutation may also show different 
disease manifestations. Typically, the germline mutations associated with FAP 
are confined to the 5' half of the APC gene, whereas somatic mutations which 
are responsible for 85% of sporadic cases are clustered to the central region of 
the open reading frame, spanning codons 1,286 to 1,513 of exon 15 . Although 
this mutation cluster region represents only 8% of the 8,535 bp APC gene. 68% 
to 77% of somatic mutations in APC are found in this region . A few recurrent 
mutations are known, but there are no hotspots which account for more than 
10% of the total known mutations. Interestingly, approximately 20-25% of 
mutations are de novo, suggesting that other factors may act as modifiers. 
1.2.4.2 Hereditary Non-polyposis Co/orectal Cancer 
HNPCC, more commonly known as Lynch syndrome, is estimated to be 
responsible for approximately 2-5% of all colorectal cancer cases. lt is the most 
commonly inherited form of colorectal cancer and increases the lifetime risk of a 
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patient to approximately 80-85% (Aarnio, Mecklin et al. 1995; Dunlop, Farrington 
et al. 1997; Lynch and de la Chapelle 1999; de la Chapelle 2004 ). HNPCC is 
characterised by early onset of colorectal cancer, but is also associated with 
non-colorectal tumours, including cancers of the endometrium, ovaries, stomach, 
pancreatico-biliary system, brain and urinary tract. 
HNPCC is caused by a fault in DNA mismatch repair (MMR) genes; with faults in 
the MMR genes hMSH2 and hMLH1 accounting for over 90% of detectable 
mutations in HNPCC patients (Liu, Parsons et al. 1996). Pilot studies in 
colorectal cancer patients under 30 years of age have shown that 41 % are 
carriers of MMR gene mutations (Farrington, Lin-Goerke et al. 1998). Such 
mutations allow deleterious changes in the mainstream cancer genes (APC, Ki-
ras and TP53) to persist and lead to development of colorectal cancer (Leach , 
Nicolaides et al. 1993; Thibodeau, Bren et al. 1993). 
Genetic testing for predisposing mutations in people with a strong family history 
of these cancers enables screening and prevention to be targeted to those most 
at risk. For people with a known mutation, especially young patients from 
HNPCC families, prophylactic surgery is often recommended, and currently a 
study in Scotland is screening all newly diagnosed colorectal cancer patients 
under the age of 55 years for MMR gene mutations. 
1.2.4.3 Hamartomatous Polyposis Syndromes 
Apart from FAP and HNPCC, hereditary factors are estimated to account for 
approximately 15-20% of colorectal cancer cases and a national collaborative 
study is currently underway to identify other genes involved in familia l colorectal 
cancer (Penegar, Wood et al. 2007). 
Currently hamartomatous polyposis syndromes can be subdivided into four 
distinct syndromes; Cowden Syndrome (CS), Bannayan-Riley-Ruvalcaba 
Syndrome (BRR), Juvenile Polyposis Syndrome (JPS) and Peutz-Jeghers 
Syndrome (PJS) (Muller, Heinimann et al. 2000; Fearnhead, Wilding et al. 2002) 
All of them predispose the sufferer to the development of multiple 
hamartomatous polyps and subsequent increased risk of gastrointestinal 
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malignancy. Germ-line mutations in the tumour-suppressor gene Phosphatase 
and Tensin homolog (PTEN) have been implicated in CS, BRR and JPS (Li, Yen 
et al. 1997; Marsh, Coulon et al. 1998) whilst germ-line mutations in 
serine/threonine kinases LBK1 and STK11 have been implicated in PJS 
(Hemminki, Markie et al. 1998; Jenne, Reimann et al. 1998). In addition to these 
high-risk predispositions, polymorphisms with moderate risk effects have also 
been described, and include variants in the APC, Harvey ras-1 variable number 
tandem repeat polymorphism (HRAS1-VNTR) and Methylene-Tetra-Hydro-
Folate-Reductase (MTHFR) genes (Houlston and Tomlinson 2001 ). Interestingly, 
the mutations behind these syndromes are rarely if at all seen in sporadic 
colorectal cancer. 
Other conditions which have also been linked to an increased risk of colorectal 
cancer include ulcerative colitis (UC) and Crohn's disease. UC is estimated to be 
responsible for around 1% of cases (Winawer 1999). Recent research suggests 
that environmental factors related to long-term inflammation of the bowel may 
contribute more to the increased cancer risk in UC than the associated inherited 
susceptibility (Wong and Harrison 2001 ). 
1.3 Biomarkers- risk factors and indicators 
The biggest limitation of all the current clinicopathological diagnostic staging 
systems is that they fail to discriminate the innate biological behaviour of 
tumours. lt has been clear for some time now that in order to address this 
problem, measurable biomarkers are needed, which can be used not in place of, 
but in conjunction with the current staging systems to allow more accurate 
predictions of patient prognosis in situations where clinical staging alone may be 
problematic and potentially misleading. This would for example, aid identification 
of high-risk Dukes' 8 patients with resected, lymph node-negative tumours that 
are likely to experience relapse. Such stratification could be carried out on pre-
operative samples which would then allow more informed planning for patients in 
terms of surgery and/or postoperative adjuvant therapies. lt would also provide 
an innovative approach for designing targeted trials to assess the benefits of 
adjuvant chemotherapy. 
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A biomarker is typically any substance that can be measured biologically and is 
associated with an increased or decreased risk of the disease. Biomarkers can 
either be present in the serum, or be genetic testing factors, and currently both 
are being studied acutely to elucidate markers that may be of use at any stage 
during the treatment of cancer. 
1.3.1 Serum Biomarkers 
Serum biomarkers are produced by the body's organs and in the case of cancer, 
by the tumours themselves (Maurya, Meleady et al. 2007). Changes in the level 
of such serum biomarkers may be indicative of tumour activity, but many of the 
current biomarkers are non-specific for cancer and are produced by normal 
organs as well, so their application must be scrutinised. 
One serum biomarker which is widely used today, and currently one of the few 
used consistently in primary care is Prostate Specific Antigen (PSA). PSA is 
produced by normal prostate cells in relatively small amounts, but it has been 
shown that elevated levels of PSA in the serum can be correlated with the 
existence of prostate cancer. However, there are also several reasons other than 
cancer that can cause a rise in PSA. For example, infection in the prostate 
(prostatitis), and even vigorous physical examination by a doctor can cause a 
PSA rise (Cancerbackup 2008). Instead, it is important to monitor factors such 
as the degree of elevation, the rapidity of increase, and the fraction of free non-
bound PSA (higher in benign causes) together in order to determine the next 
step. While no treatment is ever based solely on PSA levels, alterations above 
normal can spur further diagnostic testing to catch the disease at an early stage. 
In terms of colorectal cancer, carcinoembryonic antigen (CEA) is another 
biomarker that is routinely used in patient treatment (Cancerbackup 2008). CEA 
levels are elevated in patients with colorectal cancer; however, it is also elevated 
in patients with breast, lung, and pancreatic cancer as well as by other 
environmental factors. As a screening test, its uses are limited as it can also be 
elevated by other factors such as smoking for instance. However, its use 
following surgery is more informative. CEA levels can be monitored both pre and 
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post-operatively. CEA levels typically fall after surgical resection , and elevation 
following surgery may be indicative of the need for additional adjuvant therapies, 
whereas elevation in the long term may be indicative of local or distant relapse. 
1.3.2 Genetic Biomarkers 
So called genetic biomarkers for colorectal cancer fall into roughly six categories; 
oncogenes and tumour suppressor markers such as TP53, Bc/-2, Ki-ras and 
DCC; proliferation markers such as Proliferating Cell Nuclear Antigen (PCNA), 
Ki67 and Mib-1; DNA mismatch repair such as hMLH1; metastatic markers such 
as matrix metalloproteinases; angiogenesis markers such as v-EGF; and other 
biochemical markers such as thymidylate synthase. The use of 
immunohistochemical methods to detect these tumour-associated antigens is 
preferred in the clinical setting to the more complex and time-consuming real 
time techniques such as flow cytometry. 
Most immunohistochemical analysis of oncogenes and tumour suppressor genes 
relies on detecting aberrant expression of the protein within the cell. Increased or 
decreased levels of the protein can potentially be used to predict prognosis in 
patients, but there still exists a controversy over its reliability. For example, 
mutations in TP53 can be easily detected as a nuclear accumulation of the 
protein. Whilst this is a simple and effective technique it relies on a simple 
assumption that a genetic change in the TP53 protein will always lead to it's over 
expression. Similarly, it also assumes that an observed increase in TP53 
expression is a result of mutation within the gene. Nevertheless, there is a strong 
correlation between TP53 gene status and TP53 staining although there is a 
great deal of concern in light of so many conflicting studies as to whether this 
marker can provide significant prognostic information at present [reviewed 
(Joerger and Fersht 2007)]. 
Like TP53, studies into the use of Ki-ras as a prognostic marker for colorectal 
cancer show conflicting data, even within the international RASCAL studies 
(Andreyev, Norman et al. 1998; Andreyev, Norman et al. 2001). Whilst Ki-ras 
mutations occur in approximately 30% of colorectal cancers, mutational analysis 
has shown that not all Ki-ras mutations lead to a more aggressive tumour and 
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subsequently poorer prognosis (Andreyev, Norman et al. 2001 ). For th is reason 
alone, Ki-ras mutational status does not currently seem to be the best candidate 
for predicting patient prognosis. 
PCNA, Ki67 and Mib-1 are the favourite and most promising proliferative 
biomarkers being investigated at the moment, but to date most of the studies 
have shown little prognostic significance. A study by Palmqvist (Palmqvist. 
Sellberg et al. 1999) has however shown prognostic significance in Dukes' B, 
node-negative patients for Ki67 when determined at the invasive edge alone. 
With little evidence to support large-scale prospective studies in current 
biomarkers, attention has more recently been focussed on looking for new 
proliferative biomarkers and as such, cyclins involved in cell cycle regulation 
have been targeted. Such studies have looked at the prognostic significance of 
Cyclin A and p27/Kipl (a putative tumour suppressor) but have yet to provide 
conclusive evidence. For a comprehensive review of many of these markers see 
(Graziano and Cascinu 2003). 
The identification of other individual biomarkers such as Osteopontin; Neuregulin 
and 8-cell lymphoma/leukaemia-2 (Bc/-2) to name a couple, have been 
investigated for several years now. More recently however, work in cell lines has 
shown that transforming growth factors TGF-a and TGF-{31 have mitogenic 
properties in promoting the growth of colorectal cancer in vitro. This has been 
substantiated in recent investigations in patients linking poor survival in early 
stage colorectal cancer and is emerging as an independent prognostic factor. 
However, since many of these biomarkers are yet to be investigated in large-
scale prospective studies, these apparently promising markers cannot at present 
be adopted as the basis of routine prognostic or diagnostic assays. 
1.3.3 The emerging concept of DNA methylation in colorectal cancer 
As discussed earlier, the loss of DNA stability genes IS one pathway by which 
colorectal tumourigenesis can occur. Typically, this loss of function is through 
hypermethylation in the promoter regions of affected genes, and it is well 
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documented that silencing of the hMLH1 gene is an early event in colorectal 
cancer characterised by microsatellite instability (MSI) (Kane, Loda et al. 1997). 
Aberrant DNA methylation patterns have also been demonstrated in the colonic 
mucosa affected by ulcerative colitis (lssa, Ahuja et al. 2001 ). Similarly, it has 
been described that the 0 6-methylguanine-DNA methyltransferase (MGMT) gene 
promoter is methylated in the normal-appearing colorectal mucosae adjacent to 
colorectal cancer (Shen, Kondo et al. 2005) and that similar MGMT promoter 
hypermethylation occurs in 20% - 40% of colorectal cancers (Nagasaka, Sharp 
et al. 2003). The biological consequence of loss of MGMT expression through 
hypermethylation is that the MGMT protein removes mutagenic adducts from the 
0 6-guanine base residue in DNA. When left unrepaired, 0 6-methylguanine is 
read by DNA polymerase as adenine, resulting in multiple G~A transitions 
(Pegg 1990; Pegg and Byers 1992). Such MGMT silencing has been strongly 
associated with an increase in G~A mutations in the Ki-ras and TP53 genes in 
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colorectal tumours (Esteller, Toyota et al. 2000; Esteller, Risques et al. 2001). 
However, what is still unclear is whether MGMT promoter methylation in 
apparently normal mucosa is associated with an increased risk of colorectal 
cancer, although it would be reasonable to postulate that a neoplastic lesion 
harbouring MGMT promoter methylation is more likely to progress to malignancy 
than one which does not. 
1.3.4 Biomarkers and the pharmacodynamic potency of 
chemopreventative therapy 
Over the past ten years the number of treatment options for colorectal cancer 
has increased with many more therapeutic agents going into clinical 
development. New targeted therapies have been designed whose action is 
directed against particular molecular targets isolated through such biomarker 
studies. Examples include the already mentioned bevacizumab targeted against 
vascular endothelial growth factor (v-EGF) and cetuximab targeted against 
epidermal growth factor receptor (EGFR) (Vanhoefer 2005). These new and 
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emerging adjuvant therapies are currently being tested in combination with 
chemotherapy for both early stage and advanced colorectal cancer. 
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However, one of the greatest challenges in treating colorectal cancer is the 
problem of tumour resistance to chemopreventative therapies. Large-scale DNA 
microarray analysis is currently proving to be a powerful tool in identifying 
biomarkers that will help to predict the best treatment options for individual 
patients (Boyer, Alien et al. 2006). 
1.3.5 The future of Biomarkers 
lt is widely accepted that colorectal cancer progression is a function of multiple 
genetic alterations. As such, many individuals believe that isolating single 
biomarkers will not be reliable enough to be routinely adopted as prognostic or 
diagnostic tools. Instead, a more comprehensive approach should be 
implemented to investigate the molecular events on a wider scale in order to fully 
understand the disease mechanism and be able to predict prognosis in a 
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disease progression of this complexity. The simultaneous testing of multiple 
molecular predictors of survival may supply major information, however in such 
investigations, large multivariate models must be applied which require large 
patient groups for statistical reliability. For now at least, confirmatory 
investigations of single biomarkers in prospective studies of large-scale patient 
groups is the way forward. Such studies can then be implemented into clinical 
trials to identify high and low risk patients. As we move into the 21st century, the 
use of such individual biomarkers in predicting patient prognosis and determining 
the administration of adjuvant therapies will inevitably improve and prolong the 
lives of patients with surgically resected colorectal cancer. 
i 
1.4 Architecture of the Nucleus and implications in disf!ase 
1.4.1 The Nucleus 
At the heart of almost all eukaryotic cells is the complex and vastly dynamic 
structure known as the nucleus. This multifunctional organelle is responsible for 
storing the genetic information of the cell in the form of chromatin, and 
concomitantly regulating the expression of the genes contained within the 
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chromatin throughout all stages of the cell cycle. lt is also a key player in 
controlling the overall dynamics of the mitotic process (Lamond and Earnshaw 
1998; Mizuno 1999). 
1.4.2 The Nuclear Envelope 
The contents of the nucleus are segregated from the rest of the cell by the 
presence of the nuclear envelope, a double membranous structure constructed 
from both phospholipids and proteins (Dessev 1992). As well as providing a 
static, structural barrier role responsible for defining the boundaries of the 
nucleus, it also plays a dynamic role in gene regulation acting as an anchor point 
for the attachment of chromatin and other transcriptional regulators thus 
controlling gene transcription and expression (Pfaller and Newport 1995; 
Marshal!, Dernburg et al. 1996) 
Additionally, the nuclear envelope is studded with channels known as nuclear 
pore complexes (NPCs) which are responsible for governing the passage of 
mRNA out of and other small signalling molecules into the nucleus, thus 
regulating the transmission of information between cytoplasm and nucleoplasm 
(Macara 2001). Complex signalling pathways which originate at the'periphery of 
the cell via cell surface protein receptors and other signalling events often 
cascade in such a manner to direct information to the nucleus (Leonard, lmada 
et al. 1999; Roberts 1999). The convening of these signalling pathways at the 
nucleus then triggers the appropriate cellular response to an event which can 
include, but is not limited to responses modulating the timing of mitosis, altering 
gene expression patterns, and/or initiating an apoptotic program. 
During interphase, the dual membranous structure of the nuclear envelope 
surrounds the nucleus and is comprised of an inner nuclear membrane (INM) 
and an outer nuclear membrane (ONM), the outer being contiguous with the 
endoplasmic reticulum (Worman and Courvalin 2000). The pore membranes, 
where the NPCs reside, form a membranous connection between the INM and 
the ONM. (Ostlund and Worman 2003) as shown in figure 1.1 0. 
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Figure 1.10 Diagrammatic representation of the major structural components of the eukaryotic nucleus 
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1.4.3 The Nuclear Lamina 
In a manner very similar to that of the plasma membrane, the structure and 
stability of the nuclear envelope is responsive to a complex meshwork of 
intermediate filament proteins that underlie the inner nuclear membrane (Fawcett 
1966; Fisher, Chaudhary et al. 1986). Collectively, the components of this 
meshwork are known as the nuclear lamins and the structure they form is more 
formally known as the nuclear lamina (NL) (Stuurman, Heins et al. 1998). The 
nuclear lamina was first isolated from rat liver nuclei in 1976 (Dwyer and Blobel 
1976) and reports vary as to its exact thickness which can range from between 
10 and 100nm (Fawcett 1966; Aaronson and Blobel 1975; Dwyer and Blobel 
1976; Scheer, Kartenbeck et al. 1976; Hoger, Grund et al. 1991 ). Stabilisation of 
the nuclear lamina is mediated through complex interactions with various integral 
membrane proteins of the inner nuclear membrane, and the best characterised 
binding partners of the nuclear lam ins are the lamina associated proteins (LAPs); 
emerin, MAN1 and lamin B recaptor (Hutchison 2002). 
Nuclear lamins are classified as type V intermediate filament family proteins 
because of their close similarities in secondary structural organisation and 
moreover the striking sequence homology of their characteristic a-helical rod 
domain, to that of other intermediate filaments within the cell such as desmin, 
neurofilaments and vimentin (Fisher, Chaudhary et al. 1986; McKeon, Kirschner 
et al. 1986). 
The common secondary structure of intermediate filament proteins comprises a 
non-helical amino-terminal (N-terminal) head domain and a carboxyl-terminal (C-
terminal) tail domain interspersed with a characteristic central coiled-coil a-
helical rod domain. This rod domain is then further subdivided into four distinct 
helical regions, termed 1A, 1 B, 2A and 28. Each helical region is characterised 
by heptad repeats of apolar residues and they are separated by three non-helical 
linker segments (Fuchs and Weber 1994). 
However, despite close similarity to vertebrate cytoplasmic filaments, the nuclear 
lamins differ in that they possess an extended rod domain by virtue of a 42 
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amino acid (six heptad repeat) insertion within coil 1 8 (Erber, Riemer et al. 1998) 
and a somewhat shorter head domain (Fisher, Chaudhary et al. 1986). Similarly, 
in order to facilitate the targeting of nuclear lamins to the nucleus they also 
contain a nuclear localisation signal (NLS) in their tail domain (Loewinger and 
McKeon 1988). Other differences also include the possession of a C-terminal 
CaaX motif (C, Cysteine; a, any aliphatic residue; X, any amino acid) which is 
extremely important for localisation of the nuclear lamins at the inner nuclear 
membrane (Nigg, Kitten et al. 1992). Figure 1.11 shows a diagrammatic 
representation of the intermediate filament structure of nuclear lam ins. 
Var>abe 
gtobu·Dr 
head 
domain 
(short) 1 
A.I;JOtfiOI'<If 
'hJPtad repeal 
Vana!Jie 
giOh\lhlr 
latl 
OI.IIII.Jtll 
. _______,pSS I 6.!:::=:? =::J> caax 
Nlf ~----------------------~ 
u·httltca• co•led-coil domam 
lamln polypeptide 
Figure 1.11 Intermediate filament structure of the nuclear lamins (Adapted from 
(Hutchison and Worman 2004) 
If we look across the animal kingdom, there appears to be a general 
conservation of nuclear lamin structure across organisms. As with other protein 
fami lies, one can observe an increase in the number of genes encoding nuclear 
lamins and also the number of splice isoforms as organism complexity increases. 
For example, in the nematode worm Caenorhabditus elegans, there is only a 
single lamin (LMN-1) gene (Liu, Rolef Ben-Shahar et al. 2000). In the fruit fly 
Drosophila melanogastor there are reported to be two lam in subtypes (DmO and 
lamin C) (Gruenbaum, Landesman et al. 1988; Bossie and Sanders 1993; 
Riemer, Stuurman et al. 1995). As we increase in complexity further, we can 
identify three nuclear lamins in birds (Lehner, Stick et al. 1987) and five in 
amphibians (Benavente, Krohne et al. 1985; Stick 1988; Hofemeister, Kuhn et al 
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2002). When we look at mammalian cells, there are seven nuclear lamins in 
total, which are sub-divided into two groups; the A-type and 8-type lamins. This 
sub-classification is based on their differing biochemical and physiochemical 
properties (i.e. isoelectric point), their ultra structural characteristics, their tissue 
expression specificity and mitotic fate (Gerace and 81obel 1980; Gerace, 
Comeau et al. 1984; Krohne and 8enavente 1986; Gerace and 8urke 1988; 
8roers, Machiels et al. 1997) 
Lam ins A, All1 0, C and C2 are classified as A-type lam ins and are alternative 
splice variants of the LMNA gene (Fisher, Chaudhary et al. 1986; McKeon, 
Kirschner et al. 1986; Furukawa, lnagaki et al. 1994; Machiels, Zorenc et al. 
1996). The LMNA gene has been mapped and shown to be located on 
chromosome 1 q21.1 - 21.3 (Lin and Worman 1993; Wydner, McNeil et al. 1996). 
Lam ins 81, 82 and 83 are classified as 8-type lam ins. Lam in 81 is the only 
product of the LMNB1 gene, located on chromosome 5q23.3 - 31.1 (Lin and 
Worman 1995; Wydner, McNeil et al. 1996), whilst both lamins 82 and 83 are 
alternative splice variants of the LMNB2 gene (Pollard, Chan et al. 1990; 
8iamonti, Giacca et al. 1992; Furukawa and Hotta 1993) found on chromosome 
19p13.3 (8iamonti, Giacca et al. 1992). To date, both lamin C2 and 83 have only 
been detected in male germ cells (Furukawa and Hotta 1993; Furukawa, lnagaki 
et al. 1994). Conversely, lamins A, C All10 are developmentally regulated and 
expressed in most differentiated somatic cells (Rober, Weber et al. 1989; 
Machiels, Zorenc et al. 1996), with the most notable exceptions being the early 
embryo, embryonic stem cells, stem cells of the immune and haematopoietic 
systems as well as in cells of the neuroendocrine system (Gold man, Gruenbaum 
et al. 2002; Mounkes, Kozlov et al. 2003). Lamins 81 and 82 on the other hand 
are expressed in almost all cells since all vertebrate cells express at least one 8-
type lamin (Hutchison and Worman 2004). 
The LMNA gene is composed of 12 exons and it is the alternative splicing of 
these codons which gives rise to the isoforms previously mentioned. The 
alternative splice site for prelamin A (the precursor to lamin A) and lamin C is 
located at cod on 566, situated in exon 10. The alternative splicing gives rise to a 
common 3' end found in lamin A and Lamin C (Lin and Worman 1993) and 
alternate 5' ends. In the lamin C splice variant, codons 567 to 572 are lamin C 
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specific, and hence transcription terminates at codon 572. The prelamin A splice 
variant contains the additional 7 43 nucleotides of exon 11 and 12 which adjoin 
the 3'-end of codon 566, resulting in both exons 11 and 12 being lamin A 
specific. The lamin M10 variant also retains the laminA specific tail domain, but 
consequently misses all 30 amino acids (90 nucleotides) which are encoded by 
exon 10 (Machiels, Zorenc et al. 1996). Thus lam in A; lam in C and: lam in M 10 
only differ in their 5' tail domains, and this alternative splicing of the LMNA gene 
is diagrammatically represented in Figure 1.12. 
The main difference between A-type and B-type lamins is that A-type lamins are 
developmentally regulated and their synthesis appears to accompany cellular 
differentiation with tissue expression patterns being primarily driven by the 
developmental programs controlling embryogenesis and organ differentiation 
(Rober, Weber et al. 1989). Lamins A and C are generally not found in nascent 
embryonic cells, and do not become significantly expressed until after birth 
(Stewart and Burke 1987). In the adult, expression of lamins A and C has been 
reported to be completely absent in haematopoietic, immune and epithelial stem 
cells, however in their progeny, prelamin A expression is observed after 
differentiation (Rober, Gieseler et al. 1990). Interestingly though, the expression 
of lamin A has very recently been shown to be high in the epithelial stem cells of 
the colon located at the base of the intestinal crypts (Willis, Cox et al. 
unpublished data). 
Conversely, B-type lamins are essential for cell survival and consequently, at 
least one B-type lamin is expressed at every stage of development in all cell 
types including adult stem cells (Stick and Hausen 1985; Lebel, Lampron et al. 
1987; Stewart and Burke 1987; Paulin-Levasseur, Giese et al. 1989; Rober, 
Weber et al. 1989; Coates, Hobbs et al. 1996; Broers, Machiels et al. 1997; 
Harborth, Elbashir et al. 2001; Steen and Collas 2001 ). 
Looking more specifically, A-type lamins are expressed predominantly in highly 
differentiated cell types; they are considered neutral and become soluble during 
disassembly of the nuclear envelope during mitotic division. This is in contrast, to 
the B-type lamins, which are expressed ubiquitously in all cell types, are acidic in 
nature and remain associated with membranous structures during lamina 
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depolymerisation and mitotic breakdown of the nucleus. Such observations are 
clearly indicative that nuclear lamins have a broad spectrum of tissue specific 
effects, the implications of which are not as yet fully understood. 
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1.4.4 Nuclear Envelope Dynamics 
During cell division the process of mitosis in vertebrate cells is considered 'open'. 
That is to say that there is a complete disassembly of the nuclear envelope and 
reformation around the two sets of daughter chromosomes. In 'closed' mitosis, 
the nuclear envelope remains intact and chromosomes migrate to opposite poles 
of a spindle within the nucleus. During this process of open mitosis, the entire 
nuclear lamina and associated nuclear pore complexes must reversibly 
disassemble and this is first observed in prometaphase (Georgatos, 
Pyrpasopoulou et al. 1997). The highly coordinated step-wise reassembly of the 
nuclear lamina then occurs during late anaphase/telophase (Chaudhary and 
Courvalin 1993). 
1.4.4. 1 Filament behaviour and assembly 
Models of nuclear lamina assembly have been proposed and modified over the 
past two decades based on both in vitro and in vivo observations. The formation 
of lamin filaments is thought to result from the following series of sequential 
steps. First, obligate parallel unstaggered dimers form through interaction at the 
coiled-coil interface involving the a-helical central rod domains, similar to that 
observed in cytoplasmic intermediate filament assembly (Aebi, Cohn et al. 1986; 
Heitlinger, Peter et al. 1991; Heitlinger, Peter et al. 1992). Subsequently, lam in 
dimers associate head-to-tail and then in anti-parallel geometry to form higher-
order intermediate filaments having a diameter of between 10-13 nm (McKeon, 
Kirschner et al. 1986). Unlike vertebrate cytoplasmic intermediate filaments 
however, lamin filaments then extend longitudinally to form long protofilaments 
before arranging by lateral associations to produce the two-dimensional matrix 
which underlies the inner nuclear membrane and interconnects the nuclear pore 
complexes (Aebi, Cohn et al. 1986; Hutchison 2002). 
Evidence to support this was observed in vitro, where lateral growth of 
protofilaments resulted in the formation of paracrystals with a 24-25 nm 
transverse banding repeat. This was interpreted to represent the anti-parallel, 
half-staggered associations of lamin head-to-tail polymers (protofilaments) which 
gives rise to -1 On m wide mature filaments. So far, the higher-order organisation 
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of these filaments has only been elucidated in Xenopus oocytes where they were 
observed to be arranged in a two-dimensional orthogonal lattice with an average 
crossover spacing of 52nm (Aebi, Cohn et al. 1986; Heitlinger, Peter et al. 1991; 
Moir, Donaldson et al. 1991; Heitlinger, Peter et al. 1992; Stuurman, Heins et al. 
1998; Goldberg, Harel et al. 1999). 
In 2001, Hutchison and eo-workers (Hutchison, Alvarez-Reyes et al. 2001) 
proposed a model by which lamins A and C are incorporated into the nuclear 
lamina once B-type lamins have associated with the inner nuclear membrane. 
Since lamin C does not possess an isoprenylation signal, it was therefore 
suggested that it becomes incorporated into the nuclear lamina on the back of 
lamin A. lt was also proposed that lamin A and lamin C form anti-parallel, half-
staggered tetramers which can then make head-to-tail associations with lamin B 
tetramers already associated subjacent to the inner nuclear membrane. At the 
same time, Vaughan an eo-workers (Vaughan, Alvarez-Reyes et al. 2001) 
reported that lamin C and emerin are both dependent on lamin A for localisation 
at the nuclear envelope, and went on to postulate that the presence of lamin C 
and emerin may be essential to further stabilise the nuclear lamina (Vaughan, 
Alvarez-Reyes et al. 2001 ). 
1.4.5 Functions of the Nuclear Lamina 
The nuclear lamina is responsible for tethering chromatin to the nucleoplasmic 
face of the inner nuclear membrane hence maintaining overall nuclear 
architecture (Gotzmann and Foisner 1999). Recently it has also become known 
as a tensegrity element since it maintains the overall stability of the nucleus by 
resisting tensile and mechanical deformation exerted on the cell (Hutchison and 
Worman 2004). At the same time, correct localisation of lamins to the nuclear 
lamina is also thought to be important for the assembly and spatial organisation 
of the nuclear pore complexes (Lenz-Bohme, Wismar et al. 1997; Stuurman, 
Heins et al. 1998; Liu, Rolef Ben-Shahar et al. 2000) and more specifically the 
recruitment of nucleoporin NUP153 (Smythe, Jenkins et al. 2000), one of the key 
proteins which makes up the terminal ring of the nuclear pore basket [reviewed 
by (Bagley, Goldberg et al. 2000)]. 
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A rapidly increasing number of proteins have also been shown to directly interact 
with lam ins and the nuclear lamina. Examples of the most common proteins that 
interact at the inner nuclear membrane and with the nuclear lamina are 
chromatin (Heessen and Fornerod 2007), lamina-associated polypeptides 
(LAP's), Lamin 8 Receptor (L8R), Otefin, MAN1, Emerin, Nesprin, barrier-to-
autointegration factor (8AF) (Schirmer and Foisner 2007), and the transcription 
factors retinoblastoma (Rb), sterol regulatory element binding protein (SRE8P-
1), Germ-cell-less (Gel), and Oct-1 (Heessen and Fornerod 2007). Such work is 
providing strong evidence that the function of lamins and the nuclear lamina is 
much more dynamic and linked to a much wider range of physiological 
processes than that of the more traditional static structural role (Goldman, 
Gruenbaum et al. 2002). 
Hence at present, the nuclear lamina as well as acting as the inner nuclear 
membrane scaffold has been shown to mediate chromatin organisation and 
condensation (Paddy, 8elmont et al. 1990), nuclear assembly and disassembly 
(Uiitzur, Harel et al. 1992), DNA synthesis (Spann, Moir et al. 1997), 
transcriptional control (Mancini, Shan et al. 1994; Dreuillet, Tillit et al. 2002; 
Kumaran, Muralikrishna et al. 2002; Lloyd, Trembath et al. 2002) and apoptosis 
(Rao, Perez et al. 1996; Zhivotovsky, Gahm et al. 1997), although one would 
expect to see this list extend further in the coming years. The complexity of 
interactions occurring between the nuclear lamina, scaffolding proteins, 
chromatin, transcription factors, and other proteins have profound implications on 
not only the overall structural integrity of the cell, but also cell-cycle control, DNA 
replication, and regulation of gene expression (Hutchison and Worman 2004). 
1.4.5. 1 The Nuclear Lamina and DNA Replication 
Early research has shown that cells which are depleted in functional 8-type 
lamins are unable to support DNA replication (Newport, Wilson et al. 1990; 
Meier, Campbell et al. 1991 ). However, it was not until 1995 that evidence was 
published showing that lamins directly influence DNA replication (Goldberg, 
Jenkins et al. 1995). Research showed that upon addition of purified lamin 83 
(Liii) to depleted extracts of a Xenopus nuclear assembly system, there was a 
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reinitiation of previously halted DNA replication. What is also clear is that the 
absence of a functional lamina leads to extreme mechanical fragility of the 
nuclear envelope (Newport, Wilson et al. 1990; Liu, Rolef Ben-Shahar et al. 
2000) which subsequently results in nuclear deformations, such as invaginations, 
herniations and a greatly reduced resistance to mechanical pressure (Broers, 
Peeters et al. 2004) 
1.4.5.2 The Nuclear Lamina and Transcriptional Regulation 
lt is thought that the nuclear lamina and lamins in particular influence gene 
transcription directly through interaction with transcriptional machinery, chromatin 
and transcriptional repressors. That is not to say that they always bind directly to 
such factors, but more often than not do so through their binding partners which 
associate directly with the chromatin or transcriptional components. 
The main lamin-interacting proteins integral to the inner nuclear membrane are 
the so-called LEM domain proteins; !:AP2, Emerin and MAN 1. The LEM domain 
is a characteristic 43 amino acid sequence in the N-terminal domain of these 
proteins (Cohen, Lee et al. 2001) although at present there has been no 
conclusive evidence of direct interaction between lam ins and MAN 1. In his 
review, Foisner (Foisner 2001) nicely covers lam in interactions at the INM and 
interactions with peripheral chromatin. 
However, in a manner seemingly independent of lamins, LAP2P interacts with 
chromatin via BAF (barrier to autointegration factor) and its LEM domain 
(Furukawa 1999). lt is also capable of binding the transcription factor Gel (germ-
cell-less), a peripheral inner nuclear membrane protein, and is also able to 
repress the activity of the E2F-DP transcriptional complex, which is known to be 
under tight control by the retinoblastoma protein (pRb) (Nili, Cojocaru et al. 
2001 ). LAP2a on the other hand does not directly integrate into the inner nuclear 
membrane (Berger, Theodor et al. 1996; Dechat, Gotzmann et al. 1998). Instead 
it is capable of binding chromatin and has also been shown to target lamins A/C 
to intranuclear sites during interphase where the two proteins then form tight 
complexes which have consequently been implicated in the structural 
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organisation of the nucleus (Dechat, Gotzmann et al. 1998; Dechat, Korbei et al. 
2000). 
Emerin is definitely one of the most interesting integral membrane protein targets 
of lamin A/C, despite the fact that its exact function is still unknown. lt binds both 
lam ins A/C and BAF (Lee, Haraguchi et al. 2001) which directly constitutes it a 
functional link with chromatin. lt has also been shown more recently to bind ~­
catenin through its APC-Iike tail domain, and overexpression results in an 
inhibition of the ~-catenin signalling pathway by preventing nuclear accumulation 
(Markiewicz, Tilgner et al. 2006). The localisation of Emerin to the inner nuclear 
membrane is also closely dependent on the availability of lamin A polymers 
(Vaughan, Alvarez-Reyes et al. 2001) and it is found redistributed throughout the 
cytoplasm, when the nuclear lamina fails to form (Gruenbaum, Lee et al. 2002). 
lt has been shown that the inner nuclear membrane protein MAN1 regulates the 
nuclear translocation of the TGF-~ effecter, rSMAD. The result of this is the 
subsequent antagonising of the BMP signalling pathways (Osada, Ohmori et al. 
2003; Pan, Estevez-Salmeron et al. 2005), which are heavily involved in many 
developmental pathways. 
When considering the concept of cancer, it is clear that many proteins which 
control cell proliferation and survival are regulated by the rate at which they 
accumulate in the nucleus, and disruption of this balance (as in the case of 
constitutive ~-catenin activation in colorectal carcinogenesis) leads to the 
initiation and development of cancer. The nuclear accumulation of pRb, rSMAD 
and p-catenin (which are all implicated in controlling cell proliferation) have been 
shown to be mediated by proteins of the inner nuclear membrane. The tumour 
suppressor pRb is anchored in the nucleus by lamins A/C via LAP2a 
(Markiewicz, Dechat et al. 2002). Under normal conditions, hypophosphorylated 
pRb represses the transcription of genes which typically push cells from G1 
phase into S phase. Concomitantly, it also activates genes which promote 
cellular differentiati0n through negative regulation of the E2F transcriptional 
complexes (Chellappan, Hiebert et al. 1991; Korenjak and Brehm 2005). This 
occurs through tethering of pRb at the nuclear envelope in the manner 
mentioned earlier (Markiewicz, Dechat et al. 2002). p-catenin and rSMAD 
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nuclear accumulation is regulated by the presence of Emerin and MAN1 at the 
inner nuclear membrane (Osada, Ohmori et al. 2003; Pan, Estevez-Salmeron et 
al. 2005; Markiewicz, Tilgner et al. 2006), thus inhibiting the signal transduction 
pathways in which they are involved and preventing expression of either the Wnt 
or BMP target genes. Such evidence strongly suggests that there may be a 
mechanism by which A-type lamins are heavily implicated in tumour initiation and 
development. 
Finally, it has also been proposed that lamins may regulate gene transcription 
through direct modulation of RNA synthesis. Experiments have shown that the 
addition of mutant lamin A lacking its globular head domain to transcriptionally 
active Xenopus nuclei causes disintegration of the nuclear lamina and 
specifically halted the activity of RNA polymerase 11 (Spann, Goldman et al. 
2002). 
1.4. 5.3 Nucleoplasmic-Cytoplasmic interactions 
The rapid response of an individual cell to stimuli, either mechanical or 
biochemical is crucial for cellular functioning. Within the cell, a large network of 
physically interconnected cellular components, which starts with the structural 
components of the nuclear lamina, and via cytoskeletal filaments to adhesion 
molecules and the extracellular matrix, constitutes an integrated matrix to elicit 
such responses. Aside from an obvious mechanical role, this network also has a 
mechanotransductional function in the response to mechanical stress. This 
signalling route operates not only to regulate a rapid reorganisation of structural 
components such as actin filaments, but also stimulates for example gene 
activation via NFKB and other transcription factors. 
Over the last few years a novel family of spectrin-repeat proteins has been 
elucidated and described. Many of the members of this family are integral 
proteins of the inner nuclear membrane, whilst others are shown to specifically 
localise to the outer nuclear membrane. The family of proteins are either known 
as nesprins (Zhang, Skepper et al. 2001 ), NUANCE (NUcleus and ActiN 
Connecting Element) (Zhen, Libotte et al. 2002) or Synes (Apel, Lewis et al. 
2000). The family of proteins is typically characterised by the giant size of some 
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of the alternative splice variants (it has been reported that they may have relative 
molecular masses in excess of 800,000 Da). They also all possess multiple 
clustered spectrin repeats throughout the core of the protein, amino-terminal 
calponin homology domains and a conserved C-terminal single pass membrane 
domain. 
NUANCE has been shown to bind to actin and its distribution is thus influenced 
by the actin cytoskeleton (Zhen, Libotte et al. 2002). In vitro, nesprin 1 a binds 
directly to lamins A/C and to emerin at the inner nuclear membrane (Mislow, 
Holaska et al. 2002b). Thus its localisation at the inner nuclear membrane is 
dependent on the expression of lamins A/C (Muchir, van Engelen et al. 2003). 
Nesprins have also been shown to self associate (Zhang, Skepper et al. 2001 ). 
In addition, emerin, which directly binds to lamins A/C in vitro and is 
subsequently localized to the inner nuclear membrane is also an actin-binding 
protein (Bengtsson and Wilson 2004). Thus, lamins A and C can assemble a 
complex of proteins at the nuclear envelope that have characteristics of 
cytoskeleton linker proteins (Maatta, Hutchison et al. 2004) and potentially link 
the actin cytoskeleton to the lamina. 
1.4.5.4 The Nuclear Lamina and Apoptosis 
When considering any type of cancer it is of particular interest that nuclear 
lamins have been postulated to be involved in the regulation of apoptosis, a key 
functional target of tumourigenesis. The classical morphological features of 
apoptosis include the appearance of highly condensed chromatin, the clustering 
of nuclear pore complexes and membrane blebbing. Interestingly, all of these are 
commonly observed in lamin-deficient nuclei (Sullivan, Escalante-Aicalde et al. 
1999; Tzur, Hersh et al. 2002). At the same time, it has been shown that 
caspase induced cleavage of lam ins is one of the earliest events associated with 
apoptosis (Lazebnik, Takahashi et al. 1995), and precedes DNA fragmentation 
(Rao, Perez et al. 1996; Takano, Takeuchi et al. 2002) and degradation of other 
inner nuclear membrane-associated proteins (Duband-Goulet, Courvalin et al. 
1998; Buendia, Courvalin et al. 2001 ). lt has also been shown that failure to 
assemble B-type lamins correctly will also directly trigger apoptosis (Steen and 
Coli as 2001 ). 
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1.4.6 Lamins in Disease 
To date, there are several different disease phenotypes associated with altered 
nuclear envelope function, and these are collectively referred to as laminopathies 
(Burke and Stewart 2002; Mounkes, Kozlov et al. 2003). Most of the 
laminopathies discovered up to now have been mapped to the LMNA locus and 
subsequently nuclear lamins have become a hot topic of research. The biggest 
reason behind this is that mutations in the LMNA gene can affect cardiac, 
muscular, skeletal, neural, or adipose tissues, or any combination of these 
(Hutchison, Alvarez-Reyes et al. 2001 ). More specifically, mutations in the LMNA 
gene are associated with at least 9 different well-characterised human diseases 
including the autosomal dominant (AD) form of Emery-Dreifuss muscular 
dystrophy (EDMD) (Bonne, Di Barletta et al. 1999), dilated cardiomyopathy type 
1A (CMD-1A) with conduction system defects (Fatkin, MacRae et al. 1999), limb-
girdle muscular dystrophy 1 B with atrioventricular conduction disturbances 
(LGMD1 B) (Muchir, Benne et al. 2000), Dunnigan-type familial partial 
lipodystrophy (FPLD) (Shackleton, Lloyd et al. 2000), Charcot-Marie-Tooth 
disorder type 2B1 (CMT2B1) (De Sandre-Giovannoli, Chaouch et al. 2002), 
mandibuloacral dysplasia (MAD) (Novelli, Muchir et al. 2002), restrictive 
dermopathy (RD) (Navarro, De Sandre-Giovannoli et al. 2004), atypical Werner's 
syndrome (Chen, Lee et al. 2003) and Hutchison-Gilford progeria syndrome 
(HGPS), a premature aging disorder that affects all tissues and results in 
premature death (Eriksson, Brown et al. 2003; Goldman, Shumaker et al. 2004). 
This does not include laminopathies caused as a result of mutations in lamin 
associated proteins ,such as mutations in the STA gene encoding Emerin which 
causes the muscle wasting disease X-linked Emery-Dreifuss muscular dystrophy 
(Bione, Maestrini et,al. 1994) and which exhibits very similar clinical features to 
AD-EDMD. Below I priefly outline some of the major laminopathies and conclude 
with the role of lamins in cancer. 
1.4.6.1 Emery-Dreifuss Muscular Dystrophy (EDMD) 
There are currently three diagnosable forms of Emery-Dreifuss Muscular 
Dystrophy, autosomal dominant (AD), autosomal recessive (AR) and X-linked 
(XL). Both the autosomal dominant and autosomal recessive forms are due to 
58 
mutations in the LMNA gene (Bonne, Di Barletta et al. 1999; Raffaele Di Barletta, 
Ricci et al. 2000). As already mentioned the X-linked form is caused by a loss of 
function mutation in Emerin (Wulff, Ebener et al. 1997). All three forms display a 
very similar triad of clinical features, including early contractures of the elbows, 
Achilles tendons and posterior cervical muscles; progressive weakness and 
wasting of skeletal muscles, particularly humeral and perineal muscles; and 
cardiac conduction defects (cardiomyopathy) which often results in sudden heart 
failure (Dreifuss and Hogan 1961; Emery and Dreifuss 1966; Miller, Layzer et al. 
1985). 
The locus for AD-EDMD was mapped to chromosome 1q11-q23, a region which 
contains the LMNA gene. lt was found that mutations in the LMNA gene eo-
segregated with the disease in five families and this became the first inherited 
disorder documented due to mutations in a component of the nuclear lamina 
(Bonne, Di Barletta et al. 1999). The exact mutation can vary between patients 
with mutations being found in the head, rod and tail domains (Raffaele Di 
Barletta, Ricci et al. 2000). Incidentally, to date, only one case of EDMD has 
been reported to involve both LMNA alleles (Raffaele Di Barletta, Ricci et al. 
2000). 
The X-linked form of Emery-Dreifuss Muscular Dystrophy is a recessive form but 
shows 100% penetrance in the third decade of life. lt was first identified and 
reported in 1961 (Dreifuss and Hog an 1961) and then again in 1966 (Emery and 
Dreifuss 1966). The locus has been mapped to chromosome Xq28 (Bione, 
Maestrini et al. 1994), which contains the STA gene (also known as the EMD 
gene) encoding Emerin. So far there have been no identifiable mutation hotspots 
within the gene. Early research revealed five unique mutations resulting in loss of 
function or truncation of the protein (Bione, Maestrini et al. 1994). Later, a further 
six mutations were identified at novel locations along the gene (Wulff, Parrish et 
al. 1997). However, what they do have in common is that the vast majority are 
associated with the lamin A binding domain and hence disrupt lamin A - Emerin 
interactions (Lee, Haraguchi et al. 2001 ). This was also shown by evidence of a 
weakened interaction of mutant emerin with the nuclear lamina (EIIis; Yates et al. 
1999). 
59 
1.4.6.2 Limb Girdle Muscular Dystrophy 18 (LGMD-18) 
LGMD-1 B is an autosomal dominant disease which is associated with 
progressive muscle wasting and cardiac conduction defects (van der Kooi, 
Ledderhof et al. 1996). Clinical manifestations include a symmetrical weakness 
in proximal lower limb muscles which begins before the age of 20, progressing to 
upper limb muscles at about 30-40 years of age. Generally, the phenotype is 
considered to be somewhat milder than EDMD and patients tend to experience a 
reduced rate of contractures. However, in a manner similar to EDMD, 
cardiological abnormalities are the most life-threatening symptom. The disorder 
was mapped to chromosome 1q11-q21 (van der Kooi, van Meegen et al. 1997) 
and subsequently mutations in the LMNA gene have been identified in three 
LGMD-1 B families (Muchir, Bonne et al. 2000). 
1.4.6.3 Dilated Cardiomyopathy 1A (CMD-1A) 
Dilated cardiomyopathies are somewhat different to the two diseases already 
discussed in that they primarily affect cardiac function and exhibit minimal 
skeletal muscle involvement (Oison and Keating 1996). Acute and sudden heart 
failure is the primary cause of death in these patients usually in the fourth 
decade of life. lt has also been shown that mutations in the LMNA gene account 
for the autosomal dominant form and these mutations typically occur within the 
coiled-coil regions; 1A and 1 B of the rod domain (Fatkin, MacRae et al. 1999; 
Brodsky, Muntoni et al. 2000). Interestingly it has been shown that lamin A and 
lamin C can be affected independently of one another, with the R571S mutation 
substituting an arginine residue in the lamin C specific carboxy terminus (Benne, 
Mercuri et al. 2000), and the R644C mutation also substituting an arginine 
residue, but in the laminA specific tail domain (Genschel, Bochow et al. 2001). 
1.4.6.4 Dunnigan type- Familial Partial Lipodystrophy (FPLD) 
Familial Partial Lipodystrophy is a family of diseases within which only one form 
(Dunnigan type) has currently been directly associated with mutations in the 
LMNA gene. The clinical manifestations of FPLD usually arise at the onset of 
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puberty and are typically characterised by abnormal distribution of subcutaneous 
fat. In Dunnigan type - FPLD, adipose tissue progressively disappears 
(lipoatrophy) from upper and lower extremities, gluteal and truncal areas and 
begins to accumulate on the face, neck, back and groin (Dunnigan, Cochrane et 
al. 1974). As a result of this, patients generally develop insulin resistance. The 
disease has been mapped to chromosome 1q21 and more specifically mis-sense 
mutations in the LMNA gene have been identified in five Canadian families (Cao 
and Hegele 2000). The mutations responsible for causing Dunnigan type- FPLD 
are mostly distributed on the surface of the C-terminal globular lg domain and 
therefore do not appear to affect lamin structure (Hegele, Anderson et al. 2000; 
Speckman, Garg et al. 2000). Instead they result in nuclear lamina fragility and 
disorganisation, which subsequently results in the nuclear envelope herniations 
typically seen in lipodystrophic patients (Vigouroux, Auclair et al. 2001 ). 
1.4.6.5 Mandibuloacral Dysplasia (MAD) 
Mandibuloacral Dysplasia is an autosomal recessive disease and only 
homozygous patients show the classical clinical features associated with the 
disease. Such clinical features include; postnatal growth retardation; craniofacial 
malformations including a hypoplastic mandible producing severe dental 
crowding; skeletal abnormalities including hypoplastic clavicles; atrophy of the 
skin over hands and feet with mottled cutaneous pigmentation; alopecia; and 
partial lipodystrophy of either pattern A or B, often accompanied by extreme 
insulin resistance (Young, Radebaugh et al. 1971; Cutler, Kaufmann et al. 1991; 
Simha and Garg 2002). To date, only MAD patients which exhibit type A 
lipodystrophy have been found to harbour the homozygous mutation, R527H in 
the lamin A/C tail domain (Novelli, Muchir et al. 2002; Simha, Agarwal et al. 
2003) which appears to affect normal distribution of lamins A/C at the nuclear 
envelope resulting in lobulations and a 'honey-comb' appearance of the nuclear 
lamina (Novelli, Muchir et al. 2002). 
1.4.6.6 Charcot-Marie-Tooth type 281 (CMT2B1) 
Charcot-Marie-Tootl:l diseases are an autosomal recessive group .of disorders 
which typically manifest in the second decade of life and appear clinically and 
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genetically heterogeneous, affecting both motor and sensory nerves, and in 
particular nerve conduction velocity. Clinically CMT type 1 (CMT1) is a 
demyelinating form of the disease, whereas CMT type 2 (CMT2) of which there 
are two types CMT2B1 and CMT2B2, is an axonal disruption form. In separate 
studies on consanguineous families with CMT2B1, the disorder was directly 
mapped to chromosome region 1q21 which harbours the f.MNA gene 
(Bouhouche, Benomar et al. 1999). A unique homozygous mutation was then 
later identified in the rod domain of lamin AJC in three consanguineous Algerian 
families (De Sandre-Giovannoli, Chaouch et al. 2002). 
1.4.6.7 Hutchinson-Gilford Progeria Syndrome (HGPS) 
Hutchinson-Gilford Progeria Syndrome is a rare premature ageing syndrome 
affecting approximately 1 in 8 million people but which can occur through both 
consanguineous and non-consanguineous unions suggesting both an autosomal 
recessive and autosomal dominant mode of inheritance. Clinical features 
associated with HGPS include growth retardation, abnormal dentition, loss of 
subcutaneous fat, alopecia, reduced bone density, incomplete sexual maturation 
and poor muscle development (Mounkes, Kozlov et al. 2003). Patients suffer 
from atherosclerosis and typically die of congestive heart failure in the first or 
second decade of life. The HGPS causing gene was initially mapped to 
chromosome 1 q and then to the LMNA gene and a de novo single-base 
substitution affecting codon 608 (GGC ~ GGT) was identified as the major 
cause in 18 of 20 patients with classic HGPS (Eriksson, Brown et al. 2003). This 
substitution does not result in an amino acid change in the lamin A specific exon 
11, but is responsible for partial activation of a cryptic splice site. Activation of 
this cryptic splice site results in a 50aa deletion at the C-terminal end of lamin A. 
This effectively removes the endoproteolytic cleavage site and the site for cell-
cycle-dependent phosphorylation (Serine 625). The result of this is that post-
translational modification of prelamin A to mature lamin A cannot occur and it is 
thought that the incompletely processed lamin A may act as a dominant negative 
mutant at the nuclear envelope (Eriksson, Brown et al. 2003). 
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1.4.6.8 Werner Syndrome 
Werner syndrome is a very rare autosomal recessive disorder which is most 
recognisable for its characteristic premature aging symptoms. The syndrome 
clinically comprises features such as premature atherosclerosis, scleroderma-like 
skin changes and subcutaneous calcification (McKusick 1963). Atypical Werner 
Syndrome has a much more severe phenotype than the 'typical' form. 
Homozygous mutations in the DNA helicase-like gene RECQL2 are typically the 
cause, although four atypical Werner Syndrome patients were found to express 
normal RECQL2, but were heterozygous for novel mis-sense mutations in the 
LMNA gene (Chen, Lee et al. 2003). Thus in a small subset of cases, atypical 
Werners Syndrome is characterised by the autosomal dominant inheritance of 
LMNA mutations which result in nuclear abnormalities, and may subsequently 
affect RECQL2 function. 
1.4.7 Structural and Gene Regulatory roles in laminopathies 
There is still a great deal of controversy which surrounds the exact function of 
the nuclear lamina, especially in the case of disease. Early hypotheses stated 
that its functions were merely architectural although as I have discussed, there is 
a vastly increasing plethora of evidence that links its role to the regulation of 
gene transcription as well. Currently, there are two major hypotheses that 
attempt to explain the mechanisms responsible for A-type lamin associated 
diseases: nuclear fragility and global and/or specific gene expression changes 
(Burke and Stewart 2002; Mounkes, Kozlov et al. 2003). 
A structural model in which loss of correct lamin function causes nuclear fragility 
is an attractive explanation for phenotypes associated with skeletal muscle and 
heart tissue disorders, such a Emery-Dreifuss Muscular Dystrophy, Limb-Girdle 
Muscular Dystrophy, and Dilated Cardiomyopathy. In such a model the nuclear 
lamina maintains the structural integrity of the nucleus and resists shearing 
stress exerted by mechanical use of the muscle which would eventually lead to 
damage of the nucleus and ultimately cell death (Hutchison, Alvarez-Reyes et al. 
2001; Gold man, Gruenbaum et al. 2002). 
63 
However, this shear stress model fails to explain lamin-associated 
lipodystrophies, for example the tissue pathology of Dunnigan type - Familial 
Partial Lipodystrophy, a phenotype that affects the function of adipocytes or 
Charcot-Marie-Tooth type 281 which affects the function of neurons, both of 
which are tissues that do not experience anywhere near the same amount of 
repetitive mechanical stress as muscle. A more plausible model to explain the 
wide variety of tissue specific pathologies associated with mutations in just one 
protein is the gene-expression model. That is to say that A-type lamins and loss 
of correct function thereof must impact on other important functions of the 
nuclear lamina, other than, or as well as maintenance of nuclear architecture. 
As I have already mentioned, laminA has been found to directly interact with a 
variety of gene-regulatory factors, including SREBP1 (Lioyd, Trembath et al. 
2002), MOK2 (Dreuillet, Tillit et al. 2002), pRb (Mancini, Shan et al. 1994) and 
BAF (Gotzmann and Foisner 1999). Using a specific example of this hypothesis, 
SREBP1 is a transcription factor that is known to activate genes involved in 
cholesterol biosynthesis, adipocyte differentiation, and lipogenesis (Kim and 
Spiegelman 1996). lt has also been shown to directly interact with the globulin 
like tail of lamin A (Lioyd, Trembath et al. 2002). Thus mutations in lamin A that 
cause Familial Partial Lipodystrophy bind SREBP1 with approximately 25-40% 
less affinity (Lioyd, Trembath et al. 2002) and it therefore becomes attractive to 
link FPLD to changes in adipocyte function due to genes affected by altered 
SREBP1 function. 
In addition to binding to specific gene regulatory factors, nuclear lamins and 
lamin A in particular can also interact directly with naked DNA (Luderus, den 
Blaauwen et al. 1994), histones (Taniura, Glass et al. 1995), and is thought to 
play a role in the organisation of heterochromatin (Kourmouli, Theodoropoulos et 
al. 2000). Gross disruptions in the organisation of chromatin, which is found in 
cells from Emery-Dreifuss Muscular Dystrophy patients, has the potential to alter 
global expression patterns of hundreds, or possibly thousands of genes 
(Ognibene, Sabatelli et al. 1999). 
Recently a third model has also been proposed suggesting that malfunctions in 
the nuclear lamina and nuclear envelope may cause perturbations in 
cytoskeletal-nuclear interactions through disruption of for example the 
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microtubule-lamina interaction as mediated by proteins such as SUN (§.ad1 I 
UNC-84 homology) domain proteins which transverse the nuclear envelope. 
Such a hypothesis postulates that the cytoskeleton and nuclear lamina are 
hardwired together providing a device for transducing mechanical stress sensing 
from the plasma membrane to the nucleus. 
1.4.8 Lamins in Cancer 
The expression of nuclear lamins has previously been described in V
1
arious types 
of cancer and varies widely depending on the subtype of cancer, its 
aggressiveness, proliferative capacity and degree of differentiation. Cancers 
affecting epithelial, lymphoid and mesenchymal tissues, including basal skin cell 
carcinoma (8CC) (Venables, M clean et al. 2001; Tilli, Ramaekers et al. 2003), 
non-small cell lung cancer (Kaufmann, Mabry et al. 1991; 8roers, Raymond et al. 
1993), non-Hodgkin's lymphoma, acute lymphoblastic leukaemia, (Stadelmann, 
Khandjian et al. 1990), metastatic chondrosarcoma, rhabdomyosarcoma and 
leiomyosarcoma (Cance, Chaudhary et al. 1992) have been well documented in 
current literature. In general, the expression of A-type lamins (lamins A and C) 
has been correlated with a non-proliferating, differentiated state of cells and 
tissues (Tilli, Ramaekers et al. 2003). 
At present there have been two previous studies which have investigated the 
differential expression and changes in lamins A/C and lamin 81 in colorectal 
neoplasms. Their findings however have been somewhat contradictory. Cance 
and eo-workers (Cance, Chaudhary et al. 1992) reported that there was a 
constitutive expression of lamin 8 accompanied to a heterogeneous expression 
of lamins A/C in two colon adenocarcinomas, determined by 
immunohistochemical analysis. Moss and colleagues (Moss, Krivosheyev et al. 
1999) on the other hand reported that there was a reduced nuclear 
immunostaining for lamins A/C in colon adenomas and adenocarcinomas, 
compared to normal tissue. In their investigations, Moss and eo-workers 
evaluated a total of 17 formalin-fixed paraffin embedded tumour specimens from 
patients; 3 from Dukes' A patients, 3 from Dukes' 8 patients and 11 from Dukes' 
C patients. They report that in all 17 cases there was "reduced or absent" lamin 
A/C expression, which they classed as either 0 (no staining), 1 (weak staining) or 
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2 (moderate staining) on a 4 point scale (3 being classed as very strong, intense 
staining). They also report levels of heterogeneous non-specific cytoplasmic 
staining which is ultimately due to the use of their polyclonal antisera. Whilst 
polyconal antisera offer a cheap and more readily available method of antigen 
detection, they lack the homogeneity and consistency of their monoclonal 
counterparts, and batches vary dramatically unlike the limitless supply of a 
monoclonal equivalent. The heterogeneity of polyclonal antisera means they 
often recognise a host of antigenic epitopes both specific and non-specific which 
is most likely what is observed by Moss and eo-workers in their paper. 
Interestingly, they make no mention of the use of internal controls to validate 
absent staining as a lack of antigen as opposed to poor staining. 
Moss and eo-workers were unable to support their data in further immunoblotting 
studies, but this may be due to the heterogeneity of tissue in samples used, 
which can realistically only be overcome by laser micro-dissection or enzymatic 
separation. They speculate that reduced lamin A/C expression is not related to 
Dukes' or differentiation status, but due to a very small sample size (n=17) it is 
not surprising that no correlation could be found. Their final conclusions suggest 
that a lack of lamin A/C expression in tumours may be a marker of malignancy; 
however they did not investigate lamin A/C expression in relation to patient 
outcome, disease free survival or any other clinicopathological variables (Moss, 
Krivosheyev et al. 1999). 
In basal skin cell carcinomas, V enables (V enables, McLean et al. 2001) 
correlated a down-regulation of lamin A with a higher proliferation illdex and the 
loss of lamin C with slower growing tumours. However this was not supported in 
later work by Oguchi's team (Oguchi, Sagara et al. 2002) in which nq relationship 
between the loss of lamin A expression and increased proliferation was 
observed. Instead it was shown that such a loss of lamin A was associated 
instead with a poor differentiation status of the tumour. This uncertainty in the 
link between lamin A/C expression and cellular proliferation was further 
highlighted by analyses of keratinocyte tumours carried out by Tilli (Tilli, 
Ramaekers et al. 2003). Here they showed that in basal cell carcinomas and 
squamous cell carcinomas, lamin A/C staining was positive accompanied by a 
heterogenous expression in the suprabasal and strong staining in the basal 
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epidermis. However lamin AIC expression only correlated with Ki-67 staining (a 
proliferative index marker) in 50% of tumour cells. 
On a slightly different note, Agrelo (Agrelo, Setien et al. 2005) has shown in 
studies that CpG Island promoter methylation of the LMNA gene not only 
correlated with loss of RNA and protein in leukaemia and lymphoma 
malignancies but that it is a significant predictor of poor outcome in nodal diffuse 
large 8-cell lymphomas. 
Interestingly, a class of drugs currently used to treat some forms of cancer, 
known as farnesyl transferase inhibitors (FTis), has been shown reverse the 
phenotype of Hutchinson-Gilford Progeroid cells grown in vitro (Mallampalli, 
Huyer et al. 2005) and also in mouse model systems (Fong, Frost et al. 2006). 
FTis were originally developed to block the farnesylation of ras, a CaaX protein 
that is mutated and hyperactive in a number of cancers. This is of interest since 
LaminA also requires post-translational farnesylation to be incorporated into the 
nuclear membrane. By blocking the first step in processing of the faulty lamin in 
HGPS patients with FTis, it can in part reverse some of the disease symptoms. 
Work such as this draws not only strong links between disease such as cancer 
and premature ageing syndromes, but fundamentally supports the notion that the 
A-type lamins can be considered as 'Guardians of the soma' (Hutchison and 
Worman 2004). 
1.5 Thesis Aims 
Changes in lamin expression and their effects on patient mortality have been 
reported in a small number of cancers, but as yet no large scale studies have 
been carried out in colorectal cancer (Cance, Chaudhary et al. 1992; Moss, 
Krivosheyev et al. 1999). Similarly the exact nature of how alterations in lamin 
expression affect the biological behaviour of tumours is not clear. Given the 
importance of A-type lam ins and their binding partners to the regulation of growth 
pathways, it has been speculated that these lamins might be linked to tumour 
progression (Burke and Stewart 2006). The availability of large retrospective and 
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developing prospective archives alongside previously established in 'vitro models 
have allowed both questions to be addressed in this thesis. 
Chapter 3 describes an initial pilot study and subsequent larger follow-up studies 
undertaken to immunohistochemically examine the expression patt~rn of lamins 
A/C in colorectal cancer patients. Tumour material was selected from a 
retrospective archive of incident colorectal cancer patients participating in the 
Netherlands cohort study on diet and cancer. In the pilot study, the expression 
pattern of lam ins A/C was initially assessed in 100 incident colorectal cancer 
patients by immunoperoxidase staining. With strong evidence to support further 
investigation this was then subsequently extended to include the entire cohort of 
737 patients in a similar follow-up study. Marked differences in lamin A/C 
expression were observed between patients of similar clinicopathological grades. 
These differences in expression were analysed alongside accompanying 
clinicopathological, biological and epidemiological data. Data shows a counter-
dogma affect of A-type lamin expression in colorectal cancer. That is to say 
those patients with lamin A/C positive tumours are twice as likely to die as their 
lamin A/C negative counterparts. This lends us to conclude that tumour lamin 
AIC status can be considered a strong independent prognostic marker of survival 
in sporadic colorectal cancer. 
Chapter 4 then looks at the biological question associated with the decreased 
mortality in lamin A/C deficient tumours of why? The starting point is the 
investigation into the effects of lamin A expression on the canonical Wnt 
signalling pathway, classically at the heart of colorectal cancer development. 
Data show that differential expression of lamin A in the SW480 (Dukes' B) colon 
I 
cancer in vitro model does not directly influence P-catenin activity. Data also 
shows that this absence of change in relative p-catenin activity persists in the 
presence of either endogenous truncated or full length functional APC. Results 
hence suggest that the role lamin A plays in influencing colorectal cancer 
mortality may in this case act independently of the canonical Wnt signalling 
pathway. 
Chapter 5 uses the same SW480 (Dukes' B) colon cancer in vitro model to look 
at global gene expression changes under conditions of differential lamin A 
68 
expression. Data mining of genome-wide microarray analysis was carried out on 
lamin A transfected and control colon cancer cell lines. Here I looked for 
alternative proteins and signalling pathways which may be affected by changes 
in lamin A expression. A subset of key targets was chosen and independently 
verified at the RNA level implicating other cellular pathways and components 
such as cell-cell adhesion; cytoskeletal reorganisation; protein 
phosphatase/kinase pathways, such as MAPKIERK; EGF signalling pathways; 
BMP signalling pathways; Slit/Robo signalling pathways and more. 
Finally chapter 6 looks at BMP4, a prominent protein identified b~ microarray 
data analysis which has previously been identified as having a potential role in 
tumour suppressor pathways as a negative regulator of tumourigemesis. Data 
show that the expression of lamin A significantly down-regulates BMP4 at both 
the RNA and protein level. A down-regulation in the level of the cell-cell adhesion 
protein E-cadherin (a downstream target of BMP signalling) and a concomitant 
up-regulation in the actin bundling protein T-Piastin is also noted at the mRNA 
level and such changes pertain even in the presence of exogenously applied 
rhBMP4. Finally I show that exogenous rhBMP4 treatment partially inhibits 
migratory behaviour in scratch wound assays in the SW480 GFP-Aione 
transfected control cells, but has no effect on the SW480 GFP-Iamin A 
transfected cells suggesting that the presence of lamin A in these cells may 
abrogate BMP4 mediated growth suppression. Thus, in the absence of changes 
in p-catenin activity, data suggest that the detrimental effect of lamin A/C 
expression in patient tumours may be mediated through inhibition of BMP rather 
than Wnt signalling pathways. 
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CHAPTER 2 - Materials and Methods 
2. 1 Routine chemicals and materials 
The majority of general routine chemicals used were purchased from one of; 
BDH Laboratory Supplies (VWR International Ltd, Leicestershire, England), 
Sigma-Aidrich (Sigma-Aidrich Company Ltd., Dorset, England) or Melford 
(Melford Laboratories Ltd., Suffolk, England) unless otherwise stated. Those 
chemicals obtained from BDH Laboratory Supplies were AnalaR® analytical 
grade and all other reagents were Molecular Biology grade. All plasticware for 
tissue culture was supplied by Greiner Bio-One Ltd, Gloucestershire, GB. 
2.2 The Netherlands Cohort Study on Diet and Cancer (NLCS) -
A Retrospective Archive 
2.2.1 Population characteristics and background 
A prospective cohort study on diet and cancer was initiated in the Netherlands in 
September 1986. The study design has been described in detail elsewhere (van 
den Brandt, Goldbohm et al. 1990). Briefly, at baseline a total of 58,279 men and 
62,573 women between the ages of 55 and 69 completed a self-administered 
food frequency and lifestyle questionnaire. The study population originated from 
204 municipal population registries throughout the Netherlands. Incident 
colorectal cancer cases are identified by monitoring the entire cohort for cancer 
occurrence through annual record linkage to the Netherlands Cancer Registry 
(NCR), nine regional cancer registries throughout the Netherlands and the 
Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA), a 
national database of pathology reports (van den Brandt, Schouten et al. 1990). 
The PALGA database was also used to identify and locate colorectal cancer 
tumour tissue in Dutch pathology laboratories. 
In terms of patient follow-up, the first 2.3 years were excluded due to incomplete 
nationwide coverage of PALGA. However, from January 1989 until January 
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1994, 819 incident cases with histologically confirmed colorectal cancer were 
identified. Colorectal cancer was classified according to site using the 
International Classification of Diseases (ICD) system as follows; proximal colon: 
[caecum through transverse colon] (ICD-0 codes 153.0, 153.1, 153.4, 153.5, 
153.6); distal colon: [splenic flexure through sigmoid colon] (ICD-0 codes 153.2, 
153.3, 153. 7); rectosigmoid (ICD-0 code 154.0) and rectum (ICD-0 code154.1 ). 
Patient follow-up for all incident colorectal cancer cases (excluding the first 2.3 
years after commencing the trial in September 1986) was complete and 
subsequently obtained for the period of 1st January 1989 to 31st December 1996 
(7 years). 
2.2.2 Tissue Samples 
Tumour material of colorectal cancer patients was collected after approval by the 
Ethical Review Board of Maastricht University, PALGA and the Netherlands 
Cancer Registry. Tissue samples from the 819 identified colorectal cancer 
patients were requested from 54 pathology laboratories throughout the 
Netherlands. Tumour tissue collection started in August 1999 and was 
completed in December 2001. Forty-four tumour tissue samples (5%) could not 
be traced at all. Of 775 traceable tissue samples, 737 (90%) contained sufficient 
tumour material as confirmed by a pathologist (Professor Adriaan de Bru'ine, 
University of Maastricht, The Netherlands) for histological and molecular 
analysis. 
All specimens had· been processed according to standard Dutch Pathology 
guidelines. Briefly specimens were grossly dissected and immersed in 10% 
formalin fixative for 30 minutes at 35°C. Dehydration and embedding of tissues 
was fully automated and the procedure was as follows: 70% ethanol, 60 minutes 
at 35°C; 70% ethanol, 60 minutes at 37°C; 96% ethanol, 60 minutes at 37°C; 
96% ethanol, 1 hour 30 minutes at 40°C; 100% ethanol, 1 hour 30 minutes at 
40°C and 100% ethanol, 2 hours at 45°C. Samples were cleared in xylene for 15 
minutes at 45°C, 15 minutes at 50°C, followed by another 30 minutes in fresh 
xylene at 50°C before embedding in paraffin at 60°C for two 60 minute periods 
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and finally for 1 hour 30 minutes. The clinical stage of the tumours was then 
confirmed histologically by a resident pathologist. 
2.2.3 A Retrospective Lamin Study and the CREAM Database 
Information about age at diagnosis, sex and family history of colorectal cancer 
(at baseline) was retrieved from the NLCS database. Information concerning 
tumour sub-localisation, Duke's stage and differentiation state of the tumour was 
retrieved from the NCR database. 
DNA had previously been isolated for biochemical analysis (Brink, de Goeij et al. 
2003) from the 737 specimens and molecular information regarding the following 
had been obtained: methylation status of the 0 6-MGMT promoter; methylation 
status of the hMLH1 promoter; methylation status of the APC promoter (van 
Engeland, Weijenberg et al. 2003); mutational status of Ki-ras exon 1 (further 
subdivided as codon 12 or 13) (Brink, de Goeij et al. 2003; Brink, Weijenberg et 
al. 2004; Bongaerts, de Goeij et al. 2006); mutational status of p-catenin; 
mutational status of APC (Luchtenborg, Weijenberg et al. 2004; de Vogel, van 
Engeland et al. 2006); expression status of p53; and MSI staining status 
(Luchtenborg, Weijenberg et al. 2005; Luchtenborg, Weijenberg et al. 2005). 
These data had been entered into and stored within a new database titled the 
Colorectal Epidemiology and Mutation (CREAM) database, from which all of the 
above information was easily accessible. All 737 slides were analysed for 
expression of lamins A/C as described in section 2.3 and the reported results 
(Chapter 3) were added to the database. 
2.2.4 Statistical Analysis 
Baseline characteristics of patients (age at diagnosis, sex, family history of 
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colorectal cancer), tumours (tumour sub-localisation, Dukes' stage and tumour 
differentiation) as well as tumour biology variables (gene mutation/methylation 
status), were compared by Student's t-test (continuous variables) and Chi-
squared <l) tests (categorical variables) to the study variable (lamin A/C 
expression). Hazard Ratios (HR) for disease and 95% confidence intervals (Cl) 
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were calculated by conditional logistic regression. In multivariate analyses, 
missing values were treated as a separate category or excluded (categorical 
variables) or given the median-value (continuous variables). All statistical tests 
and corresponding p-values reported were for two-sided tests and p-values of 
less than 0.05 were considered statistically significant. SPSS version 12.0 
(Chicago, IL, USA) was used for all statistical analyses. 
2.3 Immuno-Histochemistry 
2.3.1 Heat Mediated Antigen Retrieval 
Formalin-fixed, paraffin-embedded tissue specimens obtained from the NLCS 
archive were sectioned at 4J.tm and incubated at 50°C for 24 ho~rs to allow 
adhesion to Starfrost® adhesive microscope slides (Knittel Glaser, B.raunshweig, 
Germany). Tissue sections were then de-paraffinised in xylene, . twice for 5 
minutes and rehydrated through a decreasing ethanol series: 2 x 100% ethanol 
for 5 minutes; 1 x 96% ethanol for 5 minutes; 1 x 70% ethanol fqr 5 minutes 
before finally being transferred to distilled water for 2 minutes. 
The process of heat-mediated antigen retrieval used was adapted from a method 
previously described (Barker, Huls et al. 1999). Briefly, endogenou~ peroxidase 
activity was quenched by incubating slides in 3% H20 2 in methanol for 15 
minutes. Thereafter tissue sections were immersed in 0.01 M citrate buffer, pH 
6.0 (pre-heated to 90°C) for 15 minutes in a water bath at 90°C. Following this, 
slides were transferred to 1 x Phosphate Buffered Saline (PBS) (pre-warmed to 
50°C) and allowed to cool to room temperature. 
2.3.2 Three-layer peroxidase staining 
Slides were mounted into Thermo Shandon Coverplates m (Thermo Shandon Ltd. 
UK) and loaded into Shandon Sequenza® staining racks (Thermo Fisher 
Scientific Inc. US). The setup was chosen as it allows a highly organised and 
reliable method for immunostaining which ensures consistency and excellent 
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staining quality with the ability to perform large staining runs (up to 50 slides per 
run) with a very low chance of batch variation. 
Non-specific antibody binding was blocked using 125J,tllsection of 5% goat serum 
and 2% bovine serum albumin (BSA) in PBS. Slides were washed 3 times with 
PBS containing 0.1% BSA (PBS/BSA). The anti-lam in A/C primary mouse 
monoclonal antibody (Dyer, Kill et al. 1997) was diluted 1:10 in 1 x PBS/BSA, 
applied (125J,tllsection) and incubated at 4°C for 16 hours. Unbound primary 
antibody was removed by washing 3 times with PBS/BSA. Biotinylated goat anti-
mouse lgG secondary antibodies (used at a concentration of 1 :400), diluted in 1 
x PBS/BSA were used (125J,tllsection) and incubation was for 45 minutes at 
room temperature (RT). Unbound secondary antibody was removed by washing 
3 x with 1 x PBS/BSA. This was followed by a 30 minute incubation at room 
temperature with StreptABComplex/HRP (Dako Cytomation, Glostrup, Denmark) 
made up according to manufacturer's guidance. 125J,tllsection was used, and 
unbound complex was removed by washing 3 x with 1 x PBS/BSA after 
incubation. Immunological detection was carried out using 125J,tl activated 
Diaminobenzidine (DAB) chromogen (BioGenex Laboratories Inc., San Raman, 
CA, US) (0.0225% H20 2 in 1 mg/ml filtered DAB in 1 x PBS- made up according 
to manufacturer's instructions). DAB was applied directly to tissue sections and 
colour development was monitored under a simple light microscope. Reactions 
were stopped by immersing slides in oH20. Negative controls were stained in the 
manner described above but substituting the lamin A/C primary antibody or 
biotinylated secondary for 1 x PBS/BSA. 
2.3.3 Counterstaining and mounting 
To visualise the nuclei of cells, sections were lightly counterstained with 
undiluted Mayers Haemalum for 5 seconds and rinsed in distilled water for 1 
minute. The counterstain was differentiated and fixed using alkaline alcohol (3ml 
ammonia solution in 1 OOml 70% ethanol) for 30 seconds and then rinsed in 
distilled water for 1 minute. 
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Slides were dehydrated through a graded ethanol series and cleared as follows; 
70% ethanol for 1 minute, 96% ethanol for 1 minute, 2 x 100% ethanol for 1 
minute, 2 x xylene for 5 minutes. Specimens were then mounted and 
coverslipped with Entellan® (Merck kGaA, Darmstadt, Germany) and left to dry 
overnight. 
2.3.4 Image Acquisition and Scoring 
Colorectal cancer specimens were analysed using a Nikon Diaphot 300 inverted 
microscope (Nikon Corporation, Tokyo, Japan) equipped for bright-field 
microscopy with Plan 4x/0.13, 10X/0.25, 20x/0.4 and 40x/1.3 lenses. Images 
were taken using a Nikon DXM1200 digital camera controlled by Nikon Act-1 
Version 2.20 software. Image processing was carried out using the Adobe® 
Photoshop® 7.0 imaging software (Adobe Systems Inc. San Jose, CA, US). 
Scoring of the slides was based on a +I- system with lam in +ve being classed as 
1 0% or more of tumour cell nuclei staining strongly positive for lam in A/C 
compared to an the internal control. Adjacent stromal cell nuclei were used as an 
internal positive control since they always stained positive. Lamin -ve was 
classed as less that 10% of nuclei staining strongly for lam in A/C expression 
compared to the internal control. The use of adjacent stromal cell nuclei as 
internal control demonstrated that a negative stain in tumour tissue 
corresponded to an absence of antigen rather than poor staining. In all studies, 
slides were scored blind to all database information by two independent 
observers, and followed by a consultatory evaluation of scoring before database 
information was retrieved and statistical analysis began. 
2.4 Mammalian cell culture 
2.4.1 Cell lines 
The colon carcinoma cell line SW480 used in in vitro studies was originally 
obtained from the European Collection of Cell Cultures (ECACC), (Wiltshire, UK) 
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as growing cultures. The SW480 cell line is a classified as a Grade IV carcinoma 
cell line. The cells were originally derived from a grade 3-4 colon 
adenocarcinoma and were initially populated by a mixture of epithelial-like and 
bipolar cells. Over time the epithelial-like cells have predominated (Leibovitz, 
Stinson et al. 1976) and this was evident from the cultures grown. The SW480 
cell line harbours a type 11 APC truncation which possesses both the N-terminal 
Nuclear Export Signal (n-NES) as well as the 5' most C-terminal NES (c-NES) 
(Rosin-Arbesfeld, Townsley et al. 2000) unlike cell lines harbouring Type I APC 
truncations whereby the 5'-most c-NES is also lost. The SW480 cell line has also 
been shown to strongly secrete the Carcino-Embryonic Antigen (CEA). 
The parent cell line and subsequent stably-transfected clones (described in 
section 2.4.2) were routinely cultured in 75cm2 plastic tissue culture flasks under 
the following conditions; L-15 (Leibovitz) medium with 2mM L-Giutamine 
(lnvitrogen, UK) supplemented with 10% Foetal Bovine Serum (FBS), 100 
units/m I penicillin and 1 OOj..tg/ml streptomycin. Flasks were cultured in a 
humidified, 37°C environment in the absence of C02 following recommendations 
from the ECACC. Culture media was changed every 48-72 hours. All cells were 
cultured using FBS from lot 111 K3397, obtained from Sigma. Cells were 
routinely sub-cultured between 70% and 80% confluency. Cells were detached 
by treatment with 0.25% trypsin in 0.5mM Ethylenediamine Tetraacetic Acid 
(EDTA) in PBS in a humidified environment at 37°C for 2 minutes before 
neutralisation with serum-containing L-15 media. The cells were routinely split 
1 :4 before being re-plated at a density of approximately 20-30 x 103 qells/cm2 
2.4.2 Transfected SW480 clones 
The SW480 parent cell line had been previously stably transfected with DNA 
constructs encoding fusion proteins of EGFP-Iamin A and EGFP (Willis, 2006). 
The EGFP-Iamin A full length construct was a gift from Or M. Ozumi, Institute of 
Physical and Chemical Research, Saitama, Japan. Single cell cloning of the 
stably-transfected daughter colonies was established using Geneticin® (G-418 
sulphate, lnvitrogen, UK) antibiotic selection and GFP-reporter stability within 
clones was monitored by fluorescence microscopy at monthly intervals resulting 
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in multiple stably transfected clones for use as an in vitro model. Before initial 
experimental work for this project was conducted, single cell cloned lines were 
subjected to a 2 week Geneticin® antibiotic selection (200J.1glml) followed by re-
evaluation of GFP-reporter stability. Cell lines showing no lo'ss of GFP 
expression were grown in Geneticin® free media for all subsequent experimental 
work. On a monthly basis, stable transfection was routinely re-evaluated by 
simple observation under fluorescence microscopy using a Zeiss Axioskop 
microscope (Carl Zeiss Microimaging Inc., Thornwood, NY) equipped for 
epifluorescence. 
2.4.3 Transient transfection using Lipofectamine 111 2000 reagent 
Transfection of the SW480 cell lines using Lipofectamine TM 2000 (lnvitrogen, UK) 
was carried out according to lnvitrogen technical bulletin #116668 (2004). Briefly, 
cells were grown to 80% confluency in 35mm diameter 6 well plates under 
standard culture conditions previously described. Constructs were transfected in 
at required concentrations in antibiotic free media and cells were incubated for 
48 hours without media change. Transfection utilising ooH20 was used as a 
negative control. 
2.4.4 Transient Nucleofection 
Transfection of the SW480 cell line was also carried out using the amaxa 
Nucleofector® (AAD-1001) (amaxa AG, Cologne, Germany) using the amaxa 
Cell Line Nucleofector® kit V (amaxa AG, Cologne, Germany) and exactly in 
accordance with amaxa's optimised protocol guidelines DCV-1 036 (2005) for 
SW480 cells. 
2.4.5 Dual Luciferase® Reporter Assays 
Dual Luciferase Reporter Assays for ~-catenin activity were carried out on the 
SW480 cell lines using the Duai-Luciferase® Reporter Assay System (Promega, 
UK) in accordance with Promega's technical manual TM040 (2003). Briefly, cells 
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were seeded at a density of 5 x 105 in 6 well plates 24 hours prior to transfection. 
Cells were then transfected using the Lipofectamine TM 2000 reagent as 
described in section 2.4.3. The TOPFiash and FOPFiash reporters were a gift 
from Ewa Markiewicz, Durham University, UK and were co-transfected at a 
concentration of 1 !Jgi!JI alongside the Renilla TK luciferase construct at a 
concentration of 0.1 !Jg/!JI. 24 hours post transfection, cells were lysed and the 
relative activity of firefly luciferase under the TOPFiash and FOPFiash promoters 
was measured before being quenched and measuring relative Renilla luciferase 
activity. 
2.5 One-dimensional SDS-PAGE and immunob/otting 
Cultured SW480 cells were harvested at 80% confluency and protein was 
extracted from 7 x 1 06 cells. Cell pellets were re-suspended in 500!JI of lysis 
buffer [10mM Tris-HCL (pH7.4), 10 mM KCI, 3mM MgCI2, 0.1% Triton X-100 and 
1 x protease cocktail inhibitor] and then incubated with 0.1 unitsi!JI DNase I on 
ice for 10 minutes. Cell extracts were dissolved in 500!JI of 2 x sample buffer 
[125mM Tris-HCI (pH6.8), 2% p-mercaptoethanol and 0.25% Bromophenol Blue 
(w/v)], and boiled at 95°C for 3 minutes. 
Protein samples were resolved using one-dimensional SOS-PAGE on a 6% or 
10% poly-acrylamide resolving gel with a 5% poly-acrylamide stacking gel, both 
made using ProSieve® 50 acrylamide gel solution (Cambrex Bio Science 
Wokingham Ltd., Berkshire, UK) and containing 0.1% SOS. Samples were run at 
1 00 volts (V) for 2 hours in tank buffer (25mM Tris, 192mM Glycine and 0.1% 
SOS) and transferred to nitrocellulose membrane (Protran®, grade BA85, 
Schleider and Schuell BioScience Inc., Keene, NH) at 30V for 16 hours at 4°C in 
transfer buffer (25mM Tris and 192mM Glycine, pH 9.2, plus 20% methanol and 
0.1% SOS). Nitrocellulose membranes were subsequently washed once in Blot 
Rinse Buffer (BRB) [1 OmM Tris-HCL, 150mM NaCI and 1 mM EDT A, pH 7 .4, plus 
0.1% Tween®20 (v/v)] and incubated initially in 5% blocking buffer [5% skimmed 
milk powder (w/v) in BRB] for 1 hour at room temperature on a shaker. After 
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blocking, nitrocellulose membranes were washed three times in BRB for 5 
78 
minutes. Detection of proteins was accomplished using a series of specific 
antibodies listed in Table 2.1. p-actin was used as a control for loading. 
Nitrocellulose membranes were incubated with primary antibodies diluted to their 
optimum working concentrations in BRB + 5% milk overnight at 4°C on a shaker 
and then rinsed 5 times with BRB, 15 minutes per rinse at room temperature on 
a shaker. The secondary antibody used was a horse-radish peroxidase (HRP)-
conjugated lgG and used at a concentration of 1 :2000 - 1 :4000 in BRB + 5% 
milk. Membranes were incubated with secondary antibodies for 1 hour at room 
temperature with continuous agitation and then washed with BRB, 5 times for 10 
minutes. Nitrocellulose membranes were exposed to ECL,.. western blotting 
reagents 1 and 2 (1 :1 v/v) (Amersham Biosciences) and following exposure, 
photographic film was developed using a compact X4 Automatic X-Ray Film 
Processor (Xograph lmaging Systems Ltd. , Gloucestershire, UK). Differences in 
protein expression were then quantified using densitometry (see Section 2.8.1 ). 
Table 2.1 Primary antibodies used for SOS PAGE 
Antibody Target Type Supplier Dilution 
Actin clone P-actin Mouse Sigma 1:1500 AC-40 monoclonal 
Anti-APC (Ab- APC Mouse CaiBioChem 1:1000 1) (FE9) Monoclonal 
Anti-BMP4 BMP4 Mouse R&D Systems 1:500 monoclonal 
2. 6 Semi-quantitative RT-PCR 
2.6.1 Primer Design 
Primers specific for the coding sequence (cds) of target genes being investigated 
were designed using the freely available online Primer3 web interface 
(http://frodo.wi.mit.edu/primer3/primer3_code.html) (Whitehead institute, 
Cambridge, MA. lt selects suitable primers from a given DNA sequence based 
on a number or parameters including product size, primer length, melt 
temperature (Tm) and GC%. The software parameters were set to design 
primers between 18 and 27 bases long and select primers with a minimum Tm of 
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55°C, a maximum Tm of 65°C, a maximum Tm difference between sense and 
antisense primers of 4°C and a GC content of 45% to 70%. The use of 
NetPrimer online software [PREMIER Biosoft International, CA 
(http://www.premierbiosoft.com/Netprimer/index.html) enabled the examination 
of secondary structures in primer pairs, incorporating hairpin loops, self-dimers, 
cross-dimers, palindromes and runs/repeats, which could impinge their function 
or lead to non-specific products. Table 2.2 shows primer sequences designed 
and used within this project. 
Table 2.2 Primers for semi quantitative PCR 
Gene Accession Direction Sequence (5'-3') Size (bp) 
Sense GAGGCAGAATCAGCTCCATC 
APC NM_000038 958 Anti sense CATTCCACTGCATGGTTCAC 
Sense GAGCACCTGGAAGCAGTAAC 
AREG NM_001657 348 Antisense AAGAGGACCGACTCATCATTT 
Sense GGCACCACACCTTCTACAATGAGC 
13-Actin NM_001101 834 Anti sense CGTCATACTCCTGCTTGCTGATCC 
Sense AGCATGTCAGGATTAGCCGAT 
BMP4 030751 400 
Anti sense ATGGAGATGGCACTCAGTTCAG 
Sense CCAAGTGCCTGCTTTTGATG 
CDH1 NM_005032 415 
Anti sense CACAATTATCAGCACCCACAC 
Sense CTCAGGGTAGGTTCTCGGG 
DUSP5 NM_004419 492 Antisense ATGCCAAAGTCCAAGGTCAG 
Sense CTCATCGCAAGAGTAGCAGC 
FOSL1 NM_005438 479 Anti sense GTAAAGTGGCACCTTCTGTCA 
Sense GCATCTTCCCTCTCATACCC 
PLS3 NM_004360 307 Anti sense GCAAACAGCTTGACAAAGCA 
Sense CCCAGAGAAGCACAGGAACA 
ROB01 NM_002941 599 Anti sense GGCTGATGACTGAAGCAAGAAG 
2.6.2 Total RNA Isolation 
For each experiment, total RNA was isolated from three different passages of the 
SW480 cell line using the TRIZOL ® reagent (lnvitrogen, UK). The procedure was 
carried out exactly as described in lnvitrogen's technical manual #15596-026. 
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Briefly, cells were expanded to approximately 70% confluency in 75cm2 tissue 
culture flasks and were lysed directly on the culture surface with 2ml TRIZOL ® 
per flask and allowed to stand for 10 minutes at room temperature. Lysates were 
transferred to 1.5ml RNase-free microcentrifuge tubes (Ambion Inc., Austin, TX, 
US) and centrifuged at 12,000 x g for 15 minutes at 4°C. The aqueous phase 
alone was immediately transferred to fresh tubes and 0.5ml RNase-free 
isopropanol per original 1 ml of TRIZOL ® was added. Samples were inverted 3 
times and incubated for 10 minutes at room temperature before being incubated 
at -20°C overnight. Samples were then centrifuged at 12,000 x g for 10 minutes 
at 4°C. All supernatant was removed and the RNA precipitate was washed with 
1 ml RNase-free 75% ethanol per original 1 ml TRIZOL ® and pelleted again at 
10,000 x g for 10 minutes at 4°C. All supernatant was removed and the pellets 
air-dried for 5-10 minutes in a laminar flow hood before being resuspended in 15-
20f.ll nuclease-free water. Samples were then aliquoted and stored at -80°C. 
2.6.3 Confirmation of quality, purity and concentration of RNA 
Total RNA quality was assessed by gel electrophoresis. RNA was diluted in 6 x 
RNA loading buffer [6 x Tris-acetate EDTA (TAE) buffer, BM urea, 15% ficol, 
0.25% Xylene cyanol FF (w/v) and 0.25% bromophenol Blue (w/v)] and heated at 
70°C for 5 minutes before adding ethidium bromide to a final concentration of 7 
ng/f.ll. Samples were separated alongside RNA millennium TM size markers 
(Ambion Inc., Austin TX, US) on 1% agarose gels in O.Bx TBE buffer at 80V for 1 
hour. Bands were visualised using a Gel Doe TM 2000 UV transilluminator and 
Quantity One TM, version 4.0.3 software (Bio-Rad) 
Purity was determined by measuring the ratio of absorbance in 1 OmM Tris-HCI 
(pH 7.5) at 260nm and 280nm (A2aoiA2ao) in a GeneQuest CE2301 Analyser 
(Cecil Instruments Ltd. Cambridge, UK) and the concentration was calculated by 
measuring the absorbance at 260nm (A2so) in DEPC-treated oH20. 
81 
2.6.4 Confirmation of RNA Integrity 
The human gene p-actin was used to exclude the possibility that genomic DNA 
(gDNA) may have been eo-isolated with total RNA. Primers to an 834bp 
fragment of p-actin (see table 2.2) were used to amplify any contaminating gDNA 
in 0.5~g RNA. PCR was carried out in a 25~1 reaction volume comprising 1 x 
ReddyMix™ PCR Master Mix (ABgene, Epsom, Surrey, UK) [25 units/ml 
Thermoprine Plus DNA polymerase (Taq), 75mM Tris-HCI (pH 8.8 at 25°C), 
20mM (NH4)2S04, 2.5mM MgCI2, 0.01% Tween®20 (v/v) and 200 ~M each 
dNTPs], 0.4 pmol/~1 p-actin sense primer and 0.4 pmol/~1 p-actin anti-sense 
primer. Cycling conditions were as described in section 2.6.5). 
The total volume of PCR product (25~1) was electrophoresed on a 1% TAE-
agarose gel with 0.3~g/ml Ethidium Bromide (EtBr). RNA samples showing 
evidence of gDNA contamination were treated with 0.075 units/~1 RQ1 RNase-
free DNase (Promega) in 1 x reaction buffer [40 mM Tris-HCI (pH 8.0), 1 OmM 
MgS04, 1 mM CaCI2) for 15 minutes at room temperature. The reaction was 
terminated by incubating the samples with 1 ~I DNase stop solution (20mM 
EGTA, pH 8.0) for 10 minutes at 65°C. RNA was then precipitated with 1/10 of 
the total reaction volume of Diethyl pyrocarbonate (DEPC)-treated 3M Sodium 
acetate (NaOAc), pH 5.2 and 3 volumes of 100% RNase free ethanol (-20°C), 
vortexed for 5 seconds and incubated overnight at -20°C. To recover RNA, 
samples were centrifuged at 12,000 x g for 10 minutes at 4°C, the supernatant 
removed and pellets washed with 1 ml 70% RNase free alcohol (in DE PC-treated 
8H20). Centrifugation was repeated at 12,000 x g for 5 minutes at 4°C, the 
supernatant aspirated and residual ethanol allowed to evaporate for 5-10 
minutes in a laminar flow hood. The resulting pellet was re-suspended in 20~1 
RNase free water and the quality, purity (A26o/A2ao) and concentration (A2eo) of 
the RNA was re-evaluated as described in section 2.6.3. 
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2.6.5 Reverse Transcription - Polymerase Chain Reaction (RT -PCR) 
Reverse transcription and amplification of target genes was carried out in 2 
stages using Promega's Reverse Transcription system (A3500) and PCR Master 
Mix (M7502). For all samples, RT-PCR was completed in triplicate. 
First a cDNA library was synthesised in a 40J.~.I reaction using Promega's 
Reverse Transcription System in exact accordance with their technical bulletin 
TB099 (2006). Two -ve controls substituting RNA and the AMV-RT for oH20 
were used in each run. All resulting cDNA libraries were aliquoted and stored at -
20°C. 
p-actin was amplified from all cDNA libraries and their accompanying AMV-RT 
negative controls, plus negative controls where no RNA was added to show 
equal amounts of cDNA had been reverse transcribed and that reverse 
transcription and PCR reactions were working successfully. 
PCR fragments for the chosen target genes detailed in section 2.6.1 (table 2.2) 
were amplified from all Reverse Transcriptase reactions using A 25J.~.I reaction 
containing 1 x Promega PCR Master mix [25 units/ml Taq DNA polymerase in 
buffer (pH 8.5), 200J.~.M each dNTPs and 1.5 mM MgCI2], 0.4 pmoi/J.~.I sense 
primer. 0.4 pmoi/J.~.I antisense primer, 2J.~.I cDNA library and Nuclease-free water. 
Optimisation of PCR profiles was carried out in an Eppendorf Mastercycler™ 
Gradient Thermal Cycler (Eppendorf UK Ltd, Cambridge, UK) using the following 
conditions; 94°C for 2 minutes, 26 cycles of [94°C for 45 seconds, Tm°C ± 5°C 
for 1 minute, 72°C for 1 minute] and finally 72°C for 5 minutes. 
2.6.6 Analysis 
All amplified products were run on 1% TAE-agarose gels, containing 0.3 J.~.g/ml 
EtBr, at 60V for 60 minutes. Product size was compared to a 1 OObp DNA ladder 
(Promega Cat #G21 01) and bands were visualised using a GeiDoc ™ 2000 UV 
transilluminator and Quantity One TM software, version 4.0.3 (Bio-Rad). 
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Differences in expression levels were quantified using densitometry (see section 
2.8.1) and calculated as a ratio against p-actin expression. 
2.6.7 RT-PCR confirmation of changes in expression of selected 
genes. 
Primers to target genes were designed as detailed in section 2.6.1 (table 2.2). 
Semi-quantitative RT-PCR was set-up exactly as described in section 2.6.5 
including appropriate negative controls. Experiments were carried out in triplicate 
for each target gene. Optimised PCR cycling conditions are detailed in section 
2.6.5. Optimised Tm for each primer set is as follows: APC = 60°C; AREG = 
57°C; p-Actin = 60°C; BMP4 = 57°C; CDH1 = 55°C; DUSP5 = 55°C; FOSL 1 = 
58°C; PLS3 = 58°C; ROB01 = 58°C 
PCR products were analysed by gel electrophoresis and subsequent 
densitometry as outlined in section 2.6.6. p-actin RT-PCR was performed as a 
positive and loading control for all samples. 
2.7 Cloning 
The Escherichia coli strain DH5a was used as the bacterial transformation 
recipient for the APC construct. The full length cDNA of human APC cloned into 
the pcDNA3.1/FLAG vector was a gift received from Kristi Neufeld [see Appendix 
1 (p204) for Plasmid map] 
Transformation reactions were set up using 2r.tl pFiag-APC and 50r.tl of XL 1-Biue 
Super -competent cells (recA 1 endA 1 gyrA96 thi-1 hsdR17 supE44 re/A 1 lac [F' 
proAB lacflZI1M15 Tn10 (Ten] (Stratagene, La Jolla, CA, US), and precisely 
followed Stratagene's guidelines #200236 (2004) 
Briefly, cells were thawed on ice before being transferred to pre-chilled reaction 
tubes and adding 1.7,.!1 p-mercaptoethanol per 1 OOr.tl. Upon addition of the 
construct, cells were incubated on ice for 30 minutes; heat shocked at 42°C for 
45 seconds and cooled on ice for 2 minutes. 0.5ml preheated SOC @uper 
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Optimal Broth [Q.atabolite repression](Hanahan 1983)) nutrient broth (without 
antibiotics) was added and transformation reactions were incubated at 37°C for 1 
hour with shaking at 225rpm. 250J.!I sample was then plated onto Lysogeny Broth 
(LB) agar plates (10g/l Triptone, 5g/L Yeast Extract, 10 g/L NaCI, pH 7.2) 
supplemented with 1 OOJ.!g/m; ampicillin and incubated at 37°C for 24 hours. 
Ten colonies were selected from each transformation reaction and inoculated in 
LB media containing 1 OOJ.!glml ampicillin. Bacteria were incubated at 37°C with 
shaking (225rpm) for 16 hours. Glycerol stocks were prepared using 0.3ml 
culture and the rest of the cultures were used to purify plasmid DNA using 
Promega's Wizard® Plus Minipreps DNA Purification System (Promega, UK) as 
detailed in section 2.7.1. 
2.7.1 DNA Purification 
Plasmid DNA was purified from inoculated LB-media at 16 hours using 
Promega's Wizard® Plus Minipreps DNA Purification System (Promega, UK) 
according to their technical bulletin #117 (2002). Final elution of plasmid DNA 
from the spin columns was eluted in 1 OOJ.!I nuclease free water and stored at 
minus 20°C. 
2. 7.2 Confirmation of Plasmid 
The purified DNA plasmid was checked for quantity at OD2so. quality was 
checked at OD26o/OD280 and 1 OJ.!I was checked visually by electrophoresis on a 
0.7% TAE-agarose gel against a known DNA standard. 
Plasmid DNA was analysed by restriction digestion. 20 units of Pmel 
(GTTT -l-AAC) were used per 1 J.!g plasmid DNA in NE Buffer 4 supplemented with 
1 OOJ.!g/ml BSA (New England Biolabs Inc., UK) Incubation was at 37°C for 2 
hours and the products analysed by electrophoresis on 1% TAE-agarose gel. 
Bands of 8.4Kb (APC) and 5.5Kb (vector) were considered a positive result. 
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Further confirmation was undertaken by analysing extracted plasmid DNA for the 
presence of APC through PCR amplification using the primers detailed in table 
2.2 and the methodology outlined in section 2.6.7. 
2.8 Miscellaneous applications 
2.8.1 Densitometry 
Western Blot and RT-PCR agarose gel bands were digitally scanned in a Fujifilm 
Intelligent Dark Box 11 (Fujifilm Medical Systems, Edison, HJ) directed by Fujifilm 
Image Reader LAS-1000 Pro Version 2.11 software and intensities quantified in 
Image Gauge version 4.0 (Fujifilm). 
2.9 Microarray Data Mining 
Genome wide microarray analysis was carried out on the SW480 EGFP-Iamin A 
and SW480 EGFP cell lines using the Human Genome U133 Plus 2.0 high-
density oligonucleotide Affymetrix GeneChip array (Affymetrix, Santa Clara, CA, 
USA). Normalisation of expression ratios was carried out in accordance with the 
associated Affymetrix guidelines for the HG U133 GeneChip and a targeted gene 
list was generated by means of a series of relevance thresholds for detection p-
value significance, expression change p-value significance and Signal Log Ratio 
(SLR). 
Analysis of the targeted gene list and biological interpretation of results was 
carried out using the online NetAffx Analysis Centre from Affymetrix found at 
(http://www.affymetrix.com/analysis/index.affx). Genes of interest were subjected 
to cluster analysis by Gene Ontology including; Biological Process, Molecular 
Function and Cellular component. For a detailed description of the on line NetAffx 
tools, see http://www.affymetrix.com/support./index.affx. 
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CHAPTER 3 - Lamin AIC status in colorectal tumours as 
a biomarker of patient mortality 
3. 1 Introduction 
3.1.1 Lamin AJC expression in colorectal cancer 
The differential expression of lamin A/C has already been associated with 
epithelial, lymphoid and mesenchymal tumours, including basal skin cell 
carcinoma (BCC) (Venables, Mclean et al. 2001; Tilli, Ramaekers et al. 2003), 
non-small cell lung cancer (Kaufmann, Mabry et al. 1991; Broers, Raymond et al. 
1993), non-Hodgkin's lymphoma, acute lymphoblastic leukaemia, (Stadelmann, 
Khandjian et al. 1990), metastatic chondrosarcoma, rhabdomyosarcoma and 
leiomyosarcoma (Cance, Chaudhary et al. 1992). Two groups have investigated 
the changes in lamin A/C expression in colorectal neoplasms. Their findings 
however, have been somewhat contradictory. Cance and eo-workers (Cance, 
Chaudhary et al. 1992) reported that there was a heterogeneous expression of 
lamins A/C in two colon adenocarcinomas, determined by immunohistochemical 
analysis. Moss (Moss, Krivosheyev et al. 1999) on the other hand reported that 
there was a reduced nuclear immunostaining for lamins A/C in colon adenomas 
and adenocarcinomas, compared to normal tissue. Neither group however, has 
corroborated their findings in a large randomised controlled 
immunohistochemical study, or to date have there been any investigations of this 
nature looking at lamin A/C expression and disease severity or patient mortality 
in colorectal cancer. 
Originally described as units of architecture, lamins A/C are type V intermediate 
filaments which form an orthogonal meshwork underlying the inner nuclear 
membrane. Termed the nuclear lamina, it conveys the nucleus mechanical 
strength (Aebi, Cohn et al. 1986), provides resistance to deformation (Liu, Rolef 
Ben-Shahar et al. 2000; Moir, Yoon et al. 2000b; Broers, Peeters et al. 2004) 
and regulates nuclear shape (Sullivan, Escalante-Aicalde et al. 1999; Schirmer, 
Guan et al. 2001) and size (Spann, Moir et al. 1997). Lam ins also help to shape 
the nucleoskeleton by anchoring integral proteins of the inner nuclear 
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membrane, positioning nuclear pore complexes and recruiting other lamin 
subtypes to the nuclear lamina [reviewed by (Hutchison 2002)]. Current evidence 
has also implicated lamins in the control of DNA replication (Goldberg, Jenkins et 
al. 1995) and shown they may organise interphase chromatin and play a role in 
regulating transcription [reviewed by (Foisner 2001 )] 
3.1.2 The Netherlands Cohort Study on Diet and Cancer 
The Netherlands Cohort Study (NLCS) on diet and cancer (previously described 
in section 2.2) is a prospective cohort study of 120,852 people. Incident 
colorectal cancer cases in the cohort were identified by annual record linkage to 
the Netherlands Cancer Registry (NCR) and PALGA and tumour material was 
collected after approval by the Medical Ethics Committee of Maastricht 
University, the NCR and PALGA. Initially tissue samples from 819 patients were 
requested from 54 pathology laboratories throughout the Netherlands. Incident 
cases included those patients developing colorectal cancer between 1989 and 
1994. Tumour material from forty-four patients (-5%), could not be retrieved due 
to administrative inconsistencies (9 cases), unavailability of tumour blocks in the 
pathology archives (34 cases) or incorrect tumour classification (1 case). Of 775 
available tissue samples, 737 contained sufficient tumour material for 
immunohistochemical and molecular analyses as determined by a senior 
pathologist; Professor Adriaan de Bru·ine (University of Maastricht, The 
Netherlands). Once retrieved, the formalin-fixed, paraffin-embedded tissue 
blocks were sectioned at 4 J..lm for immunohistochemical analysis as detailed in 
section 2.2.2. 
3.1.3 Summary 
With evidence in other tumour types potentially linking lamin A/C status with 
patient survival (Mounkes, Kozlov et al. 2003; Agrelo, Setien et al. 2005), the 
pivotal role of A-type lamins in such a broad range of laminopathies, the lack of 
research specifically in the colorectal cancer field and the availability of access to 
the NLCS archive, this chapter looked to investigate whether lamin A/C may be 
implicated in colorectal carcinogenesis. 
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In this chapter two studies are described. First a pilot trial to 
immunohistochemically assess the expression pattern of lamins AJC in a small 
(n=1 00), randomised subset of incident colorectal cancer cases from the NLCS 
archive. The second is a follow-up study to more rigorously test the conclusions 
drawn from the initial pilot study in the complete subset (n=737) of incident 
colorectal cancer cases from the NLCS archive. Lamin AJC expression was 
determined immunohistochemically using the mouse monoclonal anti-Lamin AJC 
Jol2 antibody (Dyer, Kill et al. 1997), assessed and evaluated against a broad 
spectrum of confounding variables. 
3.2 Results 
3.2.1 Immunohistochemical analysis of lamin AIC expression 
To determine lamin A/C expression status, slides were stained and scored for 
the presence or absence of lamin expression exactly as detailed in section 2.3. 
Lamin A/C expression was scored on +/- system with lamin positive being 
classed as 10% or more of tumour cell nuclei staining strongly positive for lam in 
A/C compared to an the internal control (figure 3.1 ). Adjacent stromal cell nuclei 
were used as an internal positive control because they always stained positive 
for lamins A/C. Lamin negative was classed as less that 10% of nuclei staining 
strongly for lamin AJC expression compared to the internal control (figure 3.2). 
The availability of an internal positive control demonstrated that a negative stain 
in tumour tissue corresponded to an absence of antigen rather than poor 
staining. Scoring was carried out blind by two independent observers followed 
by a consultatory evaluation. 
3.2.2 Patient follow-up 
Information on mortality from 1st January 1989 until 31st December 1996 (7 
years) was retrieved through linkage with the Central Bureau for Statistics. 
Differences in patient, tumour and follow-up characteristics were analysed 
through the use of the chi-square (x2) tests for categorical variables and 
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Students t-tests for continuous variables. Hazard ratios (HR) (a hazard ratio is an 
estimate of the relative effect that a variable [i.e. lamin A/C status] exerts on an 
event [in this case colorectal cancer related mortality]) and corresponding 95% 
confidence intervals (Cl) for colorectal cancer related mortality according to lamin 
AIC status were estimated using Cox regression analysis. Gender, age at 
diagnosis, family history of colorectal cancer, Dukes' stage, tumour. location and 
differentiation, MGMT, hMLH1, Ki-ras and APC promoter methylation, TP53 and 
MSI status, Ki-ras activating and APC truncating mutations were considered as 
potential confounding variables. Those variables found to have a statistically 
significant contribution to the multivariate model for colorectal cancer related 
mortality, or that influenced the risk estimates by more than 10% (age at 
baseline) as well as gender, were included as covariates in the analyses. All 
analysis was carried out in SPSS. 
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Figure 3.1 
Positive expression of lam in AJC in colorectal tumours. 
{A-H) 4J..tm thick sections of colorectal cancer tissue from patient specimen 
blocks showing strong positive Jol2 staining in tumour (T) and stromal (S) 
tissue. Stromal tissue was always positive acting as an internal p·ositive control 
for the investigation. Tissue sections were weakly stained with Mayers 
Haemalum (purple) to highlight nuclei where lamin staining was negative. 
Positive lamin staining appears brown. 
{A) Dukes' A, well differentiated tumour {B) Dukes' A, moderately well 
differentiated tumour. {C) Dukes' B, moderately well differentiated tumour. {D) 
Dukes' B, moderate/poorly differentiated tumour. {E) Dukes' C, moderately well 
differentiated tumour. {F) Dukes' C, moderate/poorly differentiated tumour. {G) 
Dukes' D, moderate/poorly differentiated tumour. {H) Dukes' D, moderately 
differentiated tumour. 
In each panel, lamin AIC expression is considered positive and was scored as 
such for statistical analysis. 
Scale bar= 30 J..lm 
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Figure 3.2 
Negative expression of lam in AJC in colorectal tumours. 
(A-H) 4J..tm thick sections of colorectal cancer tissue from patient specimen 
blocks showing negative JoL2 staining in tumour (T) and positive stromal (S) 
tissue. Stromal tissue was always positive acting as an internal positive control 
for the investigation and demonstrating that a negative stain corresponded to the 
absence of antigen rather than poor staining. Tissue sections were weakly 
stained with Mayers Haemalum (purple) to highlight nuclei where lamin staining 
was negative. Positive lamin staining appears brown. 
(A-B) Dukes' A, moderately well differentiated tumour. (C) Dukes' B, moderately 
differentiated tumour. (D) Dukes' B, moderately well differentiated tumour. (E) 
Dukes' C, moderate/poorly differentiated tumour. (F) Dukes' C, moderately 
differentiated tumour. (G-H) Dukes' D, poorly differentiated tumour. 
In each panel, lamin A/C expression is considered negative since less than 10% 
of nuclei are staining positive for lamin A/C expression and was scored as such 
for statistical analysis. 
Scale bar = 30 J..lm 
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3.3 The NLCS Pilot 
An initial pilot study was set up to investigate the expression pattern of lamins 
AIC within the NLCS archive. Of the 737 tumour specimens available, a subset 
of 100 incident colorectal cancer cases was randomly selected by an 
independent selector and immunohistochemically assessed for lamin A/C 
expression using the Jol2 anti-lamin AIC mouse monoclonal antibody (Dyer, Kill 
et al. 1997) as detailed in section 2.3. Slides were scored blind on two separate 
occasions and a consultatory evaluation was then carried out with a senior 
pathologist. A single case (1 %) was lost due to poor tumour specimen leaving a 
total of 99 cases for statistical analyses. 
During the follow-up period, from 1st January 1989 until 31st December 1996, 43 
patients died, with 37 of these patients dying as a result of colorectal cancer. 
Information on primary cause of death as well as, primary, secondary and tertiary 
complications was retrieved from the PALGA database. Colorectal cancer 
related death was concluded if colorectal cancer was determined as either the 
primary cause of death or as a primary, secondary or tertiary complication, using 
the International Classification of Diseases system. ICD-9 codes 153.0 through 
153.9; 154.0 through 154.3 and 154.8 were considered representative of 
colorectal cancer related death. 
3.3.1 Basic analysis 
Initial baseline analysis was performed on all patient and tumour characteristics 
in relation to colorectal cancer related mortality, as detailed in table 3.1. The 
study population characteristics appeared to be normal with 55% (n=55) of 
patients being male, 8% (n=8) of patients exhibiting family history of colorectal 
cancer, and Dukes' staging split as follows: Dukes' A, 23% (n=23); Dukes' B, 
26% (n=26); Dukes' C, 34% (n=34); and Dukes' D 16% (n=16). Analysis detailed 
in table 3.1 was carried out to initially identify variables as potential confounders 
which may have been influencing patient survival. 
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Tabte 3.1 Baseline population and tumour characteristics according to fate 
NoCRC CRC related 
mortality p -value 
(n=37) 
Patient characteristics 
Gender (male) 58% (n=36) 54% (n=20) 0.697 
Family history of CRC (yes) 10% (n=6) 5% (n=2) 0.451 
Age at diagnosis (years, mean) 68.18 67.92 0.764 (95% Cl) (67.07- 69.29) (66.69 - 69.15) 
Tumour characteristics 
Dukes' stage 
Dukes' A 32% (n=20) 8% (n=3) 
Dukes' B 32% (n=20) 16% (n=6) 
Dukes' C 34% (n=21) 35% (n=13) 
Dukes' D 2% (n=1) 41% (n=15) <0.001 * 
Tumour Location 
Proximal 21% (n=13) 49% (n=18) 
Distal 35% (n=22) 30% (n=11) 
Rectosigmoid 18%(n=11) 8% (n=3) 
Rectum 24% (n=15) 14% (n=5) 0.053 * 
Tumour Differentiation 
Well differentiated 24% (n=15) 11% (n=4) 
Moderately differentiated 69% (n=43) 62% (n=23) 
Poorly differentiated 6% (N=4) 27% (n=10) 0.010 * 
Molecular characteristics 
Ki-ras activating mutation (ex on 1) 37% (n=23) 35% (n=13) 0.844 
Ki-ras activating mutation (cod on 12) 29% (n=18) 22% (n=8) 0.418 
APC truncating mutation 44% (n=27) 49% (n=18) 0.622 
Ki-ras promoter methylation 3% (n=2) 3% (n=1) 0.948 
0 6-MGMT promoter methylation 45% (n=28) 30% (n=11) 0.114 
APC promoter methylation 29% (n=18) 35% (n=13) 0.811 
hMLH1 promoter methylation 13% (n=8) 14% (n=5) 0.712 
Microsatellite Instability (Positive) 3% (n=2) 5% (n=2) 0.367 
TP53 Status (Positive) 56% (n=35) 59% (n=22) 0.770 
Lamin AJC status (Positive) 47% (n=29) 68% (n=25) 0.044 * 
Follow-up 
Cigarette Smoker (yes) 23% (n=14) 14% (n=S) 0.268 
Survival Time (years, mean) 4.76 1.59 
<0.001 * (95% Cl) (4.23 - 5.27) (1 .13- 2.04) 
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Simple chi-square (x2) analysis of baseline population and tumour characteristics 
according to fate (colorectal cancer related death or not) showed the strongest 
variable to be (as expected) Dukes' staging, with more patients in the later 
Dukes' C and D stages dying of colorectal cancer related mortality than patients 
in groups A and B (p<0.001 ). 
Insofar as tumour location was concerned, the borderline significance (p=0.053) 
represented the increased number of proximal tumours correlating with 
colorectal cancer related mortality (observed 18, expected 11) and fewer 
rectosigmoid and rectal cancers correlating with colorectal cancer mortality. 
However, such observations were not in keeping with previously published work 
where distal tumours of the colon are typically much more closely associated 
with colorectal cancer related mortality and proximal tumours classically 
associated with a better outcome (Thibodeau, Bren et al. 1993). Although it must 
be said that due to the size of this study population (n=99) and also the presence 
of small subgroup values [n=3 and n=5 (rectosigmoid, rectum)] such a result 
could not be considered statistically reliable and in a larger patient population, 
observations may more closely follow those previously published. 
There was a close correlation between tumour differentiation and colorectal 
cancer related mortality in the study population (p=0.01 0). Here, fewer well 
differentiated tumours were associated with colorectal cancer related mortality 
than expected (observed 4, expected 7) and more poorly differentiated tumours 
were associated with colorectal cancer related mortality than expected (observed 
10, expected 5). This was to be expected and supported previously published 
work (Newland, Chapuis et al. 1981), however small subgroup numbers lead the 
statistical reliability of such observations to be questionable. 
Unfortunately Ki-ras promoter methylation data was only available for 20 (20%) 
of patients and could not be used in analysis. For all other molecular 
characteristic variables, missing values were below 5% (n=5). Of all the 
molecular characteristics investigated, lamin AIC status showed the only 
statistically significant correlation (p=0.044) between expression status and 
colorectal cancer related mortality. Data showed that more lamin AIC positive 
tumours correlated with colorectal cancer related mortality (observed 25, 
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expected 20), and lamin A/C negative tumours were more closely correlated with 
survival (observed 33, expected 28) (p=0.044) (Table 3.1). I 
As would be expected, there was a significant difference in the survival time of 
patients between the colorectal cancer related mortality and non-colorectal 
cancer related mortality groups (p<0.001 ). The average survival for patients 
dying of colorectal cancer related mortality was only 1.59 years (95% Cl: 1.13 -
2.04), whereas for the non-colorectal cancer related mortality group, it was 3 
times longer at 4.76 years (95% Cl: 4.23- 5.27) (Table 3.1). 
( 
When the baseline characteristics were cross-tabulated with ~ lamin A/C 
expression, correlations between variables could be assessed in ord.er to identify 
potential confounders affecting patient survival (see table 3.2). The majority of 
factors investigated showed little or no correlation with lamin A/C expression, but 
the two key variables which cross-tabulated closely with lamin A/C status were -
Ki-ras activating mutations in codon 12 (p=0.027) and tumour differentiation state 
(p=0.029). In the first instance, data showed that more lamin Ale positive 
tumours also harboured an activating mutation at codon 12 in the Ki-ras 
oncogene (observed 19, expected 14) than expected. In the second instance we 
also see that more lamin A/C positive than expected (observed 12, expected 7) 
and less lam in A/C negative tumours were than expected (observed· 2, expected 
7) were poorly differentiated. 
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Table 3.2 Baseline population and tumour characteristics according to 
lamin A/C expression 
p-value 
Patient characteristics 
Gender (male) 50% (n=27) 64% (n=29) 0.149 
Family history of CRC (yes) 6% (n=3) 11% (n=5) 0.313 
Age at diagnosis (years, mean) 68.48 67.60 0.290 (95% Cl) (67.38- 69.58) (66.34- 68.86) 
Tumour characteristics 
Dukes' stage 
Dukes' A 19% (n=10) 29% (n=13) 
Dukes' 8 30% (n=16) 22% (n=10) 
Dukes' C 37% (n=20) 31% (n=14) 
Dukes' D 15% (n=8) 18% (n=8) 0.566 
Tumour Location 
Proximal 37% (n=20) 24% (n=11) 
Distal 37% (n=20) 29% (n=13) 
Rectosigmoid 11% (n=6) 18% (n=8) 
Rectum 15% (n=8) 27% (n=12) 0.248 
Tumour Differentiation 
Well differentiated 20% (n=11) 18% (n=8) 
Moderately differentiated 57% (n=31) 78% (n=35) 
Poorly differentiated 22% (n=12) 4% (n=2) 0.029. 
Molecular characteristics 
Ki-ras activating mutation (exon 1) 43% (n=23) 29% (n=13) 0.158 
Ki-ras activating mutation (cod on 35% (n=19) 16% (n=7) 0.027. 
12) 
APC truncating mutation 41% (n=22) 51% (n=23) 0.302 
Ki-ras promoter methylation 2% (n=1) 4% (n=2) 0.413 
0 6-MGMT promoter methylation 44% (n=24) 33% (n=15) 0.365 
APC promoter methylation 33% (n=18) 29% (n=13) 0.879 
hMLH1 promoter methylation 11% (n=6) 16% (n=7) 0.205 
Microsatellite Instability (Positive) 6% (n=3) 2% (n=1) 0.391 
TP53 Status (Positive) 59% (n=32) 56% (n=22) 0.710 
Follow-up 
Cigarette Smoker (yes) 20% (n=11) 18% (n=8) 0.744 
Colorectal cancer related mortality 44% (n=25) 29% (n=12) 0.044. 
Survival Time (years, mean) 3.31 3.88 0.145 (95% Cl) (2.67 - 3.96) (3.16- 4.59) 
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3.3.2 Extended Analysis 
Since n=99 in this study, Kaplan-Meier analysis (Kaplan and Meier 1958) (also 
known as Product Limit Estimator Analysis) of survival was chosen instead of the 
more powerful multivariate statistical analysis such as Cox proportional hazards 
(Cox 1972). From baseline analysis, lamin A/C expression was closely correlated 
with colorectal cancer related patient mortality. Figure 3.3 shows the Kaplan-
Meier plot for cumulative survival in relation to lamin A/C status. The graphical 
representation shows a clear difference in cumulative patient survival between 
the lam in A/C subgroups during the first 4 years of followup. Patients harbouring 
lamin A/C negative tumours had a much better cumulative survival compared to 
their lamin A/C positive counterparts. This supported data provided by simple 
cross-tabs analysis in table 3.1 and 3.2 and added further strength to these 
observations since Kaplan-Meier analysis is a much more robust statistical 
approach than simple chi-square (x.2) cross-tabulation. This is because Kaplan-
Meier analysis takes into account censored data, that is losses from the sample 
before the final outcome is observed (for instance, if a patient dies before the 
end of follow-up, but not as a result of colorectal cancer). 
Finally, in order to test this correlation further, a binary logistic regression was 
used to predit the effect of lamin A/C status on colorectal canecr related 
mortality. Results give an odds ratio of 0.508 (95% Cl: 0.219- 0.995, p=0.047). 
Whilst this is on the limit of statistical significance (the 95% Cl almost embrace 
unity and the accompanying p-value is just less than 0.05) it nonetheless 
supports the notion that lamin A/C status is linked to colorectal cacner mortality. 
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- present 
Kaplan-Meier plot of cumulative survival for colorectal cancer patients in relation 
to lamin NC expression. Data show an increased cumulative survival for patients 
harbouring lamin NC negative tumours over patients with lamin A/C positive 
tumours. 
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3.4 The NLCS Follow-up 
3.4.1 Basic Analysis 
With the data obtained from the initial study, there was a strong case to support 
further study in a much larger patient population, and so the original pilot study 
was expanded to include the remaining 637 specimens obtained from the NLCS, 
bringing the total number of specimens immunohistochemically profiled for lamin 
A/C expression to 737. 
When expanding the pilot study, it was important to determine the minimal 
detectable risk which could be confidently detected within the projected cohort 
size and follow-up period in order to be sure that data was of sufficient statistical 
power for results to be accepted. Using standard parameters to test at the 5% 
significance level (i.e. a = 0.05) and with a 90% power (i.e. 13 = 0.1 ), using 737 
patients with an available 7 year follow-up, the minimal detectable risk or minimal 
detectable hazard ratio was calculated as 1.19 (or 0.81 ). Hazard ratios equal to 
or above 1.19 (or equal to or below 0.81 depending on the direction of 
comparison) would reach statistical significance. Concomitantly, in order to 
detect small anticipated effect sizes (f= 0.02), with a significance of 5% and a 
power of 90%, the minimum population size required was 516. Thus it was safe 
to assume that the sample size would be large enough for data produced to be 
accepted as statistically significant. 
Of the 737 specimens assessed, 673 (91%) were scored for lamin A/C 
expression. Those excluded (n=64, 9%) were due to either a poor starting 
specimen in which there was a total or significant lack of tumour material making 
scoring unreliable, or whereby there was a lack of internal control (as described 
in section 2.3) 
The subsequent retrieval of information from the associated databases led the 
total number of specimens to be reduced further to 658 unique cases (89% of 
original total) due to duplication of patient administration codes. Incidentally, of 
those duplications in patient material blocks, both slides had been scored blind 
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for lamin A/C expression and gave the same results in all cases. A further 2 
specimens were then also excluded on the grounds that they were later 
histologically confirmed by a senior pathologist (Professor Adriaan de Bru"ine, 
University of Maastricht, The Netherlands) as signet ring tumours and not 
adenocarcinomas, which left a total of 656 patients for statistical analysis. 
During the follow-up period, from 1st January 1989 until 31st December 1996, 246 
patients died, with 163 (66%) of these patients dying as a result of colorectal 
cancer. Information on primary cause of death as well as, primary, secondary 
and tertiary complications was retrieved from the PALGA database. Colorectal 
cancer related death was concluded if colorectal cancer was determined as 
either the primary cause of death or as a primary, secondary or tertiary 
complication, using the International Classification of Diseases system. ICD-9 
codes 153.0 through 153.9; 154.0 through 154.3 and 154.8 are representative of 
colorectal cancer related death. 
Of the 656 available specimens immunohistochemically assessed, nuclear lamin 
A/C expression was found to be positive in 463 (70%) patients and negative in 
193 (30%) patients. 
Simple descriptives were carried out on baseline characteristics first to assess 
the study population and identify potential factors of interest for furt~er analysis. 
These are reported in table 3.3 which presents population and tumour 
characteristics of the follow-up study according to fate. The study population was 
considered normal with 55% (n=365) patients being male, 10% (n=68) patients 
exhibiting family history of colorectal cancer and Dukes' staging being distributed 
as follows: Dukes' A, 25% (n=160); Dukes' B, 33% (n=215); Dukes' C, 26% 
n=167; and Dukes' D, 13% (n=79). 5% of patients (n=35) were not reported to 
have been graded and where necessary were excluded from analysis. 
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Table 3.3 Baseline population and tumour characteristics according to fate 
p-value 
Patient characteristics 
Gender (male) 56.1% (n=277) 53.9% (n=88) 0.625 
Family history of CRC (yes) 11.7% (n=58) 12.2% (n=20) 0.407 
Age at diagnosis (years, mean) 68.06 67.60 0.471 (95% Cl) (67.64- 68.47) (67.01-68.18) 
Tumour characteristics 
Dukes' stage 
Dukes A 30.2% (n=149) 6.7% (n=11 ) 
Dukes B 36.9% (n=182) 20.2% (n=33) 
Dukes C 22.1% (n=109) 35.5% (n=58) 
Dukes D 5.4% (n=27) 31 .9% (n=52) <0.001 * 
Tumour Location 
Proximal 31.0% (n=153) 35.5% (n=58) 
Distal 33.6% (n=166) 26.9% (n=44) 
Rectosigmoid 12.1% (n=60) 9.2% (n=15) 
Rectum 21.7% (n=1 07) 26.9% (n=44) 0.178 
Tumour Differentiation 
Well differentiated 11 .1% (n=55) 7.3% (n=12) 
Moderately differentiated 64.0% (n=316) 61 .3% (n=1 00) 
Poorly differentiated 11.7% (n=58) 17.7% (n=29) 
Undifferentiated 0.6% (n=3) 1.8% (n=3) 0.065 
Molecular Characteristics 
Ki-ras activating mutation (exon 1) 30.8% (n=152) 49.6% (n=81 ) 0.077 
Ki-ras activating mutation (cod on 12) 21 .7% (n=107) 37.4% (n=61) 0.132 
APC truncating mutation 76.6% (n=378) 90.7% (n=1 48) 0.586 
Ki-ras promoter methylation 2.4% (n=12) 3.6% (n=6) 0.922 
0 6-MGMT promoter methylation 36.7% (n=181) 42.9% (n=70) 0.172 
APC promoter methylation 32.2% (n=159) 40.4% (n=66) 0.685 
hMLH1 promoter methylation 18.0% (n=89) 22.0% (n=36) 0.600 
Microsatellite Instability (Positive) 8.1% (n=40) 4.9% (n=8) 0.032. 
TP53 status (Positive) 47.2% (n=233) 69.3% (n=113) 0.215 
Lamin AIC status (Positive) 68.1% (n=336) 77.9% (n=127) 0.018. 
Follow-up 
Cigarette Smoker (yes) 24.9% (n=123) 24.5% (n=40) 0.237 
Survival Time (years, mean) 5.01 1.59 <0 001. (95% Cl) (4.84- 5.18) (1.40- 1.77) 
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Based on a typical significance cutoff of p:S0.05, data from simple analysis 
carried out (detailed in table 3.3) showed that colorectal cancer related mortality 
was significantly higher in patients as Dukes' stage increased: Dukes' A, 
observed 11, expected 40; Dukes' B, observed 33, expected 53; Dukes' C, 
observed 58, expected 41, Dukes' D, observed 52, expected 20. This was to be 
expected since it is the original basis of the scoring system devised by Cuthbert 
Dukes in 1932 (Dukes 1932). Data did not however give strong evidence to 
support tumour location as a factor influencing colorectal cancer related mortality 
in this study group. Nor did it offer evidence to suggest that previous family 
history affects patient outcome supporting the notion that family history is 
correlated with an increased likelihood of colorectal cancer development, but not 
associated mortality in patients (Butterworth, Higgins et al. 2006). 
Tumour differentiation state showed an indication of trend (p=0.065) and 
suggested that patients harbouring poorly differentiated tumours are more 
closely correlated with colorectal cancer related mortality than are patients with 
moderately or well differentiated tumours again supporting observations which 
have been well documented in previous work (Newland, Chapuis et al. 1981 ). 
This pattern also pertained to undifferentiated tumours, but since n=6 in this sub-
group, it could not be considered statistically reliable. 
There was no difference in age at diagnosis and colorectal cancer related 
mortality supporting the notion that outcome is not linked to age at diagnosis. As 
expected, the mean survival time was significantly lower for the colorectal cancer 
related mortality patient group. Patients in the non-colorectal cancer related 
mortality group survived on average 3 times longer. The average survival time of 
5.01 years (95% Cl: 4.84 - 5.18) for non-colorectal cancer related mortality 
patients appeared lower than one might have expected but this was due to the 
follow-up period being capped to a maximum of 7 years. This suliVival time is 
often referred to as the "patient at risk" period, i.e. the time tat risk of dying as a 
result of their primary colorectal tumour following surgery. Thus it can be said 
that in the 7 years of follow-up, the average survival time, or at risk period of 
patients either surviving to the end of follow-up or dying but not as a result of 
colorectal cancer related mortality was 5.01 years 95% Cl: 4.84 - 5.18) [vs. 1.59 
105 
years (95% Cl: 1.40 - 1.77) in the colorectal cancer related patient group, 
(p<0.001 )]. 
When looking at molecular characteristic data in relation to colorectal cancer 
related mortality, there was only a single variable which reached statistical 
significance at baseline considering the scope of factors included. Unfortunately 
data for Ki-ras promoter methylation was only available for 102 (16%) patients 
(of which 18 exhibited methylation of the Ki-ras promoter region). This meant that 
the data was insufficient to support reliable conclusions in this study. For all other 
molecular characteristic variables, missing values were below 2% (n=13). 
The two molecular characteristics which differed between the two groups were; 
activating mutations in the Ki-ras oncogene which exhibited an indication of trend 
(p=0.077), suggesting that patients harbouring a Ki-ras activating mutation in 
exon 1 were more closely correlated with colorectal cancer related mortality 
(observed 81, expected 58) than those not harbouring a Ki-ras mutation 
(observed 152, expected 175). This data follows what has previously been 
published in regard to the link between Ki-ras mutations and patient mortality 
[reviewed in detail by Bos (Bos 1989)]. The other was Microsatellite Instability as 
determined by immunohistochemical analysis. Data suggested that patients with 
microsatellite instable tumours were less likely to be associated with colorectal 
cancer related mortality following surgery (p=0.032). However,' whilst this 
supports previously published work (Thibodeau, Bren et al. 1993), the number of 
microsatellite instable tumours in the general population is low (typically just less 
than 1 0%) and this was also represented in our study population (1.3%, n=48). 
Cigarette smoking was found to have no significant detectable effect of colorectal 
cancer related mortality in this study population. 
The most important finding of this study was the very close correlation of lamin 
A/C status with colorectal cancer related mortality which strongly supported the 
initial data obtained from the pilot study. The data had a high statistical 
significance (p=0.018) and from a priori power calculations, we know that the 
' 
sample size is big enough to support statistical credibility. Data showed that 
lamin A/C positive patients were more closely correlated with colorectal cancer 
related mortality (observed 127, expected 114) than lamin A/C negative patients 
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who were less closely correlated (data shown in table 3.4, [observed 36, 
expected 49]). 
Baseline population and tumour characteristics were then analysed according to 
lamin AIC expression to determine whether expression correlated with any of the 
previously mentioned factors. This was carried out to help to identify confounders 
which would need to be considered in later extended analysis. 
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Table 3.4 Baseline population and tumour characteristics according to lamin 
AIC expression 
Lamin AJC Lamin AJC 
p-value 
Patient characteristics 
Gender (male) 54.4% (n=252) 58.5% (n=1 13) 0.334 
Family history of CRC (yes) 10.0% (n=46) 11.4% (n=22) 0.581 
Age at diagnosis (year, mean) 68.20 67.25 0.010 * (95% Cl) (67.79-68.61) (66.67-67.84) 
Tumour characteristics 
Dukes' stage 
Dukes A 21 .1% (n=92) 36.6% (n=68) 
Dukes B 37.9% (n=165) 26.9% (n=50) 
Dukes C 26.7% (n=116) 27.4% (n=51 ) 
Dukes D 14.3% (n=62) 9.1%(n=17} <0.001 * 
Tumour Location 
Proximal 36.5% (n=167) 23.3% (n=44) 
Distal 31 .2% (n=143) 35.4% (n=67) 
Rectosigmoid 10.3% (n=47) 14.8% (n=28) 
Rectum 22.0% (n=101) 26.5% (n=50) 0.010. 
Tumour Differentiation 
Well differentiated 11.3% (n=45) 12.9% (n=22) 
Moderately differentiated 71.9% (n=287) 75.4% (n=129) 
Poorly differentiated 16.8% (n=67) 11 .7% (n=20) 0.290 
Molecular Characteristics 
Ki-ras activating mutation (exon 1) 38.0% (n=176) 29.5% (n=57) 0.046 * 
Ki-ras activating mutation (cod on 12) 27.6% (n=128) 20.7% (n=40) 0.160 
APC truncating mutation 82.% (n=381 ) 83.% (n=162) 0.814 
Ki-ras promoter methylation 2.80% (n=13) 2.59% (n=5) 0.806 
0 6-MGMT promoter methylation 38.8% (n=180) 36.7% (n=71) 0.613 
APC promoter methylation 36.0% (n=167) 30.0% (n=58) 0.182 
hMLH1 promoter methylation 18.% (n=85) 20.% (n=40) 0.434 
Microsatellite Instability (Positive) 7.99% (n=37) 5.69% (n=1 1) 0.287 
TP53 status (Positive) 52.6% (n=244) 52.8% (n=1 02) 0.842 
Follow-up 
Cigarette Smoker (yes) 21 .5% (n=100) 20.2% (n=39) 0.672 
Colorectal cancer related mortality 27.4% (n=127) 18.6% (n=36) 0.018 * 
Survival Time (years, mean) 3.73 4.49 <0.001 * 
(95% Cl) (3.52-3.95) (4.17-4.80) 
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Based on a typical significance cutoff of ps0.05, patients in the lam in A/C positive 
expression group were older at diagnosis by approximately 1 year [68.20 (95% 
Cl: 67.79 - 68.61) vs. 67.25 (95% Cl: 66.67 - 67.84) , p=0.010], had 
considerably higher colorectal cancer related mortality (27.4% vs. 18.6%, 
p=0.018) and exhibited a shortened survival period [3.73 (95% Cl: 3.52- 3.95) 
years to 4.49 (95% Cl: 4.17- 4.80) years, p<0.001] as compared to patients in 
the lamin A/C negative expression group. 
Moreover, Dukes' stage and tumour location were also closely correlated with 
lamin A/C expression status. A higher proportion of Dukes' A tumours were 
found in the lamin A/C negative expression group (observed 68, expected 48) as 
opposed to more Dukes' D (observed 62, expected 55) tumours being present in 
the lamin A/C positive patient population. Interestingly, Dukes' C patients were 
observed as expected in both lamin A/C positive (observed 116, expected 117) 
and lamin A/C negative (observed 51, expected 50) {p<0.001). Similarly, within 
the lamin A/C positive expression group, more tumours were found located in the 
proximal colon (observed 167, expected 149) than in other regions {p=0.010). 
As for molecular characteristics, the finding which was most significant was the 
association of Ki-ras activating mutations in exon 1 and lamin A/C status. Data 
suggested that fewer lamin A/C negative tumours exhibit a Ki-ras mutation 
(observed 57, expected 70) and more lamin A/C positive tumours harbour a Ki-
ras mutation than expected (observed 176, expected 164) {p=0.046). The p-
values for the other molecular characteristics were not statistically significant with 
p~0.160 in all cases (table 3.4). Thus it could be concluded that these variables 
are independent of lamin A/C expression and as such this does not lead one to 
believe that they may be confounding factors influencing patient survival in this 
study. The extent of the influence of Ki-ras activating mutations and other 
molecular characteristic variables on patient outcome in relation to lamin A/C 
status is assessed later in this chapter. 
The colorectal cancer related mortality data shown at the bottom of table 3.4 
shows that more patients in the colorectal cancer related mortality group are 
lam in A/C positive (observed 127, expected 114) than expected and less are 
lamin A/C negative (observed 36, expected 49) than expected {p=0.018). 
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3.4.2 Analysis 
More powerful statistical analysis using Cox regression (or proportional hazards 
regression)(Cox 1972) was used to investigate the effect of each variable 
individually and als.o in combination upon patient outcome. Cox regression gives 
much better estimates of survival probabilities and cumulative hazard than those 
provided by the simpler Kaplan-Meier function (as carried out in section 3.2.2). 
Survival probabilities and cumulative hazard ratios were calculated using 
unadjusted analyses based on the mortality risk for absence vs. ·presence of 
lamin A/C expression alone; stratified analyses based on the mortality risk for 
absence vs. presence of lamin A/C expression in patient subgroups (i.e. tumour 
location); and multivariate analyses based on absence vs. presence of lamin A/C 
expression adjusted for potential confounders. 
The cumulative hazard at a timet is the risk of dying between time 0 and timet, 
and the survivor function at time t is the probability of surviving to that time. In 
this study, the cumulative hazard refers to death as a result of colorectal cancer. 
Coefficients or hazard ratios (HR) above 1 indicate a worse prognosis (i.e. the 
hazard; colorectal cancer related mortality, is more likely to occur) and a 
coefficient of less than 1 indicates a protective effect of the variable (against 
colorectal cancer mortality) with which it is associated. A coefficient of 1 indicates 
no effect of the variable on the likelihood of hazard occurrence. 
As one would expect unadjusted survival analysis of Dukes' stage versus 
colorectal cancer related mortality (figure 3.4) showed a decreasing cumulative 
survival with increasing Dukes' stage, and this powerful analysis results in a 
graphical illustration of the correlation noted in table 3.3. In a similar unadjusted 
survival analysis of lamin A/C expression vs. colorectal cancer associated 
mortality (figure 3.5), the strong correlation between lack of lamin AJ(!; expression 
and its associated increased cumulative survival (shown in table 3.4) is clearly 
seen. The relative hazard ratio (HR) is calculated at 0.59 (95%-CI: 0.41 - 0.86, 
p=0.006) and can be considered the key finding in this study, further supporting 
the pilot study and linking lamin A/C status to patient prognosis. 
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analysis in terms of differential lamin A/C expression and colorectal cancer 
related mortality. 
HR 0.59 (0.41 - 0.86) p=0.006 
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The long term survival of Duke's D patients is known to be extremely low, 
approximately 3% (as discussed in section 1.1.3) and figure 3.4 shows this poor 
cumulative survival. Thus with this in mind, figure 3.6 shows the stratification of 
lamin A/C influence on colorectal cancer associated mortality across the Dukes' 
stages. The apparent protective effect of lamin A/C negative expression in 
tumours pertains to Dukes' A through C, but appears to be absent in Dukes' D 
(figure 3.6); Dukes' A: HR 0.10 (0.01 - 0.82) p=0.032, Dukes' 8: HR 0.60 (0.25-
1.45) p=0.254, Dukes' C: HR 0.59 (0.33 - 1.07) p=0.083, Dukes' D: HR 1.01 
(0.71 - 1.93) p=0.385. However, the only statistically significant data is for 
Dukes' A where p < 0.05. 
To further test the extent of the Dukes' D stage influence on unadjusted survival 
analysis (figure 3.5) further unplanned exploratory stratified analysis was 
performed. Figure 3.7A shows the difference in cumulative survival between pre-
metastatic (Dukes' stage A through C) and metastatic forms of the disease. 
Analysis showed that the effect of Dukes' Don the crude unadjusted hazard ratio 
was indeed present although its influence was considered relatively small. The 
relative lamin A/C negative vs. lamin A/C positive hazard ratio for Dukes' A, B 
and C decreased from 0.59 (95%-CI: 0.41 - 0.86), p=0.006 to 0.53 (95%-CI: 
0.33 - 0.85) p=0.008 (figure 3.78) when Dukes' D data was excluded. Since 
Dukes' D is an advanced post-operative clinical stage of the Dukes' system 
where distant metastasis has already occurred and will ultimately cause death, it 
seems logical that the lamin A/C status of the primary tumour bears little or no 
significant influence on survival based on the parameters of this study. 
Further survival analysis showed that decreased colorectal cancer related 
mortality was associated with patient tumour location in the following manner; 
rectosigmoid junction, distal colon, proximal colon, rectum (figure 3.8). Whilst this 
was not statistically significant in simple baseline analysis of patient outcome 
(table 3.3, x! test p-value = 0.178), tumour location was shown to be correlated 
to lamin A/C expression (table 3.4, x! test p-value = 0.010). Stratified analysis of 
tumour location with lamin A/C expression shows that the protective effect 
observed by lamin A/C negativity in tumours was highest in the rectosigmoid 
junction (HR 0.22 (95%-CI: 0.05 - 0.96) p=0.044), followed by the rectum (HR 
0.58 (95%-CI: 0.29 - 1.14) p=0.113), then the distal colon (HR 0.63 (95%-CI: 
113 
0.32 - 1.24) p=0.177) with the protective effect being almost non-existent in the 
proximal colon (HR 0.96 (95%-CI: 0.51 - 1.82) p=0.909) (figure 3.9). However, 
since there appeared to be no statistically significant effect on patient outcome in 
relation to tumour location and due to non significant p-values {p>0.05), the only 
' data which could be considered of any significance, would be that from the 
rectosigmoid junction where the protective effect of lamin A/C expression 
appeared to be at its greatest, and the p-value fell just within the confines of 
statistically significant. That said, when undertaking stratified analysis such as 
this, it is important to bear in mind that the power of such analysis decreases. 
Within the rectosigmoid junction substrata, n=75 which makes it the smallest of 
the four substratum, and as such the number of patients is insufficient to count 
such observations as statistically reliable in this case. 
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Proportional hazards regression plots of survival analysis for differential lamin 
AJC expression and colorectal cancer related mortality stratified for Dukes' stage. 
Data shows an increased cumulative survival for lamin A/C negative patients 
across Dukes' stages A to C, but a loss of this protective effect within the Dukes' 
D strata. 
Dukes' A: HR 0.10 (95% Cl: 0.01 - 0.82) p=0.032 (n = 160) 
Dukes' B: HR 0.60 (95% Cl : 0.25- 1.45) p=0.254 (n = 215) 
Dukes' C: HR 0.59 (95% Cl: 0.33- 1.07) p=0.083 (n = 167) 
Dukes' D: HR 1.01 (95% Cl : 0.71 - 1.93) p=0.385 (n = 79) 
115 
Figure 3.7 
(A) Proportional hazards regression plot of survival analysis for colorectal cancer 
related mortality stratified for Dukes' stage A, B and C vs. D. Data highlights the 
significant difference in survival rate between pre-metastatic (Dukes' A, B and C) 
and metastatic (Dukes' D) tumours. 
(B) Proportional hazards regression plot of cumulative survival for differential 
lamin A/C expression and colorectal cancer related mortality for Dukes' stages A 
through C only. Data show a small decrease in hazard ratio when Dukes' D 
patients are excluded (see figure 3.5). 
3.78 HR 0.53 (95%-CI: 0.33- 0.85) p=0.008 
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Figure 3.8 
Proportional hazards regression plot of cumulative survival for colorectal cancer 
patients in relation to tumour location. Data shows highest cumulative survival is 
observed in patients with rectosigmoid tumours and the lowest in patients with 
rectal tumours. 
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Proportional hazards regression plots of survival analysis for differential lamin 
NC expression and colorectal cancer related mortality stratified for tumour 
location. Data shows an increased cumulative survival for lamin NC negative 
patients as we move from distal to proximal locations. 
Proximal Colon: HR 0.96 (95% Cl: 0.51 - 1.82) p=0.909 
Oistal Colon: HR 0.63 (95% Cl: 0.32- 1.24) p=0.177 
Rectosigmoid Junction: HR 0.22 (95% Cl: 0.05- 0.96) p=0.044 
Rectum: HR 0.58 (95% Cl: 0.29- 1.14) p=0.113 
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Table 3.5 combines an overview of the stratified analyses of lamin NC across 
various factors graphically represented, alongside other analyses which have not 
been shown graphically but were considered interesting from baseline analysis. 
Table 3.5 Stratified analysis of potential confounders for patient outcome 
Stratification 95%CI 
n HR -value Lower u er 
Unadjusted 656 0.59 0.006 0.41 0.86 
Gender Male 365 0.58 0.019 0.37 0.92 
Female 291 0.43 0.004 0.24 0.77 
Dukes' Stage A 160 0.10 0.032 0.01 0.82 
8 215 0.60 0.254 0.25 1.45 
c 167 0.59 0.083 0.33 1.07 
D 79 1.01 0.385 0.71 1.93 
(Premetastatic) A~C 542 0.53 0.008 0.33 0.85 
Tumour Location Proximal 211 0.96 0.909 0.51 1.82 
Distal 210 0.63 0.177 0.32 1.24 
Rectosigmoid 75 0.22 0.044 0.05 0.96 
Rectum 151 0.58 0.113 0.29 1.14 
Tumour Well 67 0.29 0.100 0.06 1.27 
Differentiation Moderate 416 0.67 0.064 0.44 1.02 
Poorly 87 0.34 0.041 0.12 0.96 
Undifferentiated 6 1.42 0.775 0.13 2.43 
Family history Yes 68 0.54 0.001 0.38 0.78 
No 588 0.20 0.123 0.03 1.56 
Ki-ras activating No 423 0.64 0.015 0.42 1.05 
mutation (ex on 1) Yes 233 0.55 0.025 0.29 1.01 
Microsatellite No 608 0.54 0.475 0.16 1.43 
Instability Yes 48 0.58 0.060 0.39 0.84 
Cigarette Smoker No 517 0.49 0.030 0.209 0.718 
Yes 139 0.68 0.145 0.406 1.159 
The stratified analysis data detailed in table 3.5 looked to compare the protective 
effect of lamin NC negative tumours on survival across patient subgroups. A 
change in hazard ratio of more than 10% (± 0.06) with a corresponding 
statistically significant p-value was considered for further analysis. 
Stratified analysis for gender showed that in females the protective effect of 
lamin NC negative expression in tumours increased from a HR 0.59 to a HR 
0.43 (p=0.004) suggesting that women benefited more from tumours being lamin 
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A/C negative. Data also suggested that the protective effect wa~ marginally 
increased (HR 0.59 to HR 0.54, p=0.001, n=68) in patients with a family history 
of colorectal cancer. 
Simple baseline analysis of microsatellite instability and patient outcome had 
suggested a close correlation between the two. However, just as in baseline 
analysis of microsatellite instability and lamin A/C expression, the stratified 
analysis showed that there was no reliably detectable evidence to correlate the 
two directly. That is to say that whilst microsatellite instability as an independent 
variable may exert a protective effect on patient survival, it had no influence on 
lam in A/C status. Nor did the correlation between lamin A/C status and colorectal 
cancer related mortality alter with differential microsatellite instability status. 
What was supported from baseline analysis was the correlation between Ki-ras 
activating mutations in exon 1 and lamin A/C expression. The stratified analysis 
indicated that the protective effect noted in lamin A/C negative tumours was 
marginally increased (HR 0.59 to HR 0.55, p=0.015) in tumours harbouring a Ki-
ras exon 1 activating mutation and decreased in patients not harbouring a Ki-ras 
exon 1 activating mutation (HR 0.59 to HR 0.64, p=0.015). Such data called for 
further multivariate analysis in order to determine the extent (if any) of interaction 
between the two variables in influencing patient mortality and is discussed later. 
Another interesting finding was some clear evidence to suggest that the 
protective effect of a lamin A/C negative status in tumours was most beneficial in 
individuals that did not smoke. This is interesting considering that in simple 
univariate baseline analysis (table 3.3 and table 3.4) there appeared to be no 
correlation between cigarette smokers and colorectal cancer related mortality, or 
cigarette smokers and lamin A/C status. Data suggested that the protective 
effect is increased (HR 0.59 to HR 0.49, p=0.03) in non-smokers. 
Multivariate analysis involved observation and analysis of lamin A/C expression 
as well as another variable at the same time to look for correlations and to test 
the independence of an observed effect by one variable alone. Figure 3.5 gives 
an unadjusted hazard ratio of 0.59 for lamin A/C negative tumours vs. lamin A/C 
positive tumours. Multivariate analysis was carried out and tabulated in table 3.6 
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showing results from the analyses and highlighting significant changes in the 
unadjusted lam in AJC hazard ratio in relation to each of the separate covariates. 
Table 3.6 Multivariate analysis of Jam in AIC expression with potential confounders 
Multivariate adjustment 95%CI HR -value Lower u er 
Unadjusted lamin NC 0.593 0.006 0.409 0.858 
Adjusted for; 
Gender 0.593 0.006 0.409 0.859 
Family History 0.595 0.006 0.410 0.861 
Age at Diagnosis 0.588 0.005 0.405 0.852 
Dukes' stage 0.673 0.039 0.462 0.980 
Tumour Location 0.609 0.007 0.419 0.884 
Tumour differentiation 0.641 0.013 0.436 0.941 
Ki-ras activating mutation (exon 1) 0.603 0.007 0.411 0.883 
Ki-ras activating mutation (codon 12) 0.602 0.007 0.410 0.881 
APC truncating mutation 0.583 0.006 0.398 0.851 
Ki-ras promoter methylation 0.592 0.006 0.409 0.857 
0 6-MGMT promoter methylation 0.593 0.006 0.409 0.858 
APC promoter methylation 0.589 0.005 0.406 0.853 
hMLH1 promoter Methylation 0.594 0.006 0.410 0.860 
Microsatellite Instability 0.561 0.005 0.379 0.827 
TP53 expression 0.591 0.006 0.404 0.864 
Cigarette smoker 0.590 0.006 0.407 0.854 
Hazard ratios listed in table 3.6 show the relative effect of lamin AIC expression 
on colorectal cancer related mortality when the influence of the covariate is 
removed . Multivariate analysis is an extremely powerful statistical technique, 
much more so than univariate and stratified analyses and uses much more 
stringent parameters to avoid false positives. Typically one would not undertake 
such analysis on confounders which show little or no effect in univariate or 
stratified analysis. However, all factors investigated in univariate and stratified 
analyses have been included for completeness. 
As an example, when we carry out multivariate analysis for gender, we observed 
no change in the unadjusted hazard ratio (0.59) which indicated that any effect 
on survival related to patient gender does not influence the protective effect of 
lamin A/C negative status in tumours. lt is worth noting that the stratified analysis 
which suggested that a lamin AIC negative status was more protective in women 
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is still valid, since multivariate analysis removes the influence of the protective 
effect of gender from the observed protective effect of lamin A/C status. Typically 
changes of less than 10% (0.06) in the hazard ratio were not considered to be 
statistically significant. 
With the above in mind, when multivariate analysis adjusting for Dukes' staging 
was carried out, the relative protective effect of lamin A/C negative tumour status 
was diminished (HR 0.59 to HR 0.67, p=0.039). This was expected since Dukes' 
stage has an undeniably large effect on patient survival. lt is worth noting that 
none of the other molecular characteristics investigated exhibited any significant 
influence (on an individual basis) on the effect of lamin A/C status on colorectal 
cancer related mortality in patients. Similarly where stratified analysis seemed to 
suggest that non-smokers benefited from the protective effect of lamin A/C 
negative tumours, this was not evident in multivariate analysis. This was also 
true for Ki-ras activating mutations and microsatellite instability. Such 
observations are to be expected, since where there was little or no effect shown 
in univariate analysis of a variable on colorectal cancer related mortality, the 
removal of this 'non-existent' effect would not affect the observed influence of 
lamin A/C status on survival. 
3.5 Discussion 
The availability of access to the NLCS allowed the investigation of lamin A/C 
expression in a large scale, controlled study. Using an initial pilot study of 100 
patients allowed the feasibility of a much larger study to be tested beforehand. 
Since some of the tumour specimens had been stored for anything up to 20 
years before they were used it was important to ascertain whether it would be 
possible to achieve reproducible results in a study of this design. Following a 
successful optimisation of previously established protocols (Shi, Key et al. 1991 ; 
lgarashi, Sugimura et al. 1994; Kawai, Serizawa et al. 1994; Taylor, Shi et al. 
1996; Barker, Huls et al. 1999), the pilot study showed that A-type lam in epitopes 
can be successfully re-exposed in formalin-fixed, paraffin-embedded tissue 
sections. With a successful protocol in place which was closely related to those 
currently used in standard pathology laboratories the full archive could be 
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accessed and data obtained accepted as both reliable and reproducible. This 
would have further implications in the role of clinical diagnostic testing. 
In short, data shows that patients harbouring lamin AJC positive tumours are 
almost twice as likely to die than patients of the same clinicopathological grade 
who harbour a lamin AJC positive tumour [HR 0.59 (95%-CI: 0.41 - 0.86) 
p=0.006]. When this effect is stratified for the clinicopathological Dukes' staging, 
it is seen to be at its greatest in the earliest (Dukes' A) stage [HR 0.10 (95%-CI: 
0.01 - 0.82) p=0.032 (n = 160)], and almost non-existent in the latest (Dukes' D) 
stage [HR 1.01 (95%-CI: 0.71 - 1.93) p=0.220 (n = 79)]. Thus, when Duke's D 
patients are excluded from analysis (since greater that 90% die of colorectal 
cancer related mortality due to the presence of distant metastases), we see an 
improvement in the hazard ratio of lamin AJC negative tumours from 0.59 to 0.53 
[(95%-CI: 0.33 - 0.85) p=0.008].The inverse of this analysis gives a hazard ratio 
of is 1.88 [(95%-CI: 1.17- 3.03) p=0.008] showing that patients with lamin AJC 
positive tumours are almost twice as likely to die from colorectal cancer related 
mortality than their clinicopathologically similar lamin AJC negative counterparts 
across Dukes' stages A to C. 
When we undertake multivariate analysis to remove the effect of Dukes' stage on 
survival from the observed protective effect of lamin AJC negative status in 
tumours, we see as would be expected, a decrease in the hazard ratio of HR 
0.59 to a HR 0.67 [(95%-CI: 0.46- 0.98) p=0.039]. That is to say, that once any 
effect on patient survival which is correlated with a particular Dukes' stage is 
removed, we still see a clear yet diminished protective effect of lamin AJC 
negative status in tumours. lt is important to remember here though that Dukes' 
stage does not influence the tumour, but that the tumour influence~ the Dukes' 
stage, i.e. the tumour is of a particular Dukes' stage due to its behaviour. 
However, since the 95% confidence intervals almost embrace unity and the 
significance is markedly decreased, it suggests that whilst lamin AJC when used 
in collaboration with the clinicopathological Dukes' staging system is a strong 
predictor of patient mortality, when used as an independent biomarker it is 
unable to offer a prognosis equal to or better than Dukes' alone. As has been 
I 
previously discussed in chapter 1, there is an urgent need to identify prognostic 
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markers that can be used alongside these clinicopathological staging systems to 
highlight intermediate stage cancer patients (Dukes' B & C) that suffer tumour 
recurrence which cannot be detected by the clinicopathological staging systems 
alone. Thus one would seek to use lamin A/C expression in a clinical setting as a 
prognositic biomarker alongside the clinicopathological Dukes' staging system to 
predict high risk intermediate stage patients likely to experience sLch relapse. 
I 
Thus lamin A/C status could be used as one of a panel of biomar~ers to guide 
the administration of adjuvant therapies in intermediate stage colorectal cancer. 
When stratified for various subgroups, we see that the protective effect is most 
notable in the following categories; female patients, rectosigmdid tumours, 
absence of Ki-ras activating mutations, Dukes' A tumours and non-smokers. 
When we look more closely at lamin A/C expression across the 
clnicopathological Dukes' staging system, we note that the appareht protective 
effect of lamin A/C negative expression in tumours pertains to Duk~s· A through 
C; HR 0.53 (95% Cl: 0.33- 0.85) p=0.008. However, within a particular Dukes' 
stage alone, we only see a statistically significant contribution to the Dukes' A 
strata patients; Dukes' A: HR 0.10 (0.01 - 0.82) p=0.032, Dukes' B: HR 0.60 
(0.25 - 1.45) p=0.254, Dukes' C: HR 0.59 (0.33 - 1.07) p=0.083, Dukes' D: HR 
1.01 (0.71 - 1.93) p=0.385. This suggests that independently of Dukes' staging, 
lamin A/C expression status could only be used as a prognostic marker of 
mortality in early stage colorectal adenocarcinoma (before invasion of the 
muscularis mucosae occurs). That said, one could speculate that' since lamin 
A/C negative tumours proffer a statistically significant better prognosis in Dukes' 
A, which also pertains to Dukes' B and C (albeit non-significantly) that lamin A/C 
expression may be indicative of more aggressive tumour phenotype and hence 
earmark patients harbouring these tumours as high risk. 
When we look at the case of smoking however, we know that colorectal cancer is 
a multiple step progressive disease which develops over many years. As such it 
is impossible to tell when ex-smokers quit or when current smokers may have 
started in relation to the initiation and subsequent progression of the disease. 
Hence this single variable itself is not accurate enough to implicate it reliably in 
this study without retrieving further detailed information such as; cigarette 
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smoking status (never vs. ever and never vs. former or current), frequency 
(number of cigarettes per day), duration (years), age at first exposure (years), 
I 
and time since cessation (years). Such information is available within the NLCS 
archive and could be retrieved for further analysis but was not in this ;study. 
I 
In regard to other stratified variables, data for Ki-ras activating mutations in exon 
1 is intersting. lt has been documented in the international, collaborative 
RASCAL study that colorectal cancer patients who harbour Ki-ras activating 
mutations exhibit a poorer survival than those who do not due to an associated 
more aggressive tumour phenotype within these tumours (Andreyev, Norman et 
al. 1998; Andreyev, Norman et al. 2001 ). Data shows that there is an increase in 
the lamin A/C negative HR [0.59 to 0.64 (p=0.015)] for tumours not harbouring 
Ki-ras activating mutations and a decrease in the lamin A/C negative HR [0.59 to 
0.55 (p=0.025)] for tumours that harbour a Ki-ras activating mutation. This would 
suggest that tumours harbouring a Ki-ras mutation, a lamin A/C negative status 
may actually allow the tumour to become even more aggressive, thus resulting in 
a poorer patient outcome than their lamin A/C positive counterparts. Such an 
observation however calls for further in depth analysis before reliable 
conclusions can be drawn. 
Where we observed an effect of microsatellite instability on patient s~rvival (table 
3.3), this effect appears to have little or no influence on the protective effect of 
lamin A/C status when we consider it as a covariate. However, this1 observation 
is limited in that n=48 for MSI positive patients and so there are insufficient 
numbers in both the lam in A/C negative (n=37) and lam in A/C positive (n=11) 
groups for statistical reliability. 
To date there have been no large scale studies of this type for colorectal cancer, 
and previous work has reported ambiguous correlations of lamin A/C expression 
in colorectal adenocarcinomas. Thus findings contained here within break new 
ground in implicating A-type lamins in colorectal carcinogenesis and most 
importantly linking them to patient mortality. These results are extremely 
I 
interesting in the light of work published in other cancer types (BCC, SCC, lung 
and lymphoid) where loss of lamin A/C expression is correlated with a poorer 
survival in patients (Venables, Mclean et al. 2001; Agrelo, Setien et al. 2005). In 
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previous work, the loss of A-type lam in expression is correlated with• an increase 
in aggressiveness of the cancer due to a loss in the regulation of proiiferation. 
Moreover this work contradicts work by Moss and eo-workers (Moss, 
Krivosheyev et al. 1999) who showed that in all colorectal adenocarcinomas they 
studied (n=17), there was reduced or absent lamin A/C expression. However, as 
has been previously discussed, their investigations were limited to ia very small 
number of patients as opposed to the 656 described in this study. The use of a 
highly sensitive monoclonal anti-lamin A/C antibody and direct comparison with 
an internal control in every sample used in this study compared to the 
polycolonal antisera and lack of internal controls used by Moss and eo-workers 
lends greater credibility to the immunohistochemical staining obtained. Most 
importantly though, the size of the study population and available followup 
I 
means that for the first time, lamin A/C expression in colorectal tumdurs could be 
directly correlated with patient mortality. 
The data described in this chapter suggests that positive lamin A/C expression 
results in a poorer patient survival, therefore suggesting that the loss of lamin 
A/C expression may be detrimental to the aggressiveness of the tumour in this 
instance. In previous work in in vitro colorectal cancer cell lines, Willis (Willis 
2005) has suggested that there is a gradual loss of A-type lamin expression in 
pre-metastatic colorectal tumours, with returning strong expres1sion in the 
metastases associated with these tumours. Unfortunately, such findings could 
not be corroborated in immunohistochemical studies and may serve to highlight 
the inherent difficulties associated with extrapolating in vitro modfils to in vivo 
situations of this type. 
Work carried out concomitantly to this study by Casans, Cox et al. (unpublished 
data), has focussed on full length colonic crypt profiling and revealed both 
interesting and relevant data. Results have shown lamin A/C to be a putative 
marker of adult stem cells located at the base of the colonic crypts.: With this in 
mind, it could shed light onto the apparent protective effect of lamin A/C negative 
status in tumours. Casans, Cox et a/ have shown that stem cells residing at the 
I 
base of colonic crypts immunohistochemically stain strongly positive for lamin 
A/C using the same Jol2 anti-lamin A/C antibody (Dyer, Kill et al. 1997). 
127 
Meanwhile, cells located adjacent to this putative stem cell zone, in the transient 
amplifying zone are clearly negative for lamin A/C expression. Based on this, the 
observation that lamin A/C positive tumours result in a poorer cumulative survival 
in patients could be attributed to differences in a stem-cell like phenotype of the 
tumour cells. That is to say that lamin A/C negative tumours may possess a 
phenotype more characteristic of the transient amplifying cells, w~ereas those 
lamin A/C positive tumour possess a phenotype more characteristic of the 
colonic stem cells, thus resulting in a potentially more aggressiv~ phenotype, 
although the exact causal mechanism remains unclear. 
This hypothesis has also been tested further in in vitro models by Willis, Cox et a/ 
(unpublished data). We have shown that changes in lamin A/C expression in the 
SW480 Dukes' 8 cell line result in concomitant changes in both attin bundling 
proteins and cell adhesion molecules at both the RNA and protein level. Such 
data has led to the conclusion that loss of lamin A/C expression in these cells 
results in a less motile, more adherent cellular phenotype than the lamin A/C 
positive counterparts. Such data begins to answer the biological question as to 
why lamin A/C positive tumours proffer a poorer patient prognosis than their 
clinicopathologically similar lamin A/C negative counterparts. 
lt has long been known that whilst clinicopathological staging of solid tumours is 
the most reliable method for predicting patient outcome and determining patient 
treatment regimens, it fails to discriminate the innate biological characteristics 
and behaviour of the these tumours. As such, patients in clinicopathologically 
similar groups exhibiting markedly different outcomes and also responding in 
very different manners to adjuvant therapies. The call for promising measurable 
biomarkers which can be used in conjunction with current staging systems is 
becoming greater in order to allow more accurate predictions of patient 
prognosis in these situations where clinical staging alone may be problematic 
and potentially misleading (Mandrekar, Grothey et al. 2005; O'Connell, Atha et 
al. 2005; He 2006; Natarajan and FitzGerald 2007). 
Data shown in this chapter (figure 3.1 and figure 3.2) serve to highlight this 
problem clearly. Figure 3.1 C and 3.2D are clinicopathologically identical, Dukes' 
8, moderately well differentiated tumours. Standard classification would not 
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distinguish the two tumours as different and subsequent recommended 
treatment regimens would almost certainly be the same for both patients. lt is 
obvious however, that there must be an innate biological difference between 
these two tumours based on the markedly differential lamin A/C expression 
patterns. Studies such as this go a long way to justifying the call for biomarker 
panels to complement current clinicopathological staging systems. 
Since we observe no correlation between the clinicopathological status of 
tumours, i.e. tumour differentiation state and there also appears to be little 
correlation with other molecular variables investigated, the notion of using lamin 
AIC as a complementary prognostic marker to the clinicopathological Dukes' 
stagin system to identify high risk patients for is very promising. Just as Moss 
and eo-workers concluded in theri paper in 1999 (Moss, Krivosheyev et al. 1999) 
that altered lamin expression may be a biomarker of malignancy in the 
gastrointestinal tract, it is safe to say that evidence presented herein allows lamin 
A/C to be considered a sensitive and also independent biomarker of a high-risk 
colorectal cancer population and as such could be used in conjunction with other 
I 
markers in order to establish a reliable biomarker panel to guide the therapeutic 
strategy of colorectal cancer patients. 
3.5.1 Relevant Information: 
International Patent No: PCT/GB20071002316 University of Durham. (2007) 
Determining a Prognosis of Colorectal Cancer. 
Appendix 11 (p205) - CRT Licensing Opportunity: Lamin AIC: Prognostic 
marker in colorectal cancer. Cancer Research Technologies, Londo"', UK. 
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CHAPTER 4- Differential lam in A expression does not 
affect ~-catenin activity in the SW480 colorectal cancer 
cell line 
4.1 Background 
4.1.1 Wnt signalling and its implication in colorectal cancer, 
The proto-oncogenic and tumour suppressor effects of Wnt gen~s was first 
I 
discovered 25 years ago (Nusse and Varmus 1982) and quickly led to the 
' 
intense investigation into the role of these genes in human can~r. The later 
discovery of wingless (Wg) the Drosophila homolog of wnt-1, then led to the 
elucidation and assembling of a signalling pathway which was subsequently 
found to contain many cancer causing genes (Cabrera, Alonso et al. 1987; 
Rijsewijk, Schuermann et al. 1987). 
The normal regulation of cell growth and survival can be subverted by a variety 
of genetic defects that alter transcriptional programs responsible for controlling 
cell number. The canonical Wnt signalling pathway is an outstanding example of 
this. The Wnt ligands, of which there are approximately 20 members in 
vertebrates, are secreted glycoproteins that are loosely categorised according to 
their ability to promote neoplastic transformation [for review, see (Wodarz and 
Nusse 1998)] . 
Signalling is initiated by the secreted Wnt proteins, which bind to a class of 
seven-pass transmembrane receptors encoded by the frizzled genes (Bhanot, 
Brink et al. 1996; Yang-Snyder, Miller et al. 1996; He, Saint-Jeannet et al. 1997). 
Activation of the frizzled receptor leads to the phosphorylation of the dishevelled 
(Dsh) protein which, through its association with axin prevents glycogen 
synthase kinase 3p (GSK3p) from phosphorylating P-catenin (ltoh, Krupnik et al. 
1998; Kishida, Koyama et al. 1999; Lee, lshimoto et al. 1999; Peters, McKay et 
al. 1999; Smalley, Sara et al. 1999). Unphosphorylated p-catenin then escapes 
recognition by P-transducin repeat containing protein (p-TrCP), a component of 
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an E3 ubiquitin ligase and is able to translocate to the nucleus of the cell where it 
engages transcription factors such as Tcf and Lef (Behrens, von Kries et al. 
1996; Molenaar, van de Wetering et al. 1996; Hart, Concordet et al. 1999). 
Additional components in the pathway include casein kinases I and 11, both of 
which have been proposed to phosphorylate dishevelled (Dsh) (Willert, Brink et 
al. 1997; Peters, McKay et al. 1999; Sakanaka, Leong et al. 1999) (see figure 
1.7). 
Although Lefffcfs bind directly to DNA through their high-mobility group (HMG) 
domains, they are incapable of independently activating gene .transcription 
(Eastman and Grosschedl 1999; Roose and Clevers 1999). This h~s best been 
illustrated for Lef, which through its binding to the cofactor AL Y, makes indirect 
contacts with a second transcription factor AML (Bruhn, Munnerlyn ,et al. 1997). 
The Tcfs however do not contain the ALY binding site and like Lefs: they cannot 
independently activate genes. However, target genes are transcribed on eo-
activation with p-catenin suggesting that p-catenin supplies the additional 
cofactors required for transcriptional activation (Molenaar, van de Wetering et al. 
1996). 
The simple interpretation is that the Tcf/Lef-p-catenin complex comprises a 
bipartite positive acting transcription factor in the canonical Wnt signalling 
pathway. This interpretation agrees well with developmental studies in which the 
manipulation of Lefffcf function results in phenotypes consistent witn the genetic 
manipulation of WnUp-catenin signalling (Behrens, von Kries et al. 1996; Huber, 
Korn et al. 1996; Brunner, Peter et al. 1997; van de Watering, Cavallo et al. 
1997). Thus the manifestation of cancer by aberrant Wnt signalling· is known to 
result from inappropriate gene activation mediated by stabilised p-catenin. 
We now know that at least three regulatory genes in the Wnt signalling pathway 
are mutated in primary human cancers and several others promote experimental 
cancers in rodents. The primary cause in colorectal cancer is mutations affecting 
the Adenomatous Polyposis Coli (APC) gene (as discussed in section 1.2). Other 
mutations include those in axin, GSK3P and P-catenin itself. Nonetheless, in all 
of these cases the common denominator is the constitutive activation of gene 
transcription by p-catenin. 
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Recent evidence has been published which also implicates Emerin (a lamin A/C 
type 11 integral membrane protein target) in the regulation of p-catenin activity. 
This regulation is mediated through the APC-Iike tail domain of Emerin. When 
over-expressed in HEK293 cells, p-catenin is restricted to the cytoplasm and 
activity is inhibited. Expression of dominant negative mutant Emerin (lacking its 
APC-Iike tail domain) results in constitutive p-catenin activity and enhanced 
nuclear accumulation (Markiewicz, Tilgner et al. 2006). Such evidence has 
suggested that inner nuclear membrane proteins such as Emerin can influence 
cell signalling pathways by restricting access of transcription co-acti~ators to the 
nucleus (Markiewicz, Tilgner et al. 2006). Whilst such data holds true for the 
I 
HEK293 and human fibroblasts, to date it has not been investigated in colorectal 
cancer or the gastrointestinal epithelia. 
4.1.2 The Adenomatous Polyposis Coli (APC) protein 
The tumour suppressing APC gene is located on chromosome, 5q21 and 
encodes a large protein (312kDa) that is involved in many cellular processes . 
Central to APC's tumour suppressive function is its down-regulatory capacity of 
p-catenin, a key component of the Wnt signalling transduction p~thway. This 
pathway plays an important role in both embryonic develqpment and 
tumourigenesis. In the central region of APC, seven motifs of 20 amino acids 
have been identified, which not only bind p-catenin but also facilitate down-
regulation of p-catenin through interactions with axin and GSK3P . Tre spectrum 
of APC mutations is large, with inactivation usually mediated through truncation 
of the protein removing the central and N-terminal parts of the APC gene. The 
result is complete or partial loss of function allowing p-catenin to a~cumulate in 
the cell and translocate to the nucleus where it serves as a eo-activator of the 
Tcf/Lef proteins and activates transcription of Wnt target genes. 
Most sporadic colorectal cancers have an APC truncation in one allele and loss 
of heterozygosity in the other allele (Kinzler and Vogelstein 1 Q96; Rowan, 
Lamlum et al. 2000). The APC mutations associated with cancer are consistently 
truncated before amino acid 1638 and hence lack the axin binding domains 
(Smits, Kielman et al. 1999). The APC protein is pivotal in controlling p-catenin 
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activity in colonic epithelia and disruption of this tight regulation results in 
colorectal neoplasia. Thus it is also important in this chapter to assess the effect 
(if any) of differential lamin A expression on P-catenin activity in a system where 
the functional regulation of p-catenin by APC is in place. 
The SW480 colon cancer cell line has previously been transfected with full length 
functional APC constructs and shown to partially restore p-catenin regulation in 
these cells (Neufeld, Zhang et al. 2000). Using the same pFiag-APC construct, 
the SW480-GFP and SW480-GFP-Jamin A cell lines were transfected to restore 
APC function and to enable the potential effects of differentiallamin A expression 
on P-catenin activity to be evaluated. 
4.1 .3 Selection of colorectal cancer cell lines 
Colorectal carcinoma is known to develop over many years through a series of 
pathologically and histologically distinct stages. By explanting tissue from 
individual stages, cell lines can be created representing each order of 
malignancy and enabling in vitro studies of the molecular characteristics 
concomitant with disease progression. Previous work has already established a 
model system of cell lines with which the nature of A-type lamin expression in 
respect to colorectal cancer development could be investigated (Willis 2005). 
ECACC is a European cell repository of cell lines, particularly those derived from 
tumours. From this source, the SW480 colorectal cancer cell line - established 
from a Broders' grade IV (Broders 1925) (Dukes' B) adenocarcinoma of the 
colon in a 50 year old white Caucasian male (Leibovitz, Stinson et al. 1976) was 
obtained. The SW480 colorectal cancer cell line produces carcinoembryonic 
antigen (CEA), typical of colorectal adenocarcinomas and harbours a type I 
truncating mutation in the APC protein. That is to say that the truncated protein 
still retains its n-terminal Nuclear Export Signal (n-NES) but lack the c-terminal 
Nuclear Export signals (c-NESs). lt has also been shown to be naturally deficient 
in lamin A (Willis 2005) and as such the cell line had been previously stably 
transfected with EGFP-Iamin A and EGFP constructs (as described in section 
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2.4.2) providing an in vitro model system whereby the effects of differentiallamin 
A expression can be evaluated. 
4.1.4 Summary 
Evidence from chapter 3 has shown a protective effect of lamin AIC negative 
status in patient tumours. In this chapter I address the hypothesis that differential 
lamin A expression in an in vitro colorectal cancer cell line affects the activity of 
the transcriptional eo-activator p-catenin either directly or via its binding partners. 
The effects of differential lamin A expression on p-catenin activity are 
investigated in the presence of both the non-functional truncated and full length 
functional forms of the APC protein. Data show that the canonical Wnt signalling 
pathway is not directly implicated as the mediator of differential prognosis in the 
lamin A/C positive vs. negative tumour patients. 
4.2 Results 
4.2.1 Lamin A expression does not affect ~-catenin activity 
Dual luciferase TOPFiash reporter assays (Korinek, Barker et al. 1997) were 
carried out to determine the effect of differential lamin A expression on the 
relative activity of p-catenin in the SW480 colon cancer cell line. These assays 
are used widely to measure the transcriptional activity of TCF and ~-catenin 
[pTOPFiash contains multimerised Tcf-binding sites linked to a luciferase 
reporter; (Korinek, Barker et al. 1997)]. 
Transfection of the SW480 clones was very successful, and their TOPFiash 
activity as a ratio of firefly luciferase:Reni//a values were determined. The 
SW480-GFP and SW480-GFP-Lamin A clones were also transfected with 
pFOPFiash (whose Tcf-binding sites are mutated). All FOPFiash values were 
exceedingly low, confirming the specificity of the Tcf/~-catenin input. Triplicate 
data did not show any significant difference in relative TOPFiash mediated P-
catenin activity between the SW480-GFP-Iamin A or SW480-GFP lines (Figure 
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4.1A) ll = 7.3%, t = 1.0454, df = 4, p = 0.3548. Concomitantly to this, there was 
no statistically significant differences in relative j3-catenin activity for 
untransfected and FOPFiash transfected clones; ll = 5.0%, t = 0.2999, df = 4, p 
= 0.7792 and ll = 29.5%, t = 2.6835, df= 4, p = 0.0550 retrospectively. 
Figure 4.1 B shows whole cell extract immunoblotted with the anti-lam in AJC Jol2 
mouse monoclonal antibody (Dyer, Kill et al. 1997). Data shows a clear 
expression of both GFP-Iamin A and stabilised endogenous lamin A in the GFP-
Iamin A transfected cell line vs. control. 
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Figure 4.1 
(A) Relative 13-catenin activity as measured by Dual luciferase TOPFiash reporter 
assays. Measurements are arbitrary firefly luciferase luminosity relative to Renilla 
luminosity. Data shows no significant difference in relative TOPFiash luciferase 
activity between the SW480-GFP and SW480-GFP-Iamin A clones. 
TOPFiash ll. = 7.3% t = 1.0454, df= 4, p = 0.3548. 
FOPFiash; ll. = 29.5%, t = 2.6835, df = 4, p = 0.0550. 
Untransfected; ll. = 5.0%, t = 0.2999, df= 4, p = 0.7792. 
(B) Whole cell extract from SW480-GFP (lane 1) and SW480-GFP-Iamin A (lane 
2) resolved on a 10% SOS-PAGE gel, transferred to nitrocellulose and 
immunoblotted with mAb Jol2 - anti-lamin A/C (Dyer, Kill et al. 1997). Equal 
loading was confirmed by eo-blotting for 13-actin. Data shows an absence of lamin 
A in the SW480-GFP cells, alongside the presence of GFP-Iamin A and 
stabilised endogenous lamin A in the SW480-GFP-Iamin A cells. 
Molecular markers are in kDa. 
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4.2.2 pFiag-APC transfection of the SW480 clones 
Both the SW480-GFP and SW480-GFP-Lamin A clones were successfully 
transfected with the full length pFiag-APC construct. Following successful 
transformation of the Escherichia coli strain DH5a, the pFiag-APC construct was 
extracted and purified. After extraction and purification, gel electrophoresis 
yielded a single band of approximately 14,000 bp when run against known DNA 
standards (figure 4.2A). PCR analysis on the purified product using the APC 
primers detailed in table 2.2 and subsequent gel electrophoresis yielded the 
expected fragment size of roughly 950 bp indicating the plasmid was intact and 
also contained the full-length APC (figure 4.2B). 
Following successful transfection of the pFiag-APC construct into the SW480 
clones, APC expression was determined at both the RNA and protein level. 
Confirmation at the RNA level was via RT-PCR of whole cell RNA extracts using 
primers designed specifically for the n-terminal region of the APC gene as 
detailed in table 2.2, (figure 4.3B). This region is lost by the type I truncating 
mutation associated with the SW480 colon cancer cell line and served to 
highlight expression of the transfected full length APC construct. p-actin levels 
were also monitored to ensure equal amounts of cDNA had been reverse 
transcribed and that the reverse transcription system and PCR reactions were 
working successfully (figure 4.3A). Data show a clear band visible at 
approximately 950 bp in the pFiag-APC transfected SW480-GFP-Iamin A clone 
and an absence of this band in the untransfected SW480-GFP-Iamin A clone 
indicating successful expression of the pFiag-APC construct at the RNA level 
(figure 4.3B). 
Following a successful confirmation at the RNA level, functional expression of 
the pFiag-APC construct was evaluated by one-dimensional SOS-PAGE and 
immunoblotting of whole cell extracts as detailed in section 2.5 (figure 4.4). Data 
show equal p-actin loading (A) and equal expression levels of the endogenous 
truncated APC protein, as well as a lower expression of the pFiag-APC construct 
(*)containing full length APC, in the pFiag-APC transfected SW480-GFP-Iamin A 
clone (B). 
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Figure 4.2 Gel electrophoresis of pFiag-APC construct extracted and purified 
from E. coli DH5a. 
(A) Plasmid extraction and purification of three bacterial colonies with bands 
showing at approximately 14,000 bp representative of the full length pFiag-APC 
construct. 
(B) PCR of extracted and purified plasmid DNA for n-terminal APC fragment. 
Bands at approximately 950bp indicate the presence of the 958bp cloned n-
terminal APC fragment. 
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Figure 4.3 
(A) P-actin RT-PCR. Lane 1, negative control; Lane 2, SW480-GFP (10~1 
loading); Lane 3, SW480-GFP-Iamin A (1 0~1 loading); Lane 4, SW480-GFP (1~-tl 
loading); Lane 5, SW480-GFP-Iamin A (1 ~d loading). Data shows that p-actin 
levels are consistent between clones. 
(8) APC RT-PCR. Lane 1-3, Untransfected SW480-GFP-Iamin A; Lanes 4-6, 
SW480-GFP-Lamin A; pFiag-APC. Data shows no band in any of the 3 
untransfected SW480-GFP-Iamin A lines (lanes 1-3) indicating the absence of 
the pFiag-APC construct. Meanwhile a clear band is observed in all 3 of the 
SW480-GFP-Lamin A; pFiag-APC lines (lanes 4-6) representative of successful 
pFiag-APC transfection , at approximately equal efficiencies. 
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Figure 4.4 Western Blot analysis of pFiag-APC and ~-actin expression. 
(A) Whole cell extracts from SW480-GFP-Iamin A (lane1) and SW480-GFP-
Lamin A; pFiag-APC (lane 2) resolved on a 10% SOS-PAGE gel, transferred to 
nitrocellulose and immunoblotted with anti-~-actin which was used as a loading 
control. 
(B) Whole cell extracts from SW480-GFP-Iamin A (lane1) and SW480-GFP-
Iamin A; pFiag-APC (lane 2) resolved on a 5% SOS-PAGE gel, transferred to 
nitrocellulose and immunoblotted with anti-APC antibody (Ab-1). 
lmmunoblots show an equal loading as revealed by ~-actin staining (A). Blots 
also show a comparable level of endogenous truncated APC (-180k0a) (B) and 
a clear band in SW480-GFP-Lamin A pFiag-APC transfected line (B, lane 2) at 
approximately 320k0a indicating a positive expression of the construct at the 
protein level. 
Molecular markers are in kOa 
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4.2.3 In the presence of full length functional APC, lamin A does not 
affect ~-catenin activity 
Following successful transfection of the SW480-GFP and SW480-GFP-Lamin A 
cell lines with the pFiag-APC construct, dual luciferase TOPFiash reporter 
assays were carried out again to assess the influence of laminA expression on 
p-catenin activity in the presence of the fully functional APC protein. 
Data from reporter assays (figure 4.5) show that there is still no effect on P-
catenin activity in either the presence or absence of GFP-Iamin A with full length 
functional APC. Data shows a difference in relative TOPFiash luciferase activity 
between the SW480-GFP;pFiag-APC and SW480-GFP-Iamin A;pFiag-APC 
clones of; l:l = 7.5%, t = 0.9180, df = 4, p = 0.4106. This is comparable to the 
7.3% change observed in figure 4.1. p-catenin reporter activity is however 
repressed by approximately 40% upon transfection with pFiag-APC as would be 
expected due to the partial reinstating of its regulation (figure 4.6). 
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Figure 4.5 
SW480 (pFiag-APC) P-Catenin Reporter Assays 
SW480-GFP; 
pFiag-APC 
SW480-GFP-Lamin A; 
pFiag-APC 
' • Untransfected 
OTOPFiash 
O FOPFiash 
Relative p-catenin activity as measured by dual luciferase TOPFlash reporter 
assays. Measurements are arbitrary firefly luciferase luminosity relative to Renilla 
luminosity. Data shows no significant difference in relative TOPFiash firefly 
luciferase activity between the SW480-GFP; pFiag-APC and SW480-GFP-Iamin 
A . pFiag-APC transfected clones; b.= 7.5%, t = 0.9180, df= 4, p = 0.4106. 
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SW480-GFP SW480-GFP-Lamin A 
Relative P-catenin activity as measured by dual luciferase TOPFiash reporter 
assays. Measurements are arbitrary firefly luciferase luminosity relative to Renilla 
luminosity. Data shows no significant difference in relative TOPFiash luciferase 
activity between the SW480-GFP and SW480-GFP-Lamin A, untransfected and 
also pFiag-APC transfected clones. Data does show a down-regulation in P-
catenin activity following successful pFiag-APC transfection of approximately 
40% in both cases. 
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4.3 Discussion 
The TOPFiash assay was chosen to measure 13-catenin activity since it is highly 
quantitative and reproducible and also measures the most relevant function of 
APC In tumour suppression (i.e. its ability to reduce Tcf/13-catenin mediated 
transcription). Furthermore, it provides a direct read-out of p-catenin activity that 
is highly specific, unlike measuring endogenous target genes whose expression 
levels reflect inputs from Tcf and other signalling pathways at the same time. 
The hypothesis behind th is chapter's experiments was to determine whether the 
observed protective effects of lamin A/C negativity in colorectal tumours, which 
was established in chapter 3 was mediated through alterations in the canonical 
Wnt signalling pathway. Primary experiments showed that the relative activity of 
P-catenin was not affected by the presence or absence of GFP-Iamin A in the 
SW480 colon cancer cell line. As such this would lead one to believe that the 
Wnt target genes which are under the control of p-catenin mediated transcription 
are not altered by the presence or absence of lamin A expression in these cells. 
However, such conclusions were limited by the fact that p-catenin activity is no 
longer being correctly regulated in light of the APC type I truncating mutation 
present in the SW480 cell lines. In order to address this, full length functional 
APC was also transfected into the cells and shown to be expressed at both the 
RNA and protein level. Dual luciferase TOPFiash reporter assays were then 
undertaken but again showed no changes in P-catenin reporter activity with 
differential lamin A expression. This further supports the null hypothesis that the 
protective effect lamin A/C absence in colorectal tumours is not mediated 
through the canonical Wnt signalling pathway. 
As already mentioned, the type 11 integral membrane protein Emerin has been 
shown to play a role in the regulation of 13-catenin activity through its APC-Iike tail 
domain (Markiewicz, Tilgner et al. 2006). This work has shown that the presence 
of Emerin at the nuclear envelope down-regulates 13-catenin activity by excluding 
it from the nucleus in the HEK293 cell line and human fibroblasts. In addition to 
this, it was shown several years ago that the lamin A is required for the correct 
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localisation of Emerin to the inner nuclear membrane and in the event of a failure 
of nuclear envelope assembly, Emerin is redistributed throughout the cytoplasm 
(Vaughan, Alvarez-Reyes et al. 2001). With this in mind it would seem logical to 
assume that in the case of colorectal tumours where lamin AJC is completely 
absent from the nuclear envelope that there would be a redistribution of Emerin 
from the nuclear envelope to the cytoplasm. Concomitant to this one would also 
expect to see an increase in the activity of P-catenin in the light of this previous 
work. This could then be extrapolated further to proffer a poorer prognosis in 
patients due to still further increased P-catenin activity in lamin AJC negative 
tumour cells. 
What we actually see is the reverse of this and a better prognosis in patients with 
lamin AJC negative tumours, contradicting the mechanism proposed above. 
However it must be said that whilst these observations were true for both the 
HEK293 cells and human fibroblasts, similar experiments have not been done in 
colorectal epithelia or colorectal cancer cell lines. Since the behaviour of these 
cells is so closely regulated by the Wnt signalling pathway, it may be feasible 
that Emerin does not play a role in regulating P-catenin activity in these cells, or if 
it does, its influence is not to detected by the dual luciferase TOPFiash reporter 
assays. In terms of experimental design, if the effect of Emerin on P-catenin 
activity is small enough not to be detected then it could not account for the 
differences observed in survival between clinicopathologically similar patients 
with lamin AJC positive and lamin AJC negative tumours. 
Other work which has been carried out in the same SW480-GFP and SW480-
GFP-Iamin A cell lines has shown the mRNA expression of c-MYC, a key Wnt 
target whose expression is directly regulated by P-catenin activity and 
responsible for controlling cell proliferation (van de Wetering, Sancho et al. 2002) 
remains unchanged with differential lamin A expression (Willis 2005). Consistent 
with this, cell proliferation indices as measured by flow cytometry were also 
shown not to change (Willis 2005) also suggesting P-catenin activity remains 
unchanged with differentiallamin A expression. 
A better prognosis but concomitant lack of change in P-catenin activity between 
lamin A/C positive and lamin A/C negative tumours, indicates that the molecular 
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mechanisms behind the observed differences in patient survival must be a result 
of alterations in a pathway or pathways other than the canonical Wnt signalling 
pathway. Combined with data from chapter 3 which excludes other key 
tumourigenic factors such as Ki-ras mutations and TP53 status, it would be 
logical to look for alternative regulatory pathways which may be implicated in 
mediating this apparent protective effect. 
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CHAPTER 5- Genome-wide DNA Microarray analysis 
5. 1 Background and Introduction 
5.1.1 The call for genome-wide array studies 
Traditionally tumours have been categorised on the basis of clinicopathological 
and histological features (Cancerbackup 2008). However, the information gained 
from this type of microscopic examination of simple staining patterns does not 
reveal the underlying molecular events which are involved in tumourigenesis and 
progression leading up to that time. In order to obtain a deeper understanding of 
the biology of tumours, genome-wide DNA microarray is becoming more widely 
used. This is a powerful technique which can uncover gene expression 
signatures associated with different genotypes of clinicopathologically similar 
tumours. 
The multi-step process of tumourigenesis starts with a genetic or epigenetic 
alteration in a cell giving it a growth advantage. As aberrant cells propagate. 
genetic instability is accumulated and abnormal characteristics are gained. 
Cancer cells are typically self sufficient in growth signals, insensitive to apoptotic 
stimuli and have an increased telomerase activity enabling a larger number of 
cell divisions (Hanahan and Weinberg 2000). As a tumour grows it often further 
gains the ability to infiltrate through surrounding tissue and induce angiogenesis 
to supply itself with additional required nutrients and oxygen. The tumour will 
often ultimately spread to other organs distant from the primary tumour, and 90% 
of all cancer deaths are as a result of this secondary tumour metastasis (Sporn 
1997). Colorectal cancer is no exception to this (Fearon and Vogelstein 1990) 
Research carried out over the last decade has implicated numerous genes in the 
initiation and progression of colorectal cancer as well as highlighting the role of 
epigenetic changes as a result of DNA promoter methylation in this progression 
(Jones and Laird 1999; Herman and Baylin 2003). For example CpG island 
promoter hypermethylation of the LMNA gene in leukaemia and lymphoma has 
been correlated with the abrogation of lamin A expression at the level of 
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transcription and subsequently associated with poor survival in diffuse large 8-
cell lymphomas (Agrelo, Setien et al. 2005). 
To investigate all possible genetic aberrations in any form of cancer using 
traditional techniques is inconceivable hence the development of these high 
throughput expression microarray technologies. Such advancements have 
revolutionised our understanding of the cancer genome since they can evaluate 
changes in expression of thousands of genes at once (Ciarke, te Poele et al. 
2001; Stremmel, Wein et al. 2002; Basik, Mousses et al. 2003). DNA microarrays 
have enabled the identification of novel diagnostic and prognostic indicators 
which would not have been discovered otherwise (Dhanasekaran, Barrette et al. 
2001 ; Agrawal, Chen et al. 2002; Korkola, Estep et al. 2003) as well as enabling 
the classification of tumours according to their individual genetic signature 
(Golub, Slonim et al. 1999; Perou, Sorlie et al. 2000; Fuller, Wang et al. 2002; 
Korkola, Houldsworth et al. 2005) and subsequent genome-wide monitoring of 
responses to chemotherapeutic agents (Marton , DeRisi et al. 1998; Scherf, Ross 
et al. 2000). 
5.1.2 DNA Microarray Analysis 
The core objective in microarray data analysis is identifying genes whose 
transcript levels have been altered between different conditions. Usually this is 
presented as a ranking list of genes according to a statistical significance score. 
In the early days of microarray technology, articles were published using fold 
change as the single parameter to make a decision if a gene had changed or not 
(Sgroi, Teng et al. 1999; Rihn, Mohr et al. 2000; Carninci, Kasukawa et al. 2005). 
Considering the large number of genes and the small number of replicates the 
number of false positives produced was considerable. This is especially the case 
when we consider transcripts with high natural variation which will lead to high 
fold change values. Similarly a few of the large number of non-differentially 
expressed genes can result in deviating intensities in some experiments due to 
noise and thus again be falsely assigned as differentially expressed. That said, 
even with stringent controls and replicates, the main issue in microarray studies 
is how to retrieve valuable information from the enormous amount of generated 
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data. Since the field is relatively new, methods are continuously being developed 
to meet the demands of biological researchers. The main processes in the data 
analysis are the extraction of spot signal intensities, filtering of data, 
normalisation of data. assessment of differential expression , clustering and 
classification. Even this is not the whole story with the most important stage 
being the placing into context of other sources of information, such as biological 
databases, clinical features and other microarray experiments. There are several 
reviews which nicely summarise the complexity of these procedures (Brazma, 
Hingamp et al. 2001; Quackenbush 2006). 
In 2001, the Minimum Information About a Microarray Experiment (MIAME) was 
introduced by the Microarray and Gene Expression Data (MGED) society 
(Brazma, Hingamp et al. 2001) in an effort to standardise the manipulation and 
presentation of microarray data. These standards have now been adopted by the 
microarray community and are the basis of the majority of array databases. 
5.1.2.1 Clustering of data 
Nowadays, extraction of spot signal intensities, filtering of data, normalisation of 
data and assessment of differential expression is an automated part of genechip 
array software provided by many companies such as Affymetrix. What are then 
produced are lists of data from which researchers can begin their analysis. 
Whereas previously scientists would look for highly up- or down-regulated genes, 
the preferred approach now is that of cluster analysis, which is performed to look 
for expression changes in groups of closely related or similar genes. 
Clustering is performed to divide the massive amounts of gene expression data 
into groups based on similarity. In its simplest form this can be accomplished 
with one of two different strategies with each being suited for a different purpose. 
The first is known as unsupervised clustering and is used for exploratory analysis 
such as that undertaken later in this chapter. The second is supervised clustering 
which is often used to create a diagnostic device based on previously 
established gene expression signatures (Meyer and Ginsburg 2002; Spang 
2003; Wiese, Auer et al. 2007). 
151 
Unsupervised clustering is a way of obtaining a more comprehensible 
representation of the data set. With reduction techniques, such as principal 
component analysis (PCA), singular value decomposition (SVD) and 
multidimensional scaling, it is possible to visualise the data in two (and more 
recently three dimensional) space so that the distance relationships can be 
explored by visual inspection. Clustering aims to show relationships between 
genes or groups of genes and the biological samples which might be of 
biological relevance. 
Among the most common methods for exploratory grouping or clustering are 
hierarchical clustering, self organising maps (SOM) (Kohonen 1999; Toronen, 
Kolehmainen et al. 1999) and K-means clustering (Hartigan 1973). Hierarchical 
clustering is an agglomerative method which produces a dendrogram with a 
bottom-up structure. To start with, all data points are treated as separate 
clusters. The dendrogram is then formed by subsequently assigning the two 
closest clusters together to form new clusters. Distance between clusters can be 
calculated by using the minimum, maximum or the average distance between 
samples in two different clusters. ForK-means and SOM, the number of clusters 
to be formed is predetermined by the user. In K-means clustering, the samples 
are first randomly assigned to one of the K clusters. The centre of each cluster is 
obtained by calculating the mean or median of all Incorporated expression 
profiles. The samples are then reassigned to the closest cluster. New cluster 
locations are calculated from the new cluster members, followed by another 
reassigning procedure. This procedure is repeated until there are no more 
changes. The SOM algorithm is similar to K-means assigning samples to the 
closest cluster in an iterative process. The difference is that the samples in this 
case are mapped onto a two dimensional grid. To determine optimal numbers of 
clusters the ratio between cluster diameter and distance between clusters can be 
used. 
Supervised clustering on the other hand is performed to create a tool which can 
be used for discrimination of new data. Development of the classifier is based on 
prior information of how for instance tumour types are connected to appearance 
of the gene expression profiles. Supervised clustering techniques thus need a 
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dataset with information of the sample labels, i.e. if a tumour is malignant or not. 
The aim is to create a classifier which can classify new unlabelled samples and 
genes based on the microarray data. These can be divided into machine learning 
algorithms such as support vector machines (SVM}, ANN and K-nearest 
neighbours (KNN), and statistical linear discriminate analysis. SVM was first 
introduced by Vapnik in 1995 (Vapnik 1995) and applied to microarray data in 
2000 (Brown, Grundy et al. 2000; Furey, Cristianini et al. 2000). The algorithm 
calculates a separating hyperplane with maximised margins to the data points. 
SVM has been much used in supervised clustering of genome-wide expression 
data compared to the other methods mainly due to its capability of providing 
good generality despite the small sample sizes typical for microarray 
experiments (Furey, Cristianini et al. 2000). A weakness for clustering methods 
based on a molecular signature of thousands of features rather than a small set 
is that they are difficult to interpret in a biological context and not applicable to 
lower throughput techniques. Combining these however with feature selection 
methods makes them more useful and also reduces risk of over-fitting. Filtering 
and pruning are examples of strategies for feature selection. Filtering is based on 
the input data by filtering features based on a specific criterion. Selection can be 
performed based on a threshold or a number of top genes on a ranking or by 
evaluating the performance. 
5.1.2.2 Extraction of Biological Information 
Data mining microarray analysis often gives rise to long lists of potentially 
differentially expressed genes or clusters of genes and poses the problem of 
how to interpret these from a biological point of view. A number of tools have 
been developed to deal with this and the choice of which to use depends on the 
questions being asked. 
Identification of metabolic pathways is an extremely important part of gene 
expression profiling in order to acquire a mechanistic understanding of the 
disease in question. In order to establish the biological reasons behind why 
some genes or clusters of genes appear to be differentially expressed , one tries 
to find the biological features which are overrepresented in these groups. There 
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are several examples of biological annotations which can be used for this 
purpose which include; Gene Ontology terms, Swissprot key words and Kyoto 
Encyclopaedia of Genes and Genomes (KEGG) pathways (Ashburner, Ball et al. 
2000; Kanehisa, Goto et al. 2004). Currently the biggest effort in this field is the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) which consists of 
graphical representations of almost all currently known biochemical pathways 
(Ogata, Goto et al. 1999). 
lt may also be of interest to find out more about the function of the genes and 
how they are related to other biological pathways and processes. For this 
purpose, the Gene Ontology (GO) Consortium has constructed a vocabulary to 
describe genes and gene product attributes for biological processes, cellular 
components and molecular functions (Ashburner, Ball et al. 2000). There are 
several pieces of commercial software avai lable which enable comprehensible 
visualisation of gene expression levels in the different pathways such as 
PathwayStudio (Nikitin. Egorov et al. 2003) (Ariadne Genomics, MD, USA) and 
GeneSpring (Agilent Technologies, USA) alongside other freely available utilities 
such as Pathway Assist and GenMAPP (Dahlquist, Salomonis et al. 2002). A 
number of open access online tools are also available, which can calculate 
overrepresentation statistics for all GO terms with respect to a given data set; so 
called gene class testing (GCT) (AIIison, Cui et al. 2006), e.g. EASE (Dennis, 
Sherman et al. 2003), MAPPfinder (Doniger, Salomonis et al. 2003), Onto-
Express (Draghici, Khatri et al. 2003) and until recently the NetAffx Analysis 
centre provided by Affymetrix. 
One of the biggest reasons for genes being concordantly expressed is down to 
regulation by the same transcription factors in a particular signalling pathway. In 
eukaryotes combinations of transcription factors form cis regulatory modules in 
order for a gene to be expressed. Thus global changes in apparently unrelated 
genes can be clustered on this basis of eo-occurrence of transcription factors in 
conserved promoter regions and then evaluated with software such as CREME, 
JASPAR and cisREO (Sharan, Ben-Hur et al. 2004; Robertson, Croce et al. 
2006; Vlieghe, Sandelin et al. 2006) 
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5.1.3 Validation of array data 
Although microarray technology and data analysis is becoming more 
standardised and thus more reliable, artefacts can still be introduced at any time 
during an experiment and it is therefore necessary to validate the results. Once a 
number of target genes have been identified by microarray analysis, it is 
desirable to confirm RNA expression levels by an independent method. The 
most common method is quantitative RT-PCR (Rajeevan, Ranamukhaarachchr 
et al. 2001 ; Rajeevan, Vernon et al. 2001) because of its speed and relative 
cheapness. Northern blot has also been reported to give consistent results when 
compared to microarray (Taniguchi, Miura et al. 2001). 
In addition to validating transcript levels it is also important to measure levels of 
the corresponding proteins as we know that they are not always correlated. This 
can be done by various antibody based methods e.g. Western blot, 
immunohistochemistry, immunofluorescence or immunohistochemically via 
tissue microarrays (Kallioniemi, Wagner et al. 2001; Chuaqui, Banner et al. 2002; 
Mousses, Kallioniemi et al. 2002). These methods are however dependent on 
antibody availability, which can pose a problem in the case of unknown 
transcripts. However with the Human Proteome Atlas 
(http://www.proteinatlas.org/) well on the way, this should soon be solved. 
5.1.4 Summary 
Data from chapter 3 has shown a protective effect of lamin AIC negative status in 
tumours of colorectal cancer patients. Furthermore, data from chapter 4 has 
shown that the canonical Wnt signalling pathway classically at the heart of 
colorectal adenocarcinoma initiation and progression is not influenced by 
differential lamin A expression in our in vitro model and hence it can be 
concluded that it is not directly implicated in the observed protective effect of 
lamin A/C negative status in tumours. 
With no correlations being drawn from chapter 3 to link differential lamin 
expression with other oncogenic mutations in proteins such as TP53 and Ki-ras 
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either, this suggests that the observed protective effect is mediated through one 
or more other developmental pathways which have yet to be investigated. Thus, 
with the availability of the same SW480 colon cancer cell line model system used 
in chapter 4, an opportunity to conduct a screening genome-wide Affymetrix DNA 
Microarray analysis was accepted to explore members of other potential 
signalling pathways which may be influenced by differential lamin A expression 
and thus be implicated in mediating these observed differences in patient 
survival. 
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5.2 Results 
5.2.1 DNA Microarray dataset 
An opportunity was taken to carry out a qualitative Genome-wide DNA 
microarray pair-wise screening on the SW480-GFP-Iamin A and SW480-GFP 
cell lines using the Human Genome U133 Plus 2.0 high-density oligonucleotide 
Affymetrix GeneChip array (Affymetrix, Santa Clara, CA, USA). Extraction of spot 
signal intensity, filtering and normalisation of data was undertaken in accordance 
with the associated Affymetrix guidelines for the HG-U133 Plus 2.0 GeneChip 
using the Affymetrix GeneChip Operating Software (GCOS). 
The use of a simple 2 fold change cut-off to define differentially expressed genes 
was avoided as this is considered inadequate for elucidating pathway changes 
(Miller, Galecki et al. 2001 ; Hsiao, Worrall et al. 2004) as it does not take into 
account variance and offers no associated level of confidence (Budhraja, 
Spitznagel et al. 2003; Hsiao, Worrall et al. 2004). Instead, a preliminary gene list 
was generated by means of a series of relevance thresholds for signal detection 
level, signal detection p-value significance, expression change p-value 
significance and Signal Log Ratio (SLR) between the SW480-GFP and SW480-
GFP-Iamin A lines so as to avoid missing potentially important, yet subtle 
changes that would be missed using the simpler fold change cut-off method. 
Thanks go to Or Heiko Peters at Newcastle University for provision of this 
preliminary gene list 
At baseline the resulting gene list showed changes in expression were observed 
in a total of 7,577 genes between the SW480-GFP control and SW480-GFP-
Iamin A cell lines. 3,320 (43.8%) of these genes showed either up-regulation or 
moderate up-regulation in expression in the SW480-GFP-Iamin A cell line and 
4,257 (56.2%) showed down-regulation or moderate down-regulation in 
expression as compared to the SW480-GFP-Aione control (figure 5.1 B). 
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Figure 5.1. 
Changes in gene expression at baseline (before analysis) between the SW480-
GFP-Iamin A and SW480-GFP-Aione control cells. 
(A) Heat map showing the number of up-regulated genes (green) and down-
regulated genes (red) in the SW480 GFP-Iamin A transfected cell line compared 
to the SW480 GFP-Aione transfected control cell line. Colour intensity is 
representative of the degree of up or down-regulation, black or dark squares 
indicate little or no change. 
(B) Comparative analysis showing a higher proportion of down-regulated genes 
vs. up-regulated genes in the GFP-Iamin A transfected cell line. 
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The gene list was imported into the then freely available online NetAffx Analysis 
centre (https://www.affymetrix.com/analysis/netaffx/index.affx). The tools 
available in the NetAffx analysis centre are designed specifically for use with 
Affymetrix GeneChip catalogue arrays. 
Expression batch queries were carried out on all 7,577 genes to retrieve 
information for the complete probe list ready for further analysis. Information 
retrieved included but was not limited to the following; 
• Gene Ontology biological process classifications 
• Gene Ontology molecular function classifications 
• Gene Ontology cellular component classifications 
• GenMAPP pathway details 
• Ortholog Targets 
• Entrez Annotations and grades 
• OMIM , Ensembl, UniGene, and RefSeq entries 
• SwissProt and lnterPro descriptions 
• Chromosomal Locations 
• GenBank descriptions 
• As well as Affymetrix own descriptives 
For the purposes of this chapter, only the first three, Gene Ontology biological 
process, molecular function and cellular component were used for cluster 
analysis, the rest were used in a purely qualitative manner. 
5.2.2 Cluster Analysis 
Unsupervised hierarchical cluster analysis (as described in section 5.1.2.1) was 
carried out on the assembled gene list using the Gene Ontology Browser (GO 
Browser) provided in the Affymetrix online NetAffx Analysis Centre 
[(https://www.affymetrix.com/analysis/netaffx/) - which has now unfortunately 
been retired and replaced with the independent AMIGO GO Browser 
(http://amigo.geneontology.org/cgi-bin/amigo/go.cgi) and EBI GO Browser 
(http://ep.ebi.ac. uk/EP/GO/)]. 
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By definition, an ontology is a controlled vocabulary used to define an object or 
concept. In the case of microarray data, gene ontologies have been designed 
which encompass a structure of defined terms to describe genes by one of three 
different processes; biological process, molecular function or cellular component. 
lt is important to note here that gene products can fall into more than one 
category within an ontological branch. Such cases are observed when a gene 
falls into both a general and specific description which is classically associated 
with cluster analysis. 
Initial parameters for Gene Ontology mining were established before the process 
was run. Such parameters included the ontology branch to be investigated (i.e. 
biological process, molecular function or cellular component); the probe count 
threshold, i.e. the minimum number of clustering genes within a single node or 
cluster (also know as the ontological definition); and clustering significance, i.e. 
the chi-square (x2) value of significance of association for the genes clustering in 
a particular node, typically expressed as a p-value and set at ps0.05. Once these 
had been set, cluster analysis was carried out and resulted in a gene ontology 
map, or gene ontology graph as shown in figure 5.2. 
The gene ontology graph shown in figure 5.2 is a simple example of one 
constructed for the Biological Processes ontology branch with a minimum probe 
threshold of 5. lt is organised as such that as we move from left to right, we go 
from very general descriptions of biological process (such as cell metabolism) to 
very detailed description of biological process (such negative regulation of 
mitosis). The ontology graph is colour-coded such that the branches appearing 
red or purple are those exhibiting high chi-square (l) significance. That is to say 
that several if not all genes clustering within these nodes are closely related 
based on their ontological description and represent nodes or clusters which 
immediate attention can be focussed on. Numbers shown in brackets detail how 
many clustering genes are present in each node and this generally decreases as 
we move from left to right as nodes become more specific. 
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Figure 5.2 
Gene Ontology map clustered by Biological Process for genes differentially 
expressed between the SW480-GFP and SW480-GFP-Iamin A cell lines. 
Ontological definitions move from broad to specific as we move from left to right. 
Nodes shown in red or purple indicate tightly clustering significant genes. 
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Gene Ontology cluster analysis facilitates the identification of Gene Ontology 
terms which are enriched in a given gene list with a corresponding pre-
determined significance based on biological, physiological, and functional 
descriptions of the gene products. What results is a list of enriched and unique 
gene ontology terms and a targeted list of genes which can be further evaluated. 
Put into the context of this study, it allowed the generation of a list of biological 
processes (such as signalling pathways), molecular functions (such as cell 
adhesion) and cellular compartments (i.e. golgi apparatus) which exhibited 
differential gene expression between the SW480-GFP-Aione and SW480-GFP-
Iamin A cell lines. 
Large scale data sets such as that shown in figure 5.2 are typical of Gene 
Ontology analysis when starting with large gene lists. Whilst it does not provide 
useful direct information from the outset, it establishes a clustering platform in 
which more detailed exploration can occur. Initial isolation of those nodes or 
clusters which are shown to have strong chi-square (x2) significance allowed 
them to be looked at tn more detail and in particular allowed the inspection of 
individual node members. Such information allowed details on up- and down-
regulation of particular genes within the same node or cluster to be tabulated 
together. lt also allowed individual genes which cluster tn more than one node to 
be highlighted more easily. 
Gene ontology graphs were constructed for all three gene ontologies; biological 
process, molecular function and cellular component and nodes of particular 
interest within each ontology were extracted. Clustering according to biological 
process was the most successful, closely followed by molecular function. Since I 
was looking for genes which may be implicated in mediating the protective effect 
of lamin NC status in tumours, the cellular component ontology was explored, 
but not in any great detail. 
When looking at the clustered data, the aim was to focus initial attention on novel 
pathways not yet investigated. Since the starting gene list was over 7,577 genes, 
clustering for biological process and molecular function resulted in a huge 
number of genes and nodes being isolated (some 2,000 genes and 200 nodes). 
Inspection on an individual gene-by-gene or node-by-node basis would have 
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been an inefficient use of time. Instead in order to identify what could be 
considered as significant genes and nodes in the pathways highlighted, a filter 
was applied (as described in section 5.1.2.1 ). The initial filter was simple, yet 
stringent and was designed to isolate nodes where 3 or more of its clustering 
genes underwent a 4 fold change in expression between the SW480-GFP and 
SW480-GFP-Iamin A cell lines. This quickly reduced the list of target genes to a 
much more manageable size for visual inspection. The same analysis using a 2-
fold cut-off was also later used, but yielded little extra useful information. 
To summarise, to this point, the original 54,000+ lines of data produced from the 
microarray were initially analysed to reduce this to 7,577 genes showing 
statistically significant detectable spot intensities alongside statistically significant 
changes in gene expression between the SW480-GFP and SW480-GFP-Iamin A 
cell lines. These 7,577 genes were then clustered based on Gene Ontology 
terms for biological, physiological, and functional descriptions of the gene 
products with cluster threshold counts and chi-square (x2) significance value cut-
offs further reducing the target list of genes to approximately 2,000. 
The final step was to apply a filter which selected for ontological nodes 
containing 3 or more genes where there was a 4-fold change in expression 
between the SW480-GFP and SW480-GFP-Iamin A cell lines. The fold change 
filter reduced the list further to 133 genes and the node clustering filter reduced 
the number of nodes to approximately 40. In the interest of highlighting potential 
signalling pathways from the biological processes ontology branch, only 
ontological nodes representing cellular signalling pathways were extracted along 
with their clustering genes and are shown in table 5.1. Since the number of 
nodes within the molecular function ontology branch was much smaller. the gene 
ontology terms classically associated with cancer were selected and are detailed 
in table 5.2. 
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Table 5.1 Targeted ontological gene list (biological process) for genes showing a 4 fold change (Fe) in expression 
Biological Processes Clustering genes (4 fold change) 
Fibronectin 1 
Inflammatory response signalling Serum amyloid A 1 
Serum amyloid A2 
Serpin peptidase inhibitor, clade E, member 1 
TGFP signalling * Bone morphogenetic protein 4 
Transforming growth factor, p-induced 
Latent transforming growth factor P-binding protein 2 
A kinase (PRKA) anchor protein (gravin) 12 
G protein-coupled receptor 115 
G Protein signalling GNAS complex locus 
Guanine nucleotide binding protein (G protein), et in hi biter 1 
Guanine nucleotide binding protein (G protein), y11 
* Dual Specificity Phosphatase 5 
Wnt signalling * FOS-Iike antigen 1 
Platelet-activating factor acetylhydrolase isoform 1 b 
* Bone morphogenetic protein 4 
BMP signalling SMAD family member 6 
Activin membrane-bound homolog 
Insulin-like growth factor 2 (somatomedin A) 
Insulin receptor signalling Synaptosoma~associated protein 
Phosphoinositide-3-kinase, regulatory subunit 1 (p85et) 
RaP2 interacting protein 8 
Smal GTPase mediated signalling Ras and Rab interactor 2 
Ras homolog enriched in brain 
FN1 
SAA1 
SAA2 
SERPINE1 
BMP4 
TGFPI 
LTpP2 
AKAP12 
GPR155 
GNAS 
GNAI1 
GNG11 
DUSP5 
FOSL1 
PAFAH1B1 
BMP4 
SMAD6 
AMB 
IGF2 
SNAP25 
PIK3R1 
RPIP8 
RIN2 
RHEB 
Fe 
4.3 X Up 
5.3 X Up 
8.6 X Up 
4.9 X Up 
7.5 x Down 
4.9 x Up 
4.3 X Up 
B.Ox Up 
4.0x0own 
4.0xDown 
4.0xDown 
7.0 X Up 
4.6 X Up 
4.3 X Up 
4.1 x Down 
7.5xDown 
4.0x Down 
4.0xUp 
8.6 x Down 
9.8 x Down 
4.0 x Down 
7.0 X Down 
4.0x Down 
4.0x Down 
Table 5.2 Targeted ontological gene list (molecular function) for genes showing a 4 fold change (Fe) in expression 
Molecular Function 
Cell Adhesion 
Angiogenesis 
CeH differentiation 
Apoptosis 
Regulation of 
transcription 
Cell proliferation 
Clustering genes (4 fold change) 
Collagen, type XIII , a.1 
Fibronectin 1 
Cadherin 1, type 1, E-cadherin (epithelial) 
* Roundabout, axon guidance receptor, homolog 1 (Drosophila) 
Serum amyloid A 1 
Serum amyloid A2 
* Bone morphogenetic protein 4 
Serpin peptidase inhibitor, clade E, member 1 
Nucleolin 
* Roundabout, axon guidance receptor, homolog 1 (Drosophila) 
* Bone morphogenetic protein 4 
Doublecortin and CaM kinase-like 1 
Achaete-scute complex homolog 2 (Drosophila) 
* Roundabout, axon guidance receptor, homolog 1 (Drosophila) 
Nuclear protein 1 
Tumour necrosis factor receptor superfamily, member 11b 
Brain-derived neurotrophic factor 
* FOS-Iike antigen 1 
Paired related homeobox 1 
Zinc finger protein 33A 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog 8 (avian) 
Achaete-scute complex homolog 2 (Drosophila) 
Pinin, desmosome associated protein 
* Amphiregulin (schwannoma-derived growth factor)* 
Epithelial membrane protein 1 
lnterleukin 6 receptor 
'The amphireguhn precursor 1s Colorectum cell-derived growth factor)(CRDGF) 
COL13A1 
FN1 
CDH1 
ROB01 
SAA1 
SAA2 
BMP4 
SERPINE1 
NCL 
ROB01 
BMP4 
DCAMKL1 
ASCL2 
R0801 
NUPR1 
TNFRSF118 
BDNF 
FOSL1 
PRRX1 
ZNF33A 
MAFB 
ASCL2 
PNN 
AREG 
EMP1 
IL6R 
Fe 
4 .0 X Up 
4 .3 X Up 
4 .6x Down 
7.0 X Up 
5.3 X Up 
8.6 X Up 
7.5 x Down 
4.9 X Up 
4.0 X Up 
7.0 X Up 
7.5x Down 
5.3x Up 
4.0x Down 
7.0 X Up 
4 .0 X Up 
4 .3 x Down 
4 .6 x Down 
4 .3xUp 
4 .0xUp 
4.0x Down 
6.1 X Down 
4 .0x Down 
4 .3x Down 
4.0 X Up 
4 .3 X Up 
4 .3 X Up 
When looking at the molecular function ontologies, the keys terms which arose 
as significant are all those typically associated with cancer, cancer progression 
and ultimately patient survival such as cell adhesion, angiogenesis, cell 
differentiation, apoptosis, cell proliferation and regulation of transcription. On the 
other hand when looking at biological processes and in particular at the 
signalling pathways which were overrepresented, we see the canonical Wnt. 
TGF~ and BMP signalling pathways which are classically associated with tumour 
initiation and progression. Other pathways involved in Inflammatory response, G-
protein, small GTPase and Insulin receptor signalling are also present indicating 
the complexity of signalling pathway disruption which often occurs in cancers. 
5.2.3 Semi-Quantitative confirmation of gene expression 
Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR) (as 
detailed in section 2.6) was carried out to confirm the expression levels of 
chosen transcripts highlighted from the Microarray. A subset of 5 genes was 
selected from table 5.1 and table 5.2 and whole cell RNA extracts were 
evaluated for expression of these genes. The genes chosen were Amphiregulin 
(AREG), Bone morphogenic protein 4 (BMP4), Dual specificity Phosphatase 5 
(OUSP5), FOS-Like Antigen 1 (FOSL 1) and Roundabout 1 (ROB01). The 
decisions behind gene selection are discussed in section 5.3. 
Quantification was carried out in three separate passages of the two cell lines to 
evaluate RNA transcript expression using the primers shown in table 2.2. RT-
PCR reactions were carried out and products were resolved on 1% agarose gel 
(figure 5.3). Densitometric analysis assessment of the gels was carried out 
(figure 5.4) and confirmed either the up- or down-regulation of m RNA transcripts. 
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Figure 5.3 
Expression of AREG, BMP4, DUSP5, FOSL 1 and ROB01 in GFP and GFP-
Iamin A transfected SW480 colon carcinoma cells. Microarray data identified 
significant changes in the level of these 5 transcripts which was confirmed by 
semi-quantitative RT-PCR. Primers were designed to amplify Amphiregulin (A), 
Bone morphogenic protein 4 (B), Dual Specificity Phosphatase 5 (C), FOS-Like 
Antigen 1 (D) and Roundabout Homolog 1 (E). Equal loading of starting material 
was verified by monitoring the p-actin levels. 
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SW480/ SW480/ SW480/ SW480/ 
A GFP GFP- B GFP GFP-
lamA lamA 
13-actin l3-actin 
AREG BMP4 
AREG BMP4 
AREG BMP4 
SW480/ SW480/ 
C GFP GFP-
SW480/ SW480/ 
0 GFP GFP-
IamA IamA 
13-actin J3-actin 
DUSP5 FOSL1 
DUSP5 FOSL1 
DUSP5 I FOSL1 
-
SW480/ SW480/ 
E GFP GFP-
IamA 
J3-actin 
ROB01 
ROB01 
ROB01 
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Figure 5.4 Densitometric analysis of Semi-quantitative RT -PCR 
(A) Densitometric analysis of Amphiregulin (AREG) mRNA expression in 
SW480-GFP and SW480-GFP-Iamin A cell lines. Data show an up-regulation in 
amphiregulin expression of the SW480-GFP-Iamin A transfected cell line; 
ll = +1.84, t = 4.3558, df = 4 and p-value 0.012 ('two-tailed' Students t-test). 
(B) Densitometric analysis of Bone morphogenic protein 4 (BMP4) mRNA 
expression in SW480-GFP and SW480-GFP-Iamin A cell lines. Data show a 
down-regulation of BMP4 expression in the SW480-GFP-Iamin A cell line; 
ll = -5.89, t= 5.9319, df= 4 and p-value 0.004 ('two-tailed' Students t-test). 
(C) Densitometric analysis of Dual Specificity Phosphatase 5 (DUSP5) mRNA 
expression in SW480-GFP and SW480-GFP-Iamin A cell lines. Data show an up-
regulation of DUSP5 expression in the SW480-GFP-Iamin A transfected cell line; 
ll = +3.71, t= 15.9216, df= 4 and p-value <0.001 ('two-tailed' Students t-test). 
(D) Densitometric analysis of FOS-Like Antigen 1 (FOSL 1) m RNA expression in 
SW480-GFP and SW480-GFP-Iamin A cell lines. Data show an up-regulation of 
FOSL 1 expression in the SW480-GFP-Iamin A transfected cell line; 
ll = +2.66, t = 3.4669, df = 4 and p-value 0.026 ('two-tailed' Students t-test). 
(E) Densitometric analysis of Roundabout homolog 1 (ROB01) m RNA 
expression in SW480-GFP and SW480-GFP-Iamin A cell lines. Data show an up-
regulation of ROB01 expression in the SW480-GFP-Iamin A transfected cell line; 
ll = +9.22, t = 17.6643, df = 4 and p-value <0.001 ('two-tailed' Students t-test). 
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Data show that the level of all 5 genes evaluated by semi-quantitative RT-PCR is 
in keeping with data obtained from the microarray. We see a 1.84 fold increase 
in AREG expression in the SW480-GFP-Iamin A cell line which is less that the 
observed 4 fold up-regulation shown in Microarray analysis, but still supports the 
notion of an up-regulation of expression in the presence of lamin A. There is a 
5.89 fold down-regulation in the expression of BMP4 expression in the SW480-
GFP-Iamin A transfected cell line which is in keeping with the 7.5 fold down-
regulation observed in the microarray. There is a 3.71 fold up-regulation in 
DUSP5 expression in the GFP-Iamin A transfected SW480 cell line, again in 
keeping, albeit slightly lower than the 4.6 fold up-regulation noted in the 
microarray. The expression of FOSL 1 is 3.4 fold up-regulated in the SW480-
GFP-Iamin A cell line according to densitometric studies reflecting the 4.3 fold 
up-regulation noted in the microarray. Finally there is a 9.22 fold up-regulation in 
the expression of ROB01 in the SW480-GFP-Iamin A cell line which is actually 
higher than the observed 7.0 fold up-regulation noted in the microarray. These 
results strongly support data provided by the genome-wide microarray. 
5.3 Discussion 
lt is well known in cancers that down-regulation of cell-cell adhesion molecules is 
associated with tumour metastases: up-regulation of angiogenic factors and cell 
proliferation genes alongside a down-regulation of apoptotic factors is associated 
with tumour growth (Yu, May et al. 2004; Pedraza-Farina 2006); loss of cellular 
differentiation is associated with poorer patient survival (Rindi, D'Adda et al. 
2007), and loss of transcriptional regulation is associated with malignant tumour 
progression (Gonciarz, Pierzchalski et al. 2004; de Lau, Barker et al. 2007). Thus 
it is not surprising that these clusters were highlighted in the SW480-GFP lamin 
A transfected cell line which, if the in vivo observation of poor prognosis in 
patients with lamin AJC positive tumours (Chapter 3) were applied to the in vitro 
model system, should exhibit poorer prognosis. 
The genome-wide microarray analysis work carried out within this chapter was 1n 
essence a qualitative screening exercise aimed at highlighting potential 
candidates for further experimental investigation. This is due to the lack of 
biological replicates undertaken, but the independent validation through the use 
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of RT-PCR allowed a much greater degree of reliability to be assigned to the 
data obtained. The selection of the five genes which were subsequently 
confirmed from the microarray was based on current literature at the time and is 
discussed shortly. The experiment was successful with expression data for all 
genes subsequently investigated correlating closely with data obtained from the 
microarray, and so qualitative data obtained from the data-mining exercise could 
reliably be used as the basis for further experiments. 
ROB01 is an integral member of the SliUROBO pathway. Whilst this pathway did 
not significantly cluster on its own, the presence of ROB01 in the cell adhesion 
and angiogenesis molecular function groups draws light to it. Results show that 
there is a significant up-regulation of R0801 expression in SW480-GFP-Iamin A 
transfected cells over the GFP control. 
A review of the literature reveals it is a member of the immunoglobulin 
superfamily and was originally shown to play a major role in the process of 
axonal guidance in neurogenesis (Grone, Doebler et al. 2006). More recently 
however it has been implicated in tumour angiogenesis via the Slit2 ligand 
(Hohenester 2008). Similar work has also shown ROB01 to be a novel 
hepatocellular carcinoma antigen and work is currently being undertaken to 
assess its potential as a therapeutic and diagnostic target (lto, Funahashi et al. 
2006). lto et al. have shown a high over-expression in hepatocellular carcinoma 
and a much lower expression in surrounding normal tissue. Work then went on to 
show that treatment with the monoclonal mouse antibody mAb 82318C was 
capable of inducing complement-dependent cytotoxicity in the R0801 
expressing hepatocellular carcinoma cells. 
This work has been further supported by another group who showed that in a 
human oral squamous cell carcinoma line, a ROB01 over-expressing cell line, 
treatment with the mouse monoclonal antibody mAb RS lead to decreased 
proliferation and increased apoptosis as mediated by fas and fasl (Ma, Wang et 
al. 2006) 
The third study which is more closely linked to this work was by Grone et al. 
(Grone, Doebler et al. 2006). Their work was carried out in colorectal cancer 
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tissue samples and they showed by microarray analysis and real-time PCR that 
R0801 is significantly up-regulated in cancerous tissue vs. normal in just fewer 
than 80% of patients at the mRNA level. lt is interesting to note here that data 
shown in chapter 3 reports 70% of patients harbour lamin NC positive tumours. 
If we assume that data from our SW480 colon cancer in vitro model can be 
extrapolated to an in vivo setting, then one would expect to see an up-regulation 
of ROB01 expression in 70% of patients in the NLCS study, which would 
correlate closely with that observed by Grone et al. 
Dual Specificity Phosphatase 5 (DUSP5) is a nuclear, heat shock and growth 
factor inducible (lshibashr, Bottaro et al. 1994; Kwak and Dixon 1995) VH-1-Iike 
enzyme which hydrolyses substrates phosphorylated on both the tyrosine and 
serine/threonine residues. DUSP5 was shown by microarray to be up-regulated 
by 4.6 fold in the SW480-GFP-Iamin A transfected cell line as opposed to the 
SW480-GFP control. 
Among other roles DUSP5 is involved in mediating responses to oxrdative stress 
(Foltz, Ryu et al. 2006) and in the ERKIMAPK pathway acting as a negative 
regulator of ERK signalling (Mandl, Slack et al. 2005) thus regulating MAPK 
signal propagation. The Ras/extracellular signal-regulated kinase (ERK) 
mitogen-activated protein (MAP) kinase signalling pathway mediates a diverse 
array of distinct intracellular responses to extracellular stimuli (Nishida and Gotoh 
1993; Robinson and Cobb 1997; Chang and Karin 2001). These include cell 
proliferation, differentiation , transformation, and survival, and these responses 
are mediated via ERK-dependent phosphorylation. As a result, this pathway is 
often up regulated in human tumours and as such currently represents an 
attractive target for the development of anticancer drugs. 
The precursor to Amphiregulin (AREG) is the Colorectum cell-derived growth 
factor (CRDGF). Microarray data showed an up regulation of Amphiregulin 
expression of 4 fold which was confirmed by semi-quantitative RT-PCR as closer 
to 2 fold . Nonetheless, Amphiregulin expression has been shown to be up-
regulated in a number of tumours, including colorectal cancer and is an EGF 
family rigand for the ERBB family receptors. lt has also been characterised as an 
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autocrine growth factor and as a potent target gene of the Wntlp-catenin 
stgnalling pathway 
Picihard et al. (Picihard, Berthois et al. 2006) have shown that Amphiregulin is 
strongly involved in colorectal carcinoma cell adhesion, growth and differentiation 
and its involvement is mediated through the ERB1/ERK1 ,2 and ERB1/FAK 
pathways which are themselves directly involved in pRb regulation. 
Concomitantly, Shao et al. (Shao, Lee et al. 2003) have shown that Amphiregulin 
exerts a strong mitogenic effect on the human colon carcinoma LS-17 4 cell line 
and partially mediates a Prostaglandin E2 - induced growth stimulation in these 
cells. Prostaglandin E2, a major product of cycle-oxygenase enzymes is closely 
Implicated 1n colorectal carcinogenesis and has been shown to stimulate the 
growth of human colorectal carcinoma cells. 
Thus, in keeping with th is previously published data, it would make sense to 
observe an up-regulation of Amphiregulin expression in the SW480-GFP-Iamin A 
transfected cell line which one would postulate to be more aggressive based on 
conclusions drawn from chapter 3. Thus, the lack of lamin A/C expression in 
tumours may be mediating an increased surv1val through the down-regulation of 
growth stimulatory factors such as amphiregulin. 
FOS-Like antigen 1 (FOSL 1) expression was up-regulated in the SW480-GFP-
Iamin A cell line by approximately 4 fold and this was confirmed by semi-
quantitative RT-PCR. FOSL 1 is a member of the FOS gene family which consists 
of 4 leucine zipper proteins that can dimerise the proteins of the JUN family, 
thereby forming the transcription factor complex AP-1. To this end the FOS 
genes have been implicated as regulators of proliferation, differentiation and 
transformation. 
Previous work has shown that the over expression of FOSL 1 enhances the 
motility and invasion of breast and colorectal cancer cells, but inhibits the 
tumourigenicity of cervical carcinoma cell lines (Milde-Langosch 2005). 
Research concomitant to this by Zhang et al. (Zhang, Hart et al. 2005), has 
shown that in 75 human colorectal neoplasms the level of FOSL 1 was markedly 
elevated when compared to normal non-neoplastic colorectal epithelial cells. 
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They also postulate that the up-regulation is an early event in human colorectal 
tumourigenesis. 
Again, data produced here would be in keeping with previously published work 
insofar that the presence of lamin A expression and concomitant up regulation of 
FOSL 1 expression could correlate with a poorer prognosis in patients by 
increasing the motility and invasiveness of lamin A/C positive tumours through 
increased transcription of AP-1 target genes. 
Bone morphogenic protein 4 (BMP4) is a member of the transforming growth 
factor-p (TGF-P) superfamily, which utilise BMP receptors and intracellular 
SMADs to transduce their signals in order to regulate cell differentiation, 
proliferation and apoptosis. Currently the contribution of BMPs generally to the 
development of epithelia l-derived colorectal cancers remains largely unknown 
since its effects have been more widely investigated in tissues of mesenchymal 
origin. However with a 7.5 fold down-regulation in BMP4 expression reported in 
the microarray and subsequent 5.9 fold down regulation as confirmed by semi-
quantitative RT-PCR, BMP4 would certainly be a target for further investigation. 
Work by Nishanian et al. (Nishanian, Kim et al. 2004) has previously shown the 
tumour suppressive properties of BMP4. They showed a successful elimination 
of tumourigenic potential from the undifferentiated human cancer cell line 
NTERA2 by exogenous treatment with BMP4. They also went on to show that 
over expression of BMP4 can induce a variety of Wnt signalling molecules and 
that th is activation of the Wnt pathway by BMP4 has functional consequences. 
In lung cancer, an up-regulation of BMP4 signalling has also been shown to 
induce senescence and modulate the oncogenic phenotype of A549 lung 
adenocarcinoma cells (Buckley, Shi et al. 2004). In gastric cancer, data has 
indicated that BMP4 mRNA is under expressed in poorly differentiated tumours 
classically associated with poorer survival (Katoh and Terada 1996). Lastly, 
Piccirillo et al. have shown that BMP4 will inhibit the tumourigenic potential of 
human brain tumour-initiating (human glioblastoma) cells (Piccirillo, Reynolds et 
al. 2006). 
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Thus it seems that BMP4 is heavily implicated in tumourigenesis as a negative 
regulator of proliferation and activator of apoptotic programs, as well as an 
important mediator of cell cycle profiles. The current hypothesis is that the effects 
of BMP4 are mediated at least in part by activation of the canonical Wnt 
signalling pathway (Nishanian, Kim et al. 2004). The exact mechanism behind 
this proposed theory is still unclear but activation would not necessarily involve 
direct alteration of the activity of p-catenin but would instead be mediated 
through interaction of transcriptional eo-activators in promoter regions containing 
both S MAD and T cf binding sequences 
Thus the significant down-regulation of BMP4 expression in GFP-Iamin A 
transfected SW480 cells would suggest that BMP4 and its associated signalling 
pathway(s) may be responsible for mediating the observed difference in patient 
survival between lamin A/C negative and lam in A/C positive patient groups. 
In short this chapter serves to highlight the genome-wide changes which occur 
as a result of changes in a single protein. The observed change in over 7,500 
genes between the SW480-GFP and SW480-GFP-Iamin A cell lines indicates 
that the function of lamin A irrefutably extends beyond that of structural. We 
know from chapter 3 that patients with lamin A/C positive tumours exhibit a much 
poorer survival than their dinicopathologically similar lamin A/C negative 
counterparts. Evidence from chapter 4 has shown that this differential lamin 
expression does not appear to directly influence p-catenin activity in the Wnt 
signalling pathway. Instead, data from this chapter suggests that these 
differences are perhaps mediated though other pathways such as the TGFP-
BMP signalling pathway, through the alteration of endogenous expression of 
growth-stimulatory factors such as Amphiregulin , or by potentially increasing the 
level of specific transcription factors such as AP-1 instead. 
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CHAPTER 6 - Lamin A down-regulates BMP4 and 
abrogates BMP4-mediated growth suppression in the 
SW480 colorectal cancer cell line 
6.1 /ntroduction 
6.1.1 The bone morphogenic protein signalling pathway 
Bone morphogenic proteins are members of the Transforming Growth Factor-P 
(TGF-P) superfamily which have been shown to regulate proliferation, 
differentiation, chemotaxis and apoptosis in various cell types Including 
mesenchymal cells, epithelial cells, haematopoietic cells and neuronal cells 
(Leivonen and Kahari 2007). Whilst their participation in the mesenchymal 
development of most tissues and organs is well known, their role in epithelial 
growth regulation is currently not well understood. As part of the TGF-P 
superfamily, BMPs utilise a similar signalling cascade to that of TGF-p. The BMP 
ligands use serine/threonine kinase receptors type lA (BMPRIA), type IB 
(BMPRIB) and type 11 (BMPRII) to transmit their signals into the cell (Koenig, 
Cook et al. 1994; ten Dijke, Yamashita et al. 1994; Gilboa, Nohe et al. 2000). 
The BMP ligands bind either cooperatively to preformed receptor complexes or 
first to a BMPRI receptor that then recruits BMPRII (Kirsch , Sebald et al. 2000). 
Additionally BMPs can bind to activin type 11 (ACVRII) and type IlB (ACVRIIB) 
receptors (Liu, Ventura et al. 1995; Rosenzweig, lmamura et al. 1995; 
Yamashita, ten Dijke et al. 1995). lt has been shown that BMP7 preferentially 
binds to ACVRII and ACVRI but also has an affinity for BMPRII , BMPRIA and 
BMPRIB, whereas BMP2 and BMP4 appear to only bind to BMPRII and BMPRI 
(Macias-Silva, Hoodless et al. 1998; Greenwald, Groppe et al. 2003). Biologically 
active BMP4 is a disulphide-linked homodimer of the carboxyl-terminal 116 
amino acid residues, which contains the characteristic seven conserved cysteine 
residues involved in the formation of the cysteine knot and the single interchain 
di-sulphide bond. Cellular responses to BMP4 have been shown to be mediated 
by the formation of hetero-oligomeric complexes of the type I and type 11 
serine/threonine kinase receptors. Upon ligand binding, BMPRII phosphorylates 
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BMPRI which in turn phosphorylates intracellular SMAD1 , SMAD5 or SMAD8 at 
the COOH terminals (Kretzschmar, Liu et al. 1997). lt is thought that the 
phosphorylated (p)SMADs then associate with SMAD4, and the complex 
translocates to the nucleus to regulate the expression of various genes 
controlling cell proliferation, cell differentiation and apoptosis (Balemans and Van 
Hu12002). 
BMPs and their receptors have already been linked to the pathogenesis of some 
solid tumours. BMPRIA, BMPRII , and BMP2 mRNA levels have been found to be 
up-regulated in pancreatic cancers, 55% of which also have biallelic loss of 
SMAD4 (Moskaluk, Hruban et al. 1997, Zhang, Zhou et al. 1997). BMP2 is also 
thought to promote pancreatic cancer progression by enhancing the growth of 
pancreatic cancer cells (Kieeff, Maruyama et al. 1999; Dicuonzo, Angeletti et al. 
2001). mRNAs for BMP receptors and BMP ligands have also been shown to be 
greater in cancer cells with less metastatic potential than in cells with higher 
metastatic potential (Arnold. Tims et al. 1999). However. BMP2 inhibits the 
proliferation of breast cancer cell lines that express both SMAD1 and SMAD4 
(CAMA-1. MCF7. MDA-MB-231 , T-470 and ZR-75-1) and up-regulates the 
cyclin-dependent kinase inhibitor p21WAF1 in these cells (Pouliot and Labrie 
2002). BMP2 has also been shown to inhibit the proliferation of and cause cell 
cycle arrest in the G1 phase of the MKN74 gastric cells (Wen, Miyake et al. 
2004). Furthermore, the growth inhibitory effects of BMP2 have been seen in the 
androgen-sensitive prostate cancer cell line LNCAP, but no effect has been seen 
in the androgen-insensitive PC-3 and DU145 cell lines (Brubaker, Corey et al. 
2004) 
Recently Hardwick et al. (Hardwick, Van Den Brink et al. 2004) found that BMP2 
inhibits normal colonic epithelial growth by promoting apoptosis and 
differentiation and inhibiting proliferation. They also found that BMP2, BMPRIA, 
BMPRIB, BMPRII pSMAD1, and pSMAD4 are expressed predominantly 1n 
mature colonocytes at the epithelial surface in normal adult human and mouse 
colon tissue samples and expression is significantly lower and/or absent at the 
base of the colonic crypts (Hardwick, Van Den Brink et al. 2004). Such work has 
been complemented by Kosinski (Kosinski , Li et al. 2007) who has shown high 
levels of expression of BMP antagonists at the base of colonic crypts. 
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Colorectal cancer develops as a result of uncontrolled cellular proliferation and 
dysregulation of cell death mechanisms. As such the inactivation of TGF-~ 
superfamily signalling appears to play a key role in this and such inactivation of 
TGF-~ signalling is seen in -80% of all colorectal cancers (Grady, Rajput et al. 
1998). On the other hand, inactivation of activin signalling via mutations in 
ACVRII, another TGF-P superfamily receptor, occurs in the majority of colon 
tumours with microsatellite instability (MSI) (Hempen, Zhang et al. 2003; Jung, 
Doctolero et al. 2004). Previous work has shown that BMP signalling 
mechanisms are in essence intact in human colon cancer specimens and also in 
several colorectal cancer cell lines and exogenous activation of these signalling 
pathways is moderately growth suppressive (Beck, Jung et al. 2006) 
6.1 .2 SW480 Colorectal cancer cell line 
Review of the literature reveals that the SW480 colon cancer cell line used as 
the in vitro experimental model is Chapter 4 and 5 is microsatellite stable and 
SMAD4 null (Goyette, Cho et al. 1992; Hahn, Schutte et al. 1996). lt has been 
shown that treatment with exogenous rhBMP2 and rhBMP7 does not lead to an 
increase in transcriptional activity of BMP target genes as determined by the 
BMP-specific SMAD-induced Luciferase reporter BRE-Luc (Beck, Jung et al. 
2006). That said however, whilst transcriptional activity of target genes was 
unchanged by exogenous rhBMP treatment, data did show that treatment of the 
SW480 colon cancer cell line with rhBMP2 and rhBMP7 showed significant 
growth suppression even in the absence of SMAD4 as determined by direct cell 
counting (Beck. Jung et al. 2006). This was then taken further to show that 
treatment with exogenous rhBMP2 and to a lesser extent rhBMP? significantly 
decreased scratch wound closure in the SW480 cell line such that wound closure 
was almost inhibited upon rhBMP treatment. (Beck, Jung et al. 2006) 
Previous work by Willis, Cox et al. (unpublished data) has shown that there is a 
concomitant up-regulation of the actin-bundling protein T-plastin and down-
regulation of the cell adhesion protein E-cadherin [a key regulator of adhesive 
properties in epithel ial cells (Masciari, Larsson et al. 2007)] in the SW480 GFP-
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Lamin A transfected cell line. lt has previously been shown that E-cadherin is a 
down-stream target of the BMP signalling pathways and is also implemented in 
other solid tumours including breast and pancreatic (Zeisberg, Shah et al. 2005; 
van der Hardt, Bakkers et al. 2007; Yang, Du et al. 2007) 
6.2 Results 
Based on data from the chapter 5 microarray BMP4 appeared to be a good 
target to investigate as one of the potential mechanisms mediating the observed 
survival differences in patients harbouring lamin A/C positive and negative 
tumours. 
In order to confirm data obtained from the transcriptomic analysis of chapter 5, 
work initially set out to assess the pattern of BMP4 expression at the protein 
level in both the SW480-GFP and SW480-GFP-Iamin A cell lines. Whole cell 
extracts from 3 passages of both cell lines were taken and resolved on a 12% 
SOS-PAGE gel, transferred to nitrocellulose and immunoblotted with the Anti-
human BMP4 mouse monoclonal antibody (R&D Systems Inc., MN, USA). The 
antibody is stated to have no cross-reactivity with BMP-2, -3, -5, -6, and -7 in 
Western Blot analyses (R&D Systems Inc., MN, USA). Equal loading was 
confirmed by blotting for p-actin (figure 6.1 B). Data showed a significant down-
regulation of BMP4 in the presence of lamin A in the SW480-GFP-Iamin A cells 
(figure 6.1 A). This down-regulation was determined by densitometry to be 6.67 
fold (p=0.0012) (figure 6.2) correlating with the observed down-regulation of 
BMP4 expression at the mRNA level. 
6.2.1 Exogenous rhBMP4 does not alter CDH1 or PLS3 transcript 
levels 
In order to assess the effect of exogenous Recombinant Human (rh)BMP4 
treatment on the SW480-GFP-Iamin A cell line, 100ng/ml of recombinant human 
BMP4 (R&D Systems Inc.) was added to media of cells. Whole cell extracts were 
then taken at t = Ohr, 2hr, 4hr, 6hr, 12hr, 18hr, 24hr and 48hr following 12hr 
pulsed rhBMP4 treatment. RNA was extracted and RT-PCR was run (as detailed 
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in section 2.6) to evaluate the transcript levels of E-cadherin (CDH1) and T-
plastin (PLS3) based on previous work by Willis, Cox et al. (unpublished data). 
E-Cadherin is a calcium-dependent cell adhesion molecule whose intact function 
is crucial for the establishment and maintenance of epithelial tissue polarity and 
structural integrity. Thus it is generally known that loss of E-cadherin expression 
is associated with the development of more diffuse and aggressive colorectal 
and other solid tumours (Seeker, Atkinson et al. 1994; Oda, Kanai et al. 1994; 
Yoshiura, Kanai et al. 1995). Plastins are a family of actin bundling proteins 
which are involved in organising the actin cytoskeleton and are expressed in a 
wide range of tissues (Lin, Park et al. 1993; Delanote, Vandekerckhove et al. 
2005). Enhanced expression of T-plastin has been associated with both drug 
and radiation resistant cancer cells. Of particular note is the significantly 
increased expression ofT-plastin reported in cisplatin-resistant human cancers 
(Delanote, Vandekerckhove et al. 2005) and it follows that drug-resistant 
tumours are often associated with a much more aggressive phenotype. 
Work carried out in duplicate shows an up-regulation in T-plastin mRNA levels in 
the SW480-GFP-Iamin A transfected cell line and a concomitant down-regulation 
of E-cadherin vs. the SW480-GFP-Aione cell line at t = 0 (untreated). However, 
there was no detectable differences in the expression of these RNAs following 
treatment with 1 OOng/ml exogenous rhBMP4 at 12hr intervals (figure 6.3), 
suggesting that exogenous rhBMP4 treatment does not affect the transcriptional 
activity of these genes in this instance. 
183 
Figure 6.1 Western Blot analysis of BMP4 expression. 
(A) Whole cell extracts from SW480-GFP (lane1) and SW480-GFP-Lamin A 
(lane 2) resolved on a 12% SOS-PAGE gel, transferred to nitrocellulose and 
immunoblotted with anti-human BMP4. 
(B) Whole cell extracts from SW480-GFP (lane1) and SW480-GFP-Iamin A (lane 
2) resolved on a 12% SOS-PAGE gel, transferred to nitrocellulose and 
immunoblotted with anti-~-actin. 
lmmunoblots show an equal loading as revealed by ~-actin staining (B). Blots 
also show a down regulation of BMP4 protein expression in the SW480-GFP-
Iamin A transfected cell line. 
Molecular markers are in kOa. 
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Densitometric analysis of Bone morphogenic protein 4 (BMP4) protein 
expressions in SW480-GFP and SW480-GFP-Iamin A cell lines. Data show a 
down-regulation of BMP4 expression in the SW480-GFP-Iamin A transfected cell 
line; 
ll = -6.67, t = 8.2187, df= 4 and p-value 0.0012 ('two-tailed' Students t-test) 
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Figure 6.3 T-Piastin and E-cadherin mRNA transcript levels do not change 
following rhBMP4 treatment in the SW480-GFP-Lamin A cell line 
Two step RT-PCR was performed on 0.1J..tg total RNA isolated from whole cell 
extracts taken at t = Ohr, 2hr, 4hr, 6hr, 12hr, 18hr, 24hr and 48hr. Expression of 
E-cadherin (CDH1) and T-Piastin (PLS3) was investigated using specific primers 
as detailed in table 2.2 
L =Ladder 
1 = SW480-GFP-Aione Control, t=Ohr 
2 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=Ohr 
3 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=2hr 
4 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=4hr 
5 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=6hr 
6 = SW480-GFP-Lamin A+ 100ng/ml rhBMP4, t=12hr 
7 = SW480-GFP-Lamin A+ 100ng/ml rhBMP4, t=18hr 
8 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=24hr 
9 = SW480-GFP-Lamin A + 1 OOng/ml rhBMP4, t=48hr 
Equal loading of RNA in each sample was verified by monitoring the 
transcriptional level of ~-actin. 
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6.2.2 Exogenous rhBMP4 partially decreases wound closure in 
SW480 control but not lamin A transfected cells 
Despite a lack of change in mRNA expression of both T-plastin and E-cadherin, 
the effects of exogenous rhBMP4 treatment on cells was tested at a functional 
level by means of a simple wounding assay similar to that carried out by Beck et 
al. (Beck, Jung et al. 2006). 
Briefly, cells were plated in six-well plates and grown to 95% confluency. A 
wound was then created in the shape of a cross with a p1 0 plastic pipette tip. 
Following wounding cells were washed twice with pre-warmed media and fresh 
media applied with and without 1 OOng/ml rhBMP4. Wounds were then 
photographed using a Nikon Diaphot 300 inverted microscope (Nikon 
corporation , Tokyo, Japan) at t = Ohr, 2hr, 4hr, 6hr, 12hr, 18hr, 24hr and 48hr. 
Media was replaced every 12hr, with or without fresh rhBMP4. 
Results show that GFP-Iamin A transfected cells are capable of closing scratch 
wounds at a rate approximately 5 times faster that the GFP-Aione control (figure 
6.4 and figure 6.5A). However application of 1 OOng/ml exogenous rhBMP4 did 
not affect closure time of scratch wounds in the GFP-Iamin A transfected cell line 
(figure 6.4 and figure 6.5B), but did significantly slow wound closure by 
approximately 2 fold in the GFP-Aione transfected cell line (figure 6.4 and figure 
6.5C). 
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Figure 6.4 Expression of lamin A causes increased cell motility in SW480 colon 
cancer cells. 
Three wounds more than 1 Omm in length and of equal thickness were made in 
95% confluent cultures of SW480/cntl or SW480/IamA cells with a 1 01-JI 
disposable Eppendorf tip. Cultures were then either left untreated or media was 
supplemented with 1 OOng/ml recombinant human BMP4 and 'pulsed with the 
I 
same dose every 12hr thereafter. Phase contrast images were taken at t = Ohr, 
2hr, 4hr, 6hr, 12hr, 18hr, 24hr and 48hr from identical regions. 
Results show that the untreated SW480-GFP-Lamin A cell line is capable of 
closing the scratch wound within 18 hours whereas the wound remains unclosed 
after 48 hours in the SW480-GFP-Aione control cell line. Results also show that 
treatment with 1 OOng/ml recombinant human BMP4 has no observable effect on 
the SW480-GFP-Lamin A cell line but partially inhibits wound closure in the 
SW480-GFP-Aione control cell line. 
Scale bar = 200~m 
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Figure 6.5 Relative wound size of SW480-GFP-Iamin A and SW480-GFP-Aione 
control cells with or without exogenous rhBMP4 treatment over time. 
The wound size relative to the starting wound size was measured using Zeiss 
LSM Image Browser software, version 3.1 at each time point in three 
independent experiments and expressed as a % of starting wound size. Both 
rhBMP4 treated and untreated SW480-GFP-Iamin A cells closed the wound 
within 18 hours showing no difference in speed of closure between treatments. 
Wound closure was however approximately 5 times faster than the SW480-GFP-
Aione untreated cell line. Despite no observable differences in the SW480-GFP-
Lamin A cell line, rhBMP4 treatment did significantly suppress wound closure in 
the SW480-GFP-alone control cells by approximately 2 fold, with the wound 
reaching 40% of its starting size in untreated cells vs. -70% in rhBMP4-treated 
cells at t = 48hr. 
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6.3 Discussion 
BMPs are known to play a role in tissue development but until recently little work 
has been done examining the significance of BMP signalling in colorectal cancer. 
Work by several groups has however previously shown BMP signalling to affect 
normal epithelial cell growth (Pouliot and Labrie 2002; Brubaker, Corey et al. 
2004; Hardwick, Van Den Brink et al. 2004). TGF-~ and activin receptor ligands 
from the same superfamily as BMPs are known to be growth suppressors and 
have been shown to be inactivated in a subset of colon cancers. The loss of 
TGF~RI , TGF~RII and ACVR2 cell surface receptors have been shown to confer 
resistance of cancer cells to TGF-~ induced growth suppression and as such 
have been postulated as candidate tumour suppressor genes in gastrointestinal 
cancers. (Markowitz and Roberts 1996; Grady, Rajput et al. 1998; Hempen, 
Zhang et al. 2003; Jung, Doctolero et al. 2004). 
Data from chapter 5 has shown that there is a down-regulation of BMP4 mRNA 
in the GFP-Iamin A transfected SW480 cell line vs. the GFP transfected control. 
Data from this chapter has also shown that this down-regulation subsequently 
results in a functional down regulation of BMP4 at the protein level by 
approximately 6.5 fold. 
Previous work utilising the same microarray data as that used in Chapter 5 
(Willis, Cox et al., unpublished data) has shown that transfection of SW480 with 
GFP-Iamin A results in the down-regulation in expression of E-cadherin, a down-
stream target of BMP signalling and an important cell adhesion molecule and a 
simultaneous up-regulation in T-plastin whose primary function is as a mediator 
of actin bundling. Data from transcriptomic analysis in this chapter supports this 
previous work by showing an up-regulation of T -plastin and down-regulation of 
E-cadherin at the mRNA level in the SW480-GFP-Lamin A transfected cell line 
(figure 6.3). Data also shows that upon treatment with exogenous rhBMP4 there 
are no detectable changes in these transcript expression levels which would 
follow work from Beck et al. (Beck, Jung et al. 2006) who have shown that 
treatment of the SW480 cell line with exogenous BMP2 and BMP7 does not alter 
the transcriptional activity of BMP target genes. 
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Concomitant to this (Willis, Cox et al., unpublished data) and independent 
validation in this chapter has shown that the SW480-GFP-Iamin A cell line also 
exhibits a much faster wound closure in wounding assays with the SW480-GFP-
Iamin A cell line closing a wound within 18 hours and the SW480-GFP 
transfected control failing to close the wound at 48 hours. This data supports 
similar work by Beck et al. where the SW480 parent cell line fail to close 
identically created wounds at 48 hours. 
E-Cadherin is a calcium-dependent cell adhesion molecule whose intact function 
is crucial for the establishment and maintenance of epithelial tissue polarity and 
structural integrity. Thus it is generally known that loss of E-cadherin expression 
is associated with the development of more diffuse and aggressive colorectal 
and other solid tumours (Seeker, Atkinson et al. 1994; Oda, Kanai et al. 1994; 
Yoshiura, Kanai et al. 1995). Work by Wen and colleagues has shown that 
rhBMP2 treatment significantly increases the levels of E-Cadherin at the protein 
level in OUMS-37 gastrointestinal tumour cells partially rescuing their aggressive 
phenotype (Wen, Miyake et al. 2004). Plastins are a family of actin bundling 
proteins which are involved in organising the actin cytoskeleton and are 
expressed in a wide range of tissues (Lin, Park et al. 1993; Delanote, 
Vandekerckhove et al. 2005). Enhanced expression of T-plastin has been 
associated with both drug and radiation resistant cancer cells. Of particular note 
is the significantly increased expression ofT -plastin reported in cisplatin-resistant 
human cancers (Delanote, Vandekerckhove et al. 2005) and it follows that drug-
resistant tumours are often associated with a much more aggressive phenotype. 
Several recent findings suggest the involvement of BMP signalling in the 
tumourigenesis of several organs including the gastrointestinal tract. First the 
anti-proliferative activity of rhBMP2 in vitro has been implicated in several cancer 
cells, such as prostrate, gastric and colon (lde, Yoshida et al. 1997; Hardwick, 
Van Den Brink et al. 2004; Horvath, Henshall et al. 2004; Wen, Miyake et al. 
2004). Second, loss of BMP2 expression has been reported in several cancers, 
including prostrate and colon (Hardwick, Van Den Brink et al. 2004; Horvath, 
Henshall et al. 2004). Third, the close similarity of BMP2 and BMP4 and their 
shared receptors suggests a tight correlation in signalling mechanism. Thus, any 
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molecular alterations in the BMP signalling cascade may contribute to enhanced 
tumourigenesis. 
Hence one could postulate that in this situation, the expression of lamin A/C in 
colorectal adenocarcinomas results in the down regulation of BMP4 expression 
as well as the abrogation of BMP4 mediated growth suppression and therefore 
directly influences colorectal carcinogenesis. However, what cannot be 
concluded from these studies is whether the two are mutually dependent and in 
this case, data would even suggest that they are in fact independent of one 
another. Thus the down-regulation of BMP4 at the protein level is not the 
mechanism of action by which BMP4 mediated growth suppression is occurring. 
This is not unusual as it has been shown in other cancers that the intra- or extra-
cellular localisation of the same protein exhibit markedly different roles (Erler. 
Bennewith et al. 2006). Nonetheless, such evidence provided in this chapter 
does link expression of lamin A/C to colorectal tumour malignancy through loss 
of the anti-proliferative and growth suppressive effects of BMP4 mediated 
signalling, although the exact mechanism(s) by which this is occurring remain 
unknown. 
At such a point one could postulate a mechanism by which that above data can 
be drawn together. The up-regulation of laminA expression in colorectal tumours 
has been shown to be associated with a poor mortality in patients. Using in vitro 
models it has been shown that laminA expression results in a significant down-
regulation at both the RNA and protein level of BMP4. Similarly, we see a down-
regulation of the same magnitude in E-cadherin which is known to be a 
downstream target of BMP signalling (Zeisberg, Shah et al. 2005; van der Hardt, 
Bakkers et al. 2007; Yang, Du et al. 2007) and is an important cell adhesion 
molecule. We also observe an increase in expression of the actin bundling 
protein T-plastin and work by Willis (Willis, Cox et al. unpublished data) has 
shown that expression levels of these two proteins are mutually dependent. 
lt has previously been shown that activation of BMP signalling suppresses Wnt 
signalling (Nishanian, Kim et al. 2004), through the merger of these signall ing 
pathways via PTEN and this interplay between Wnt and BMP signalling is 
critically important in normal vertebrate development (He, Zhang et al. 2004; 
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Huang and Klein 2004). However, data from chapter 4 would suggest that such 
suppression is not occurring by direct alteration in 13-catenin activity as measured 
by dual luciferase reporter assays, nor does previous work by Willis (Willis 2005) 
suggest that Wnt target genes such as c-Myc are altered by lamin A expression 
in the SW480 colon carcinoma cell line. 
Data herein has shown that transfection of GFP-Iamin A into the SW480 cell line 
also results in a more motile and less adherent cellular phenotype as determined 
by scratch wounding assays (figure 6.4). Similar assays carried out on BMP 
treated SW480 parent cells (Beck, Jung et al. 2006) has shown that the 
presence of exogenous BMPs almost completely inhibits would closure in this 
cell line and such work would suggest that treating the SW480 colon cancer cell 
line with exogenous BMPs can therefore exert SMAD4 independent growth 
effects by an as-yet-uncharacterised pathway. 
However data here show that exogenous treatment of the SW480-GFP-Iamin A 
transfected cell line with high levels of rhBMP4 does not alter mRNA levels of the 
BMP target gene CDH1 (E-cadherin) nor PLS3 (T-plastin) in either the short or 
long term. Concomitant to this, treatment fails to show any observable effect on 
wound closure as reported in previous similar experiments suggesting that lamin 
A expression in the SW480 cell line may abrogate BMP4 mediated responses in 
these cells, whereas in the SW480-GFP-Aione cell line wound closure is 
observed to be partially inhibited by exogenous BMP4 treatment. 
Data obtained in chapter 4 has shown that p-catenin activity remains unchanged 
between the SW480-GFP-Iamin A and SW480-GFP control transfected cell lines 
discounting the direct involvement of the canonical Wnt signalling pathway as the 
central mediator in the observed differences in cellular behaviour. Thus one 
could propose that the differences in patient survival between lamin AJC negative 
tumour patients and lamin AJC positive tumour patients is not mediated through 
the canonical Wnt signalling pathway. Instead it is perhaps mediated through the 
TGF-P signalling pathway via the bone morphogenic proteins resulting in a less 
adherent, more motile cellular phenotype in the lamin AJC positive cells through 
abrogation of BMP mediated responses. This difference in phenotype would go 
part way to explain the higher colorectal cancer related mortality in lamin AJC 
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positive tumour patients by means of potentially conferring a more invasive and 
aggressive phenotype to those tumours. 
The mechanism by which abrogation of BMPffGF~ signalling may be occurring 
could be through disruption of receptor expression and/or the signalling cascade. 
lt would be interesting to assess the expression and localisation of BMP4 
receptors BMPRII and BMPRI (which are BMP4 specific) in both the laminA and 
control transfected cell lines at both the mRNA and protein levels. 
Similarly, the expression of lamin A/C and in particular its many binding partners 
may be involved in the regulation of nuclear translocation of the TGF~ SMAD 
effectors thus antagonising BMP signalling pathways directly in this manner. lt 
has recently been shown that a complex of MAN1 and A-type lamins has been 
shown to interact with the receptor regulated SMAD (rSMAD) and to antagonise 
TGF-P signalling by inhibiting rSMAD at the inner nuclear membrane (Lin, 
Morrison et al. 2005; Van Berlo, Voncken et al. 2005). Thus in lamin A/C 
negative tumours, the absence of nuclear lamin A/C expression, would allow 
nuclear translocation of TGFf3-SMAD signals and mediation of their associated 
growth suppressive properties. 
Alternatively, another mechanism by which lamin A/C expression may regulate 
BMP signalling is via the upregulation of other pathways such as the ERKIMAPK 
pathway. lt has been shown that up-regulation of this pathway leads to the 
phosphorylation of intracellular SMADs at their mid-linker regions (Kretzschmar, 
Liu et al. 1997) by activated ERK kinases (Beck, Jung et al. 2007) resulting in the 
inhibition of nuclear accumulation of BMP-activated SMAD1 . Thus the negative 
regulation of BMP signalling by lamin A/C via this mechanism would be a means 
by which inhibition of BMP growth suppression could occur in the absence of 
mutation in BMP signalling components. 
The mechanisms discussed above are purely speculative but what is true, ts that 
evidence presented within this chapter may for the first time implement A-type 
lam in expression as a negative regulator of TGFf3/BMP signalling. More work is 
definitely needed to elucidate the exact mechanism by which this may be 
occurring, but it is intriguing to speculate that restoration of functional TGFf3/BMP 
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signalling could contribute to new therapeutic strategies for colorectal carcinoma 
in the future. 
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CHAPTER 7 - General Discussion 
7. 1 Background to project 
The implications of non-functional lamin A/C are borne out in the tissue-specific 
disorders such as autosomal inherited Emery-Dreifuss Muscular Dystrophy, 
Dilated Cardiomyopathy type-1A, Dunnigan type-Familial Partial Lipodystrophy, 
Mandibuloacral Dysplasia and Charcot-Marie-Tooth type-281 (Bonne, Di Barletta 
et al. 1999; Fatkin, MacRae et al. 1999; Cao and Hegele 2000; Raffaele Di 
Barletta, Ricci et al. 2000; De Sandre-Giovannoli, Chaouch et al. 2002; Novelli, 
Muchir et al. 2002). Mutations in the lamin A binding region of Emerin also give 
rise to an X-linked form of Emery-Dreifuss Muscular Dystrophy with similar 
clinical features to Autosomal Dominant Emery-Dreifuss Muscular Dystrophy 
(Bione, Maestrini et al. 1994; Lee, Haraguchi et al. 2001 ). Therefore a role for A-
type lamins and their binding partners in tissue-specific diseases is well 
established. Considering that such disorders are not associated with the 
development of any malignancy, it is very interesting that altered expression and 
distribution of A-type lamins has also been reported in a growing number of 
neoplasms affecting epithelial, mesenchymal and lymphoid lineages, to the 
extent that the importance of A-type lamins and their binding partners in the 
regulation of growth pathways may be closely linked to tumour progression 
The expression of nuclear lamins has been studied most extensively in lung 
cancer (Kaufmann, Mabry et al. 1991 ; Broers, Raymond et aL 1993) and 
keratinocytic tumours of the skin (V enables, Mclean et al. 2001 ; Oguchi, Sagara 
et al. 2002; Till i, Ramaekers et al. 2003), but work has also focussed on acute 
lymphoblastic leukaemia, non-Hodgkin's lymphoma (Stadelmann, Khandjian et 
al. 1990) and colorectal cancer (Cance, Chaudhary et al. 1992; Moss, 
Krivosheyev et al. 1999). In general these investigations have reported down-
regulation of lamin A/C in association with increased proliferation and 
dediffer,entiation in tumours. 
The aforementioned studies provided the first indications that lamins may be 
important in the development and progression of cancer. However they failed to 
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link changes in expression to patient prognosis or directly to tumour progression 
and to date immunohistochemical investigations into A-type lamin expression in 
colorectal cancer have produced highly contradictory results (Cance, Chaudhary 
et al. 1992; Moss, Krivosheyev et al. 1999). 
Colorectal cancer is the third most commonly diagnosed malignancy and the 
second most important cause of cancer mortality within the general population in 
the UK (Toms 2004). While methods for early detection have been developed, 
and in the case of Faecal Occult Blood (FOB) testing, are currently being rolled 
out in a nationwide program across the UK (Alexander and Weller 2003), the 
majority of treatment is curative rather than preventative. Clinicians still rely on 
the Dukes' staging and TNM classifications of colorectal tumours (Dukes 1932; 
AJCC 2002) in order to determine patient treatment regimens and predict 
prognosis. Although one cannot deny the contribution made by pathologists such 
as Cuthbert Dukes in improving treatment of the disease through the 
establishment of a universal staging system, the current morphological and 
pathological staging criteria are simply unable to provide detailed predictions of 
individual patient outcome [discussed by (Johnston 2004)]. Many biomarkers of 
tumour advancement and prognosis have been proposed, but a definitive marker 
or genetic signature has yet to be demonstrated. Given the intriguing data 
currently being expounded on nuclear lamin expression in epithelial tumours of 
the lung and skin , it is perhaps surprising that detailed investigations into the 
expression and regulation of lamins in a malignancy as common as colorectal 
cancer have not be undertaken so far. This thesis has aimed to go some way in 
rectifying this. 
7.2 Differential Expression of lamin A/C in colorectal cancer is 
linked to patient prognosis 
The expression of A-type lamins (lamins A and C) was evaluated both in a 
preliminary pilot and subsequent larger retrospective tissue archive originating 
from the Netherlands. Formalin fixed, paraffin embedded tumour specimens from 
656 incident colorectal cancer patients taking part in the Netherlands Cohort 
Study on Diet and Cancer were immunohistochemically assessed using the anti-
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lamin AJC Jol2, mouse monoclonal antibody (Oyer, Kill et al. 1997). 
Interestingly, differential lamin A/C expression was noted in patients of identical 
clinicopathological staging and appeared to have no correlation with standard 
clinical or pathological features of the tumours. Of the 656 patients assessed, 
463 (70%) patients exhibited positive lamin AJC staining in the nuclei of tumour 
cells whilst the remaining 193 (30%) stained negative for nuclear lamin A/C 
expression in tumour nuclei. The availability of an internal control in terms of 
adjacent stromal tissue which always stained positive confirmed that a negative 
stain was as a result of an absence of lamin AJC and not poor staining. Within 
the follow-up period, 246 patients died with 163 of these patients dying as a 
result of CRC. Of those patients who died of colorectal cancer related causes 
within the study period (seven years) 127 (78%) scored positive for lamins A/C 
while 36 (22%) scored negative. 
Statistical analysis carried out on data obtained in conjunction with patient, 
tumour and other molecular data extracted from the NLCS database showed that 
expression of lamin A/C in colorectal adenocarcinomas is more closely 
correlated with colorectal cancer related mortality following surgery than an 
absence of expression. Cox Hazard regression analysis indicates that this 
pertains to a Hazard ratio of 0.59 (95% Cl: 0.41 - 0.86, p=0.006) for lamin A/C 
negative tumours or 1.89 (95% Cl: 1.16 - 2.97, p=0.006) for lamin positive 
tumours indicating that patients with lamin A/C positive tumours are almost twice 
as likely to die from colorectal cancer related mortality than their 
clinicopathologically similar lamin AJC negative counterparts. 
Further statistical analysis showed that the protective affect of lamin A/C 
negative status in tumours is independent of all other investigated patient, 
tumour and molecular characteristics supporting the notion that lamin AJC status 
could be used as an independent prognostic biomarker in colorectal cancer 
patients. 
The find ing that expression of lamin A/C in colorectal cancer tissue is correlated 
with a two fold increase in colorectal cancer related mortality. for the first time 
directly links these proteins to progression of a common disease. Previous 
stud ies have described altered expression of A-type lamins in a range of 
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cancers, including cancers of the skin, lung, lymphatics and soft tissue. However 
none of these studies was able to link either absence or presence of A-type 
lamins to tumour progression, although at least one study suggested that loss of 
expression of lamins AJC was correlated with enhanced proliferation rates in 
tumours. The other problems with these previous studies is that a limited number 
of samples were available for analysis and consequently study sizes fell below 
the threshold for reliable statistical analysis and made use of batch dependent 
polyclonal antisera (Cance, Chaudhary et al. 1992; Moss, Krivosheyev et al. 
1999). In contrast, the findings presented in this thesis are based on a sufficiently 
large enough cohort to offer complete confidence in the significance levels 
reported and made use of the highly sensitive mouse monoclonal Jol2 anti-
lamin A/C antibody. 
7.3 Differential lamin A expression does not affect jJ-catenin 
activity in the SW480 colorectal cancer eel/line 
In order to address the question as to why there is a difference in survival 
between patients harbouring lamin A/C negative and lamin AJC positive tumours, 
I first looked to the canonical Wnt signalling pathway. Wnt signalling is an 
extremely important regulator of developmental pathways and has been shown 
to be implicated in over 90% of sporadic colorectal cancer cases (Miyoshi, 
Nagase et al. 1992; Powell, Zilz et al. 1992; Kinzler and Vogelstein 1996) 
through constitutive activation of the signalling pathway. With this in mind 
investigations were carried out to determine whether further changes in the Wnt 
signalling pathway were observed between lamin A positive and negative 
tumours using the naturally lamin A null SW480 colorectal cancer cell line. 
Results showed that there was no difference in p-catenin activity as investigated 
by Dual luciferase Tcf reporter assays. Upon stable transfection with full length 
pFiag-APC there was a decrease in p-catenin mediated transcriptional activity in 
both the GFP-Iamin A transfected and GFP-alone control transfected cell lines. 
There was however no differences noted between cell lines thus rejecting the 
hypothesis that differential lamin A expression was exerting any significant 
influence on the canonical Wnt signalling pathway. 
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7.4 Differential lamin A expression results in multiple genome 
wide changes 
Data from chapter 4 showed that the canonical Wnt signalling pathway, 
classically at the heart of colorectal adenocarcinoma initiation and progression is 
not influenced by differential lamin A expression. Thus it would suggest that the 
canonical Wnt signalling pathway is not centrally implicated in the protective 
effects mediated by lamin A/C negative status in patient tumours. Similarly with 
no correlations being drawn from chapter 3 to link differential lamin expression in 
tumours with other oncogenic mutations in proteins such as TP53 and Ki-ras, it 
suggests that the observed protective effect is mediated through one or more 
other developmental pathways which had yet to be investigated. Hence a 
genome-wide Affymetrix DNA Microarray analysis of the SW480 colorectal 
cancer cell line was embarked upon to explore members of other potential 
signalling pathways which may have been influenced by differential lamin A 
expression and thus may be implicated in mediating these observed differences 
in patient survival. 
Simple microarray data mtnmg based on international ontological definitions 
highlighted a series of genes implicated in other cellular pathways and 
components such as cell-cell adhesion; cytoskeletal reorganisation; protein 
phosphatase/kinase pathways, such as MAPKIERK; EGF signalling pathways; 
BMP signalling pathways; Slit/Robo signalling pathways and more. A subset of 5 
genes selected was independently confirmed using RT -PCR providing a platform 
for further investigation. 
7. 5 Differential lamin A expression may abrogate BMP4-
mediated signalling in the SW480 colorectal cancer eel/line 
The expression of the GFP-Iamin A fusion protein in the SW480 colorectal 
cancer cell line was shown in chapter 5 to dramatically down-regulate the 
expression of BMP4 at the mRNA level (by approximately 7 fold) and this was 
independently confirmed using RT-PCR to be approximately 6.5 fold. This down-
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regulation was then shown to pertain to a functional down-regulation at the 
protein level (chapter 6) of approximately 6.5 fold, potentially implicating laminA 
expression in BMP signalling pathways. 
Work carried out by Willis. Cox et al. (unpublished data) has shown that in the 
same GFP-Iamin A transfected SW480 cell line there is a 5 fold up-regulation in 
expression of the actin bundling protein T-Piastin and a concomitant 7 fold down-
regulation in the expression of the cell adhesion molecule E-cadherin. Their work 
also showed that this down-regulation pertains to the functional protein level in 
terms of E-cadherin, although unfortunately reliable T-Piastin antibodies are 
currently unavailable. As such, scratch wound assays performed on the GFP-
Aione and GFP-Iamin A transfected cell lines show a remarkable difference in 
wound closure time (chapter 6), with the GFP-Iamin A transfected SW480 cells 
closing the wound roughly 5 times faster within 18 hours and remaining unclosed 
after 48 hours in the SW480-GFP-Aione cells. Thus a hypothesis can be put 
forward that the synergistic down-regulation in the cell-cell adhesion protein E-
cadherin. and up-regulation in the actin-bundling protein T-plastin leads to a less 
adherent, more motile cellular phenotype which is functionally observed in 
scratch wound assays. 
Work has also been carried out in the SW480 parent cell line by Beck (Beck, 
Jung et al. 2006) whereby using a similar wounding assay they show that wound 
closure time is greatly increased to a point of almost total inhibition upon 
treatment with exogenous BMP2 or BMP7. However, using the BMP-specific 
SMAD-induced Luciferase reporter (BRE-Luc) they also show that whilst there 
appears to be growth suppressive properties of exogenous BMP treatment, the 
transcriptional activity of BMP target genes appear to remain unchanged. Data 
from chapter 6 supports such work since E-cadherin is known to be a down 
stream target of BMP signalling, yet we observe no changes in CDH1 mRNA 
expression levels upon treatment with high levels of exogenous BMP4 in the 
SW480-GFP-Iamin A cell line, nor do we see changes in the mRNA expression 
levels of PLS3. 
In line with Beck's study, treatment with exogenous recombinant BMP4 does 
partially inhibit wound closure in the SW480-GFP-Aione control cell line by just 
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under 2 fold, but does not appear to affect wound closure time in the SW480 
GFP-Iamin A transfected cell line. Such data would suggest that the expression 
of lamin A seems to abrogate BMP mediated growth suppressive responses and 
as such may be implicated as a central mediator in the protective effects 
observed by a lamin negative status in colorectal tumours. The exact mechanism 
by which this is facilitated remains unclear, but for the first time, this evidence 
may implicate A-type lam ins in the regulation of TGF~/BMP signalling pathways. 
7. 6 Final Conclusions and Future Work 
In summary I have shown that the expression of lamin A/C in a large 
retrospective archive of incident colorectal cancer cases is closely linked to 
patient mortality and as such a lamin A/C positive status in tumours is linked to a 
2 fold increase in patient mortality. I have then moved on to show that differential 
expression of lamin A/C in a colorectal cancer in vitro model cell line does not 
influence P-catenin activity in the case of either truncated or full-length APC and 
as such determine that the protective effects observed due to a lamin A/C 
negative status of tumours must be mediated by other mechanisms. Through the 
use of a genome-wide microarray, I then identify a series of other cellular 
pathways which may be implicated instead and move to investigate the effects of 
BMP4 signalling as the central mediator, showing the presence of laminA results 
in a more motile, less adherent cellular phenotype by potentially abrogating the 
growth suppressive responses of BMP signalling 
Future work should concentrate on investigating BMP signalling further in our 
lamin A in vitro models with the recent acquisition of the full length BMP4 
construct (Wyeth , UK). By stably transfecting the BMP4 gene into the SW480-
GFP-alone and GFP-Iamin A transfected cells lines under an inducible promoter, 
I could test whether overexpression of BMP4 at the transcriptional level is 
capable of overcoming the effects of lamin A expression. Continuing this work, 
the use of BMP-inducible reporters such as the BMP-specific SMAD-induced 
Luciferase reporter (BRE-Luc) used by Beck et al. could be used to monitor the 
transcriptional activity of BMP4 target genes under the above conditions. The 
reverse experiment would be to knockdown the expression of BMP4 in the 
205 
SW480-GFP-alone cell line in order to assess whether it adopted phenotypic 
characteristics more closely resembling that of the GFP-Iamin A cell line, for 
example, decreases in scratch wound closure time. These experiments would 
then shed light on whether or not the protective effects of laminA expression are 
primarily mediated through BMP signalling. 
Elucidating the exact mechanism by which lamin A is affecting BMP signalling is 
of central importance. Evaluation of BMP receptor expression and also of 
intracellular SMAD expression and phosphorylation status would also be of 
particular interest to ascertain whether or not lamin A transfected cells possess 
the capability to respond to BMP signals in terms of receptors, and if so whether 
the nuclear translocation of such signals is intact and functional in lamin A 
expressing cells. 
Further work into other potential gene targets identified from the genome-wide 
microarray would also be pertinent in order to find secondary markers which can 
be taken back to the NLCS and screened in order to create a bank of biomarkers 
which can be used as a prognostic tool. Similarly, it may be interesting to look at 
other available archives such as the Western Australian tissue array bank which 
also contains over several thousand specimens alongside similar detailed 
information for patients as that obtained from the NLCS. With such a large 
repository of tissue samples available, it would allow individual substrata to be 
investigated, for example colon vs. rectal, in order to determine the full extent of 
A-type lamins role in colorectal cancer. lt would also allow investigations to be 
conducted subdividing patients into those who did and did not receive adjuvant 
therapies and such a trial would allow one to determine whether differentiallamin 
AJC expression also influences the response of tumours to these adjuvant 
therapies. 
lt would also be of interest to explore whether or not the expression of Apoptotic 
markers correlated with lamin NC status in order to determine whether lamin A/C 
negative tumour cells are more likely to undergo programmed cell death thus 
conferring the apparent protective effect observed in vivo. 
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In terms of re-probing the microarray database, one would like to perform further 
cluster analysis based on conserved promoter regions and cis-regulatory 
modules in order to determine whether the absence of lamin AJC may be directly 
(or through its binding partners) affecting gene transcription, such as would be 
the case of the AP-1 transcription factor complex mentioned in section 5.3. 
Software such as that mentioned in 5.1.2.2 would facilitate such an investigation. 
In conclusion, one would postulate from evidence provided herein that 
expression of nuclear lamin A in colorectal adenocarcinomas could confer a 
more stem-cell like characteristic to tumour cells which is mediated through 
multiple genome wide changes including suppression of BMP-mediated and 
other developmental signalling responses, activation of endogenous growth-
stimulatory factors and loss of regulation of transcription factor complexes 
resulting in a more motile, less adherent phenotype of the cells. Such changes in 
cellular phenotype would then manifest themselves clinically in terms of poorer 
patient prognosis and as such, based on this work lamin A expression may be an 
important, independent prognostic marker for colorectal cancer in the future. 
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Cancer Research Technologies licensing opportunity: 
Lam in AIC: Prognostic marker in co/orectal cancer 
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CRT Licensing Opportunity 
Lam in A/C: Prognostic marker in colorectal cancer 
Urgent unmet medical need for improved stratification of CRC patients 
Lamin A/C is an independent prognostic marker for relapse or progression of early CRC 
Validated by immunohistochemist ry in 656 independent patient samples 
Expression of Lam in A/C correlates with an increased risk of colorectal cancer death 
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